Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


Daily Top 10 COVID-19 papers

DEU | ENG | ESP | FRA | ITA | POR | TUR | VNM


  Gynecology

  Free Subscription


Articles published in Gynecol Oncol

Retrieve available abstracts of 1003 articles:
HTML format



Single Articles


    May 2020
  1. MATSUO K, Novatt H, Matsuzaki S, Hom MS, et al
    Wait-time for hysterectomy and survival of women with early-stage cervical cancer: A clinical implication during the coronavirus pandemic.
    Gynecol Oncol. 2020 May 18. pii: S0090-8258(20)31087.
    PubMed     Abstract available


  2. NGUYEN JMV, Hogen L, Laframboise S, Bouchard-Fortier G, et al
    The use of indocyanine green fluorescence angiography to assess anastomotic perfusion following bowel resection in surgery for gynecologic malignancies - A report of 100 consecutive anastomoses.
    Gynecol Oncol. 2020 May 15. pii: S0090-8258(20)31076.
    PubMed     Abstract available


  3. STEENBEEK MP, Bulten J, Snijders MPLM, Lombaers M, et al
    Fallopian tube abnormalities in uterine serous carcinoma.
    Gynecol Oncol. 2020 May 11. pii: S0090-8258(20)31017.
    PubMed     Abstract available


  4. JAREEMIT N, Horowitz NS, Goldstein DP, Berkowitz RS, et al
    EMA vs EMACO in the treatment of gestational trophoblastic neoplasia.
    Gynecol Oncol. 2020 May 11. pii: S0090-8258(20)31009.
    PubMed     Abstract available


  5. MATSUO K, Chang EJ, Matsuzaki S, Mandelbaum RS, et al
    Minimally invasive surgery for early-stage ovarian cancer: Association between hospital surgical volume and short-term perioperative outcomes.
    Gynecol Oncol. 2020 May 10. pii: S0090-8258(20)30304.
    PubMed     Abstract available


  6. WASHINGTON CR, Haggerty A, Ronner W, Neff PM, et al
    Knowledge of endometrial cancer risk factors in a general gynecologic population.
    Gynecol Oncol. 2020 May 10. pii: S0090-8258(20)30257.
    PubMed     Abstract available


  7. FREITAS F, Braga A, Viggiano M, Velarde LGC, et al
    Gestational trophoblastic neoplasia lethality among Brazilian women: A retrospective national cohort study.
    Gynecol Oncol. 2020 May 8. pii: S0090-8258(20)31014.
    PubMed     Abstract available


  8. LUO S, Zhang Y, Yang Y, Zhu S, et al
    Clonal tumor mutations in homologous recombination genes predict favorable clinical outcome in ovarian cancer treated with platinum-based chemotherapy.
    Gynecol Oncol. 2020 May 8. pii: S0090-8258(20)30995.
    PubMed     Abstract available


  9. BOGANI G, Casarin J, Maggiore ULR, Ditto A, et al
    Survival outcomes in endometrial cancer patients having lymphadenectomy, sentinel node mapping followed by lymphadectomy and sentinel node mapping alone: Long-term results of a propensity-matched analysis.
    Gynecol Oncol. 2020 May 7. pii: S0090-8258(20)30991.
    PubMed    


  10. BOUCHARD-FORTIER G, Cusimano MC, Fazelzad R, Sajewycz K, et al
    Oncologic outcomes and morbidity following heated intraperitoneal chemotherapy at cytoreductive surgery for primary epithelial ovarian cancer: A systematic review and meta-analysis.
    Gynecol Oncol. 2020 May 6. pii: S0090-8258(20)30259.
    PubMed     Abstract available


  11. LENTZ SE, Salyer CV, Dontsi M, Armstrong MA, et al
    Comparison of two Lynch screening strategies in endometrial cancer in a California health system.
    Gynecol Oncol. 2020 May 6. pii: S0090-8258(20)30992.
    PubMed     Abstract available


  12. WENZEL HHB, Van Kol KGG, Nijman HW, Lemmens VEPP, et al
    Cervical cancer with </=5 mm depth of invasion and >7 mm horizontal spread - Is lymph node assessment only required in patients with LVSI?
    Gynecol Oncol. 2020 May 4. pii: S0090-8258(20)31015.
    PubMed     Abstract available


  13. SIVAKUMARAN T, Mileshkin L, Grant P, Na L, et al
    Evaluating the impact of dose reductions and delays on progression-free survival in women with ovarian cancer treated with either three-weekly or dose-dense carboplatin and paclitaxel regimens in the national prospective OPAL cohort study.
    Gynecol Oncol. 2020 May 4. pii: S0090-8258(20)31016.
    PubMed     Abstract available


  14. DAI Y, Wang Z, Wang J
    Survival of microsatellite-stable endometrioid endometrial cancer patients after minimally invasive surgery: An analysis of the Cancer Genome Atlas data.
    Gynecol Oncol. 2020 May 4. pii: S0090-8258(20)30984.
    PubMed     Abstract available


  15. SONG F, Li L, Zhang B, Zhao Y, et al
    Tumor specific methylome in Chinese high-grade serous ovarian cancer characterized by gene expression profile and tumor genotype.
    Gynecol Oncol. 2020 May 1. pii: S0090-8258(20)30988.
    PubMed     Abstract available


    April 2020
  16. PAIVA CE, Paiva BSR, Menezes D, Zanini LE, et al
    Development of a screening tool to improve the referral of patients with breast and gynecological cancer to outpatient palliative care.
    Gynecol Oncol. 2020 Apr 30. pii: S0090-8258(20)31011.
    PubMed     Abstract available


  17. STAPLES JN, Peres LC, Camacho F, Alberg AJ, et al
    Cardiometabolic comorbidities and epithelial ovarian cancer risk among African-American women in the African-American Cancer Epidemiology Study (AACES).
    Gynecol Oncol. 2020 Apr 30. pii: S0090-8258(20)31010.
    PubMed     Abstract available


  18. CHEN Y, Li G
    Gynecological malignancies with asymptomatic SARS-CoV-2 infection during the convalescence of outbreak.
    Gynecol Oncol. 2020 Apr 29. pii: S0090-8258(20)31019.
    PubMed    


  19. MONK BJ, Coleman RL, Moore KN, Herzog TJ, et al
    COVID-19 and ovarian cancer: Exploring alternatives to intravenous (IV) therapies.
    Gynecol Oncol. 2020 Apr 29. pii: S0090-8258(20)31013.
    PubMed    


  20. NASIOUDIS D, Ko EM, Haggerty AF, Cory L, et al
    Performance of lymphadenectomy for apparent early stage malignant ovarian germ cell tumors in the era of platinum-based chemotherapy.
    Gynecol Oncol. 2020 Apr 28. pii: S0090-8258(20)30306.
    PubMed     Abstract available


  21. HELPMAN L, Pond GR, Elit L, Anderson LN, et al
    Endometrial cancer presentation is associated with social determinants of health in a public healthcare system: A population-based cohort study.
    Gynecol Oncol. 2020 Apr 27. pii: S0090-8258(20)30993.
    PubMed     Abstract available


  22. NASIOUDIS D, Mastroyannis SA, Latif NA, Ko EM, et al
    Effect of bilateral salpingo-oophorectomy on the overall survival of premenopausal patients with stage I low-grade endometrial stromal sarcoma; a National Cancer Database analysis.
    Gynecol Oncol. 2020 Apr 27. pii: S0090-8258(20)30260.
    PubMed     Abstract available


  23. HWANG JH, Kim BW, Jeong H, Kim H, et al
    Comparison of urologic complications between laparoscopic radical hysterectomy and abdominal radical hysterectomy: A nationwide study from the National Health Insurance.
    Gynecol Oncol. 2020 Apr 27. pii: S0090-8258(20)30986.
    PubMed     Abstract available


  24. KOGAN L, Matanes E, Wissing M, Mitric C, et al
    The added value of sentinel node mapping in endometrial cancer.
    Gynecol Oncol. 2020 Apr 27. pii: S0090-8258(20)30987.
    PubMed     Abstract available


  25. SEARLE G, Pounds R, Phillips A, Kehoe S, et al
    Prolonged interruption of chemotherapy in patients undergoing delayed debulking surgery for advanced high grade serous ovarian cancer is associated with a worse prognosis.
    Gynecol Oncol. 2020 Apr 25. pii: S0090-8258(20)30307.
    PubMed     Abstract available


  26. LIN H, Ye M, Chan SW, Zhu J, et al
    The effectiveness of online interventions for patients with gynecological cancer: An integrative review.
    Gynecol Oncol. 2020 Apr 24. pii: S0090-8258(20)30990.
    PubMed     Abstract available


  27. FREY MK, Blank SV
    Coronavirus concerns: What do women with gynecologic cancer need to know during the COVID-19 crisis?
    Gynecol Oncol. 2020 Apr 24. pii: S0090-8258(20)30997.
    PubMed    


  28. POTHURI B, Alvarez Secord A, Armstrong DK, Chan J, et al
    Anti-cancer therapy and clinical trial considerations for gynecologic oncology patients during the COVID-19 pandemic crisis.
    Gynecol Oncol. 2020 Apr 23. pii: S0090-8258(20)30994.
    PubMed     Abstract available


  29. KIM SR, Cloutier BT, Leung S, Cochrane D, et al
    Molecular subtypes of clear cell carcinoma of the endometrium: Opportunities for prognostic and predictive stratification.
    Gynecol Oncol. 2020 Apr 21. pii: S0090-8258(20)30302.
    PubMed     Abstract available


  30. MAJIDI A, Na R, Dixon-Suen S, Jordan SJ, et al
    Common medications and survival in women with ovarian cancer: A systematic review and meta-analysis.
    Gynecol Oncol. 2020 Apr 18. pii: S0090-8258(20)30253.
    PubMed     Abstract available


  31. YU YL, Yeo H, Kang S
    The impact of depressive symptoms on health value in patients with gynecologic cancer: A comparison with physical symptoms and performance status.
    Gynecol Oncol. 2020 Apr 16. pii: S0090-8258(20)30303.
    PubMed     Abstract available


  32. BRUEGL AS, Joshi S, Batman S, Weisenberger M, et al
    Gynecologic cancer incidence and mortality among American Indian/Alaska Native women in the Pacific Northwest, 1996-2016.
    Gynecol Oncol. 2020 Apr 15. pii: S0090-8258(20)30258.
    PubMed     Abstract available


  33. KALAMPOKAS E, Payne F, Nomikos A, Gurumurthy M, et al
    Corrigendum to "An update on the use of immunohistochemistry and molecular pathology in the diagnosis of pre-invasive and malignant lesions in gynecological oncology" [Gynecol. Oncol. 150 (2018) 378-386].
    Gynecol Oncol. 2020 Apr 13. pii: S0090-8258(20)30230.
    PubMed    


  34. TEMKIN SM, Rubinsak L, Benoit MF, Hong L, et al
    Take me to your leader: Reporting structures and equity in academic gynecologic oncology.
    Gynecol Oncol. 2020 Apr 7. pii: S0090-8258(20)30256.
    PubMed     Abstract available


  35. BATMAN S, Skeith A, Allen A, Munro E, et al
    Cost-effectiveness of second curettage for treatment of low-risk non-metastatic gestational trophoblastic neoplasia.
    Gynecol Oncol. 2020 Apr 7. pii: S0090-8258(20)30254.
    PubMed     Abstract available


  36. HOOGSTAD-VAN EVERT JS, Bekkers R, Ottevanger N, Jansen JH, et al
    Harnessing natural killer cells for the treatment of ovarian cancer.
    Gynecol Oncol. 2020 Apr 5. pii: S0090-8258(20)30236.
    PubMed     Abstract available


  37. KORENAGA TK, Tewari KS
    Gynecologic cancer in pregnancy.
    Gynecol Oncol. 2020 Apr 5. pii: S0090-8258(20)30231.
    PubMed     Abstract available


  38. AREND RC, Beer HM, Cohen YC, Berlin S, et al
    Ofranergene obadenovec (VB-111) in platinum-resistant ovarian cancer; favorable response rates in a phase I/II study are associated with an immunotherapeutic effect.
    Gynecol Oncol. 2020 Apr 5. pii: S0090-8258(20)30180.
    PubMed     Abstract available


  39. GRIGSBY PW, Massad LS, Mutch DG, Powell MA, et al
    FIGO 2018 staging criteria for cervical cancer: Impact on stage migration and survival.
    Gynecol Oncol. 2020 Apr 2. pii: S0090-8258(20)30252.
    PubMed     Abstract available


  40. CHEVROT A, Pouget N, Bats AS, Huchon C, et al
    Fertility and prognosis of borderline ovarian tumor after conservative management: Results of the multicentric OPTIBOT study by the GINECO & TMRG group.
    Gynecol Oncol. 2020;157:29-35.
    PubMed     Abstract available


  41. GERSHENSON DM, Okamoto A, Ray-Coquard I
    Rare Gynecologic Tumors: Coming of Age.
    Gynecol Oncol. 2020;157:1-2.
    PubMed    


  42. MUELLER JJ, Pedra Nobre S, Braxton K, Alektiar KM, et al
    Incidence of pelvic lymph node metastasis using modern FIGO staging and sentinel lymph node mapping with ultrastaging in surgically staged patients with endometrioid and serous endometrial carcinoma.
    Gynecol Oncol. 2020 Apr 1. pii: S0090-8258(20)30250.
    PubMed     Abstract available


  43. NARASIMHULU DM, Kumar A, Weaver AL, Langstraat CL, et al
    Less guessing, more evidence in identifying patients least fit for cytoreductive surgery in advanced ovarian cancer: A triage algorithm to individualize surgical management.
    Gynecol Oncol. 2020 Apr 1. pii: S0090-8258(20)30249.
    PubMed     Abstract available


    March 2020
  44. BENNETSEN AKK, Baandrup L, Aalborg GL, Kjaer SK, et al
    Non-epithelial ovarian cancer in Denmark - Incidence and survival over nearly 40years.
    Gynecol Oncol. 2020 Mar 26. pii: S0090-8258(20)30246.
    PubMed     Abstract available


  45. GONZALEZ R, Gockley AA, Melamed A, Sugrue R, et al
    Multivariable analysis of association of beta-blocker use and survival in advanced ovarian cancer.
    Gynecol Oncol. 2020 Mar 25. pii: S0090-8258(20)30228.
    PubMed     Abstract available


  46. TYMON-ROSARIO JR, Miller DT, Novetsky AP, Goldberg GL, et al
    Risk factors associated with delayed discharge following robotic assisted surgery for gynecologic malignancy.
    Gynecol Oncol. 2020 Mar 23. pii: S0090-8258(20)30235.
    PubMed     Abstract available


  47. DHOLAKIA J, Llamocca E, Quick A, Salani R, et al
    Guideline-concordant treatment is associated with improved survival among women with non-endometrioid endometrial cancer.
    Gynecol Oncol. 2020 Mar 23. pii: S0090-8258(20)30232.
    PubMed     Abstract available


  48. RUSH SK, Swisher EM, Garcia RL, Pennington KP, et al
    Pathologic findings and clinical outcomes in women undergoing risk-reducing surgery to prevent ovarian and fallopian tube carcinoma: A large prospective single institution experience.
    Gynecol Oncol. 2020 Mar 19. pii: S0090-8258(20)30101.
    PubMed     Abstract available


  49. WONG CHL, Sundberg T, Chung VCH, Voiss P, et al
    Prevalence and predictors of mind-body medicine use among women diagnosed with gynecological cancer: Findings from the 2017 US National Health Interview Survey.
    Gynecol Oncol. 2020 Mar 17. pii: S0090-8258(20)30227.
    PubMed     Abstract available


  50. BETELLA I, Turbitt WJ, Szul T, Wu B, et al
    Wnt signaling modulator DKK1 as an immunotherapeutic target in ovarian cancer.
    Gynecol Oncol. 2020 Mar 16. pii: S0090-8258(20)30226.
    PubMed     Abstract available


  51. WOLFORD JE, Bai J, Moore KN, Kristeleit R, et al
    Cost-effectiveness of niraparib, rucaparib, and olaparib for treatment of platinum-resistant, recurrent ovarian carcinoma.
    Gynecol Oncol. 2020 Mar 13. pii: S0090-8258(20)30176.
    PubMed     Abstract available


  52. AWAD E, Paladugu R, Jones N, Pierce JY, et al
    Minority participation in phase 1 gynecologic oncology clinical trials: Three decades of inequity.
    Gynecol Oncol. 2020 Mar 13. pii: S0090-8258(20)30218.
    PubMed     Abstract available


  53. MIGNOT F, Gouy S, Schernberg A, Bockel S, et al
    Comprehensive analysis of patient outcome after local recurrence of locally advanced cervical cancer treated with concomitant chemoradiation and image-guided adaptive brachytherapy.
    Gynecol Oncol. 2020 Mar 13. pii: S0090-8258(20)30222.
    PubMed     Abstract available


  54. LIONTOS M, Sotiropoulou M, Kaparelou M, Tzannis K, et al
    Lymphocytic infiltration and Chemotherapy Response Score as prognostic markers in ovarian cancer patients treated with Neoadjuvant chemotherapy.
    Gynecol Oncol. 2020 Mar 12. pii: S0090-8258(20)30224.
    PubMed     Abstract available


  55. SUN Z, Huang B, Liu C, Yang Y, et al
    Comparison of neoadjuvant treatments followed by radical surgery or chemoradiation on quality of life in patients with stage IB2-IIA cervical cancer.
    Gynecol Oncol. 2020 Mar 12. pii: S0090-8258(20)30092.
    PubMed     Abstract available


  56. RAUH LA, Sullivan MW, Camacho F, Janke MJ, et al
    Validation of the surprise question in gynecologic oncology: A one-question screen to promote palliative care integration and advance care planning.
    Gynecol Oncol. 2020 Mar 12. pii: S0090-8258(20)30223.
    PubMed     Abstract available


  57. ROZE JF, Veldhuis WB, Hoogendam JP, Verheijen RHM, et al
    Prognostic value of radiological recurrence patterns in ovarian cancer.
    Gynecol Oncol. 2020 Mar 11. pii: S0090-8258(20)30219.
    PubMed     Abstract available


  58. VAN WALREE IC, Bretveld R, van Huis-Tanja LH, Louwers JA, et al
    Reasons for guideline non-adherence in older and younger women with advanced stage ovarian cancer.
    Gynecol Oncol. 2020 Mar 11. pii: S0090-8258(20)30221.
    PubMed     Abstract available


  59. LIN DI, Hemmerich A, Edgerly C, Duncan D, et al
    Genomic profiling of BCOR-rearranged uterine sarcomas reveals novel gene fusion partners, frequent CDK4 amplification and CDKN2A loss.
    Gynecol Oncol. 2020 Mar 7. pii: S0090-8258(20)30160.
    PubMed     Abstract available


  60. LEVY T, Migdan Z, Aleohin N, Ben-Shem, et al
    Retroperitoneal lymph node recurrence of epithelial ovarian cancer: Prognostic factors and treatment outcome.
    Gynecol Oncol. 2020 Mar 6. pii: S0090-8258(20)30158.
    PubMed     Abstract available


  61. HAQUE R, Skates SJ, Armstrong MA, Lentz SE, et al
    Feasibility, patient compliance and acceptability of ovarian cancer surveillance using two serum biomarkers and Risk of Ovarian Cancer Algorithm compared to standard ultrasound and CA 125 among women with BRCA mutations.
    Gynecol Oncol. 2020 Mar 4. pii: S0090-8258(20)30164.
    PubMed     Abstract available


  62. HOSKINS PJ, Le N, Kumar A, Pina A, et al
    Single or two drug combination therapy as initial treatment for low risk, gestational trophoblastic neoplasia. A Canadian analysis.
    Gynecol Oncol. 2020 Mar 3. pii: S0090-8258(20)30100.
    PubMed     Abstract available


  63. PIERSON WE, Peters PN, Chang MT, Chen LM, et al
    An integrated molecular profile of endometrioid ovarian cancer.
    Gynecol Oncol. 2020 Mar 2. pii: S0090-8258(20)30144.
    PubMed     Abstract available


  64. GONTHIER C, Douhnai D, Koskas M
    Lymph node metastasis probability in young patients eligible for conservative management of endometrial cancer.
    Gynecol Oncol. 2020 Mar 2. pii: S0090-8258(20)30157.
    PubMed     Abstract available


  65. REINHOLDT K, Kjaer SK, Guleria S, Frederiksen K, et al
    Risk of endometrial cancer among women with benign ovarian tumors - A Danish nationwide cohort study.
    Gynecol Oncol. 2020 Mar 2. pii: S0090-8258(20)30178.
    PubMed     Abstract available


  66. KIM H, Cho WK, Kim YJ, Kim YS, et al
    Significance of the number of high-risk factors in patients with cervical cancer treated with radical hysterectomy and concurrent chemoradiotherapy.
    Gynecol Oncol. 2020 Mar 2. pii: S0090-8258(20)30177.
    PubMed     Abstract available


  67. LENCK C, Chopin N, Gouy S, Bonsang-Kitzis H, et al
    The French national network dedicated to rare gynecological cancers diagnosis and management could improve the quality of surgery in daily practice of granulosa cell tumors. A TMRG and GINECO group Study.
    Gynecol Oncol. 2020 Mar 1. pii: S0090-8258(20)30145.
    PubMed     Abstract available


  68. MOORE KN, Zorn KK
    Germline and Somatic Testing in Ovarian Cancer: Shifting Sands of Recommendations.
    Gynecol Oncol. 2020;156:515-516.
    PubMed    


    February 2020
  69. CHANG CP, Chen Y, Blackburn B, Abdelaziz S, et al
    Genitourinary disease risks among ovarian cancer survivors in a population-based cohort study.
    Gynecol Oncol. 2020 Feb 28. pii: S0090-8258(20)30162.
    PubMed     Abstract available


  70. LI X, Xia L, Li J, Chen X, et al
    Reproductive and obstetric outcomes after abdominal radical trachelectomy (ART) for patients with early-stage cervical cancers in Fudan, China.
    Gynecol Oncol. 2020 Feb 28. pii: S0090-8258(20)30152.
    PubMed     Abstract available


  71. PLETT H, Harter P, Ataseven B, Heitz F, et al
    Fertility-sparing surgery and reproductive-outcomes in patients with borderline ovarian tumors.
    Gynecol Oncol. 2020 Feb 27. pii: S0090-8258(20)30102.
    PubMed     Abstract available


  72. KIM CH, Lefkowits C, Holschneider C, Bixel K, et al
    Managing opioid use in the acute surgical setting: A society of gynecologic oncology clinical practice statement.
    Gynecol Oncol. 2020 Feb 24. pii: S0090-8258(20)30068.
    PubMed     Abstract available


  73. GLASER GE, Kalogera E, Kumar A, Yi J, et al
    Outcomes and patient perspectives following implementation of tiered opioid prescription guidelines in gynecologic surgery.
    Gynecol Oncol. 2020 Feb 24. pii: S0090-8258(20)30161.
    PubMed     Abstract available


  74. CHOI CH, Chung JY, Kang JH, Paik ES, et al
    Chemoradiotherapy response prediction model by proteomic expressional profiling in patients with locally advanced cervical cancer.
    Gynecol Oncol. 2020 Feb 24. pii: S0090-8258(20)30153.
    PubMed     Abstract available


  75. PRAISS AM, Huang Y, St Clair CM, Tergas AI, et al
    A modern assessment of the surgical pathologic spread and nodal dissemination of endometrial cancer.
    Gynecol Oncol. 2020 Feb 21. pii: S0090-8258(20)30150.
    PubMed     Abstract available


  76. AVIKI EM, Chen L, Dessources K, Leitao MM Jr, et al
    Impact of hospital volume on surgical management and outcomes for early-stage cervical cancer.
    Gynecol Oncol. 2020 Feb 21. pii: S0090-8258(20)30165.
    PubMed     Abstract available


  77. NASIOUDIS D, Sakamuri S, Ko EM, Haggerty AF, et al
    Radical hysterectomy is not associated with a survival benefit for patients with stage II endometrial carcinoma.
    Gynecol Oncol. 2020 Feb 20. pii: S0090-8258(20)30098.
    PubMed     Abstract available


  78. COHEN PA, Powell A, Bohm S, Gilks CB, et al
    Corrigendum to "Pathological chemotherapy response score is prognostic in tubo-ovarian high-grade serous carcinoma: A systematic review and meta-analysis of individual patient data" [Gynecol. Oncol. 154 (2019) 441-448].
    Gynecol Oncol. 2020 Feb 20. pii: S0090-8258(20)30159.
    PubMed    


  79. ACOSTA-TORRES S, Murdock T, Matsuno R, Beavis AL, et al
    The addition of metformin to progestin therapy in the fertility-sparing treatment of women with atypical hyperplasia/endometrial intraepithelial neoplasia or endometrial cancer: Little impact on response and low live-birth rates.
    Gynecol Oncol. 2020 Feb 18. pii: S0090-8258(20)30103.
    PubMed     Abstract available


  80. O'MALLEY DM, Matulonis UA, Birrer MJ, Castro CM, et al
    Phase Ib study of mirvetuximab soravtansine, a folate receptor alpha (FRalpha)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients with platinum-resistant ovarian cancer.
    Gynecol Oncol. 2020 Feb 18. pii: S0090-8258(20)30090.
    PubMed     Abstract available


  81. CHARO LM, Vaida F, Eskander RN, Binder P, et al
    Rapid dissemination of practice-changing information: A longitudinal analysis of real-world rates of minimally invasive radical hysterectomy before and after presentation of the LACC trial.
    Gynecol Oncol. 2020 Feb 17. pii: S0090-8258(20)30154.
    PubMed     Abstract available


  82. SINNO AK, Pinkerton J, Febbraro T, Jones N, et al
    Hormone therapy (HT) in women with gynecologic cancers and in women at high risk for developing a gynecologic cancer: A Society of Gynecologic Oncology (SGO) clinical practice statement: This practice statement has been endorsed by The North American
    Gynecol Oncol. 2020 Feb 14. pii: S0090-8258(20)30088.
    PubMed    


  83. CHEN B, Ji M, Li P, Liu P, et al
    Comparison between robot-assisted radical hysterectomy and abdominal radical hysterectomy for cervical cancer: A multicentre retrospective study.
    Gynecol Oncol. 2020 Feb 14. pii: S0090-8258(20)30155.
    PubMed     Abstract available


  84. TRAN LKH, Tran PMH, Mysona DP, Purohit SB, et al
    A 73-gene proliferative transcriptomic signature predicts uterine serous carcinoma patient survival and response to primary therapy.
    Gynecol Oncol. 2020 Feb 14. pii: S0090-8258(20)30151.
    PubMed     Abstract available


  85. UEHARA T, Yoshida H, Fukuhara M, Yoshida M, et al
    Efficacy of ascitic fluid cell block for diagnosing primary ovarian, peritoneal, and tubal cancer in patients with peritoneal carcinomatosis with ascites.
    Gynecol Oncol. 2020 Feb 13. pii: S0090-8258(20)30099.
    PubMed     Abstract available


  86. ALLDREDGE J, Serna-Gallegos T, Gallegos N, VanLeer JP, et al
    Erratum to "Evaluation of clear cell subtypes of ovarian and uterine malignancies with anti-PD-L1 and anti-PD1 immunohistochemical expression and their association with stage and survival" [Gynecol. Oncol. 155 (2019) 483-488].
    Gynecol Oncol. 2020 Feb 12. pii: S0090-8258(20)30146.
    PubMed    


  87. FREY MK, Lee SS, Gerber D, Schwartz ZP, et al
    Facilitated referral pathway for genetic testing at the time of ovarian cancer diagnosis: uptake of genetic counseling and testing and impact on patient-reported stress, anxiety and depression.
    Gynecol Oncol. 2020 Feb 11. pii: S0090-8258(20)30007.
    PubMed     Abstract available


  88. WESTON E, Noel M, Douglas K, Terrones K, et al
    The impact of an enhanced recovery after minimally invasive surgery program on opioid use in gynecologic oncology patients undergoing hysterectomy.
    Gynecol Oncol. 2020 Feb 11. pii: S0090-8258(20)30094.
    PubMed     Abstract available


  89. PETERSEN S, Wilson AJ, Hirst J, Roby KF, et al
    CCNE1 and BRD4 co-amplification in high-grade serous ovarian cancer is associated with poor clinical outcomes.
    Gynecol Oncol. 2020 Feb 7. pii: S0090-8258(20)30091.
    PubMed     Abstract available


  90. MAESTA I, Nitecki R, Desmarais CCF, Horowitz NS, et al
    Effectiveness and toxicity of second-line actinomycin D in patients with methotrexate-resistant postmolar low-risk gestational trophoblastic neoplasia.
    Gynecol Oncol. 2020 Feb 6. pii: S0090-8258(20)30096.
    PubMed     Abstract available


  91. COLEMAN RL, Handley KF, Burger R, Molin GZD, et al
    Demcizumab combined with paclitaxel for platinum-resistant ovarian, primary peritoneal, and fallopian tube cancer: The SIERRA open-label phase Ib trial.
    Gynecol Oncol. 2020 Feb 6. pii: S0090-8258(20)30095.
    PubMed     Abstract available


  92. PIAO J, Lee EJ, Lee M
    Association between pelvic inflammatory disease and risk of ovarian cancer: An updated meta-analysis.
    Gynecol Oncol. 2020 Feb 6. pii: S0090-8258(20)30097.
    PubMed     Abstract available


  93. ROJAS C, Tian C, Powell MA, Chan JK, et al
    Racial disparities in uterine and ovarian carcinosarcoma: A population-based analysis of treatment and survival.
    Gynecol Oncol. 2020 Feb 3. pii: S0090-8258(20)30057.
    PubMed     Abstract available


  94. SOLSKY I, Chen J, Rebbeck TR
    Precision prophylaxis: Identifying the optimal timing for risk-reducing salpingo-oophorectomy based on type of BRCA1 and BRCA2 cluster region mutations.
    Gynecol Oncol. 2020;156:363-376.
    PubMed     Abstract available


  95. DOGAN NU, Dogan S, Erol M, Uzun BT, et al
    Cisterna chyli: An important landmark in laparoscopic paraaortic lymphadenectomy.
    Gynecol Oncol. 2020;156:511.
    PubMed     Abstract available


  96. DILLEY S, Miller KM, Huh WK
    Human papillomavirus vaccination: Ongoing challenges and future directions.
    Gynecol Oncol. 2020;156:498-502.
    PubMed     Abstract available


  97. RISHI A, Rollins M, Ahmed KA, Hunt DC, et al
    High-dose intensity-modulated chemoradiotherapy in vulvar squamous cell carcinoma: Outcome and toxicity.
    Gynecol Oncol. 2020;156:349-356.
    PubMed     Abstract available


  98. VENERIS JT, Matulonis UA, Liu JF, Konstantinopoulos PA, et al
    Choosing wisely: Selecting PARP inhibitor combinations to promote anti-tumor immune responses beyond BRCA mutations.
    Gynecol Oncol. 2020;156:488-497.
    PubMed     Abstract available


    January 2020
  99. MILLER DS, Randall ME, Filiaci V
    Progress in endometrial cancer: Contributions of the former Gynecologic Oncology Group.
    Gynecol Oncol. 2020 Jan 31. pii: S0090-8258(20)30019.
    PubMed     Abstract available


  100. KORENAGA TR, Ward KK, Saenz C, McHale MT, et al
    The elevated risk of ovarian clear cell carcinoma among Asian Pacific Islander women in the United States is not affected by birthplace.
    Gynecol Oncol. 2020 Jan 30. pii: S0090-8258(20)30086.
    PubMed     Abstract available


  101. LONG B, Clarke MA, Morillo ADM, Wentzensen N, et al
    Ultrasound detection of endometrial cancer in women with postmenopausal bleeding: Systematic review and meta-analysis.
    Gynecol Oncol. 2020 Jan 30. pii: S0090-8258(20)30085.
    PubMed     Abstract available


  102. MATERN T, Kang E, Lim PC
    Factors in the feasibility and safety of outpatient robotic-assisted hysterectomy for endometrial or cervical carcinoma.
    Gynecol Oncol. 2020 Jan 30. pii: S0090-8258(20)30081.
    PubMed     Abstract available


  103. SIEMON J, Galli J, Slomovitz B, Schlumbrecht M, et al
    Disparities in care among patients with low-grade serous ovarian carcinoma.
    Gynecol Oncol. 2020 Jan 30. pii: S0090-8258(19)31871.
    PubMed     Abstract available


  104. NASIOUDIS D, Mastroyannis SA, Latif NA, Ko EM, et al
    Trends in the surgical management of malignant ovarian germ-cell tumors.
    Gynecol Oncol. 2020 Jan 30. pii: S0090-8258(20)30087.
    PubMed     Abstract available


  105. CABASAG CJ, Butler J, Arnold M, Rutherford M, et al
    Exploring variations in ovarian cancer survival by age and stage (ICBP SurvMark-2): A population-based study.
    Gynecol Oncol. 2020 Jan 28. pii: S0090-8258(19)31877.
    PubMed     Abstract available


  106. TRIMBLE CL, Levinson K, Maldonado L, Donovan MJ, et al
    A first-in-human proof-of-concept trial of intravaginal artesunate to treat cervical intraepithelial neoplasia 2/3 (CIN2/3).
    Gynecol Oncol. 2020 Jan 28. pii: S0090-8258(19)31865.
    PubMed     Abstract available


  107. MULLEN MM, Porcelli BP, Cripe J, Massad LS, et al
    Modified frailty index is predictive of wound complications in obese patients undergoing gynecologic surgery via a midline vertical incision.
    Gynecol Oncol. 2020 Jan 27. pii: S0090-8258(19)31629.
    PubMed     Abstract available


  108. XUE C, Xu Y, Ye W, Xie Q, et al
    Expression of PD-L1 in ovarian cancer and its synergistic antitumor effect with PARP inhibitor.
    Gynecol Oncol. 2020 Jan 24. pii: S0090-8258(19)31804.
    PubMed     Abstract available


  109. JORDAN SE, Schlumbrecht M, George S, Pearson JM, et al
    The Moore Criteria: Applicability in a diverse, non-trial, recurrent cervical cancer population.
    Gynecol Oncol. 2020 Jan 23. pii: S0090-8258(20)30001.
    PubMed     Abstract available


  110. STEWART LM, Stewart CJR, Spilsbury K, Cohen PA, et al
    Association between pelvic inflammatory disease, infertility, ectopic pregnancy and the development of ovarian serous borderline tumor, mucinous borderline tumor and low-grade serous carcinoma.
    Gynecol Oncol. 2020 Jan 23. pii: S0090-8258(20)30080.
    PubMed     Abstract available


  111. TAKEHARA K, Yamashita N, Watanabe R, Teramoto N, et al
    Clinical status and prognostic factors in Japanese patients with uterine leiomyosarcoma.
    Gynecol Oncol. 2020 Jan 23. pii: S0090-8258(20)30064.
    PubMed     Abstract available


  112. MATSUO K, Matsuzaki S, Mandelbaum RS, Matsushima K, et al
    Association between hospital surgical volume and perioperative outcomes of fertility-sparing trachelectomy for cervical cancer: A national study in the United States.
    Gynecol Oncol. 2020 Jan 22. pii: S0090-8258(20)30021.
    PubMed     Abstract available


  113. HAVRILESKY LJ, Lim S, Ehrisman JA, Lorenzo A, et al
    Patient preferences for maintenance PARP inhibitor therapy in ovarian cancer treatment.
    Gynecol Oncol. 2020 Jan 22. pii: S0090-8258(20)30070.
    PubMed     Abstract available


  114. MATSUO K, Mandelbaum RS, Adams CL, Roman LD, et al
    Corrigendum to "Performance and outcome of pelvic exenteration for gynecologic malignancies: A population-based study" [Gynecol. Oncol. 153 (2019) 368-375].
    Gynecol Oncol. 2020 Jan 22. pii: S0090-8258(20)30069.
    PubMed    


  115. BOGANI G, Ditto A, Lopez S, Bertolina F, et al
    Adjuvant chemotherapy vs. observation in stage I clear cell ovarian carcinoma: A systematic review and meta-analysis.
    Gynecol Oncol. 2020 Jan 21. pii: S0090-8258(19)31875.
    PubMed     Abstract available


  116. TIMMERMAN S, Van Rompuy AS, Van Gorp T, Vanden Bempt I, et al
    Analysis of 108 patients with endometrial carcinoma using the PROMISE classification and additional genetic analyses for MMR-D.
    Gynecol Oncol. 2020 Jan 21. pii: S0090-8258(20)30061.
    PubMed     Abstract available


  117. SLOMOVITZ B, Gourley C, Carey MS, Malpica A, et al
    Low-grade serous ovarian cancer: State of the science.
    Gynecol Oncol. 2020 Jan 20. pii: S0090-8258(19)31862.
    PubMed     Abstract available


  118. LOOPIK DL, IntHout J, Ebisch RMF, Melchers WJG, et al
    The risk of cervical cancer after cervical intraepithelial neoplasia grade 3: A population-based cohort study with 80,442 women.
    Gynecol Oncol. 2020 Jan 20. pii: S0090-8258(20)30067.
    PubMed     Abstract available


  119. ENGERUD H, Berg HF, Myrvold M, Halle MK, et al
    High degree of heterogeneity of PD-L1 and PD-1 from primary to metastatic endometrial cancer.
    Gynecol Oncol. 2020 Jan 20. pii: S0090-8258(20)30062.
    PubMed     Abstract available


  120. FEKETE JT, Osz A, Pete I, Nagy GR, et al
    Predictive biomarkers of platinum and taxane resistance using the transcriptomic data of 1816 ovarian cancer patients.
    Gynecol Oncol. 2020 Jan 20. pii: S0090-8258(20)30006.
    PubMed     Abstract available


  121. NASIOUDIS D, Frey MK, Chapman-Davis E, Caputo TA, et al
    Primary malignant ovarian carcinoid; management and outcomes.
    Gynecol Oncol. 2020 Jan 17. pii: S0090-8258(20)30002.
    PubMed     Abstract available


  122. CADOO KA, Grisham RN, O'Cearbhaill RE, Boucicaut NN, et al
    A phase 1 dose-escalation study of intraperitoneal cisplatin, intravenous/intraperitoneal paclitaxel, bevacizumab, and olaparib for newly diagnosed ovarian cancer.
    Gynecol Oncol. 2020 Jan 17. pii: S0090-8258(20)30060.
    PubMed     Abstract available


  123. JUN F, Peng Z, Zhang Y, Shi D, et al
    Quantitative proteomic analysis identifies novel regulators of methotrexate resistance in choriocarcinoma.
    Gynecol Oncol. 2020 Jan 16. pii: S0090-8258(20)30020.
    PubMed     Abstract available


  124. PUROHIT S, Ferris DG, Alvarez M, Tran PMH, et al
    Better survival is observed in cervical cancer patients positive for specific anti-glycan antibodies and receiving brachytherapy.
    Gynecol Oncol. 2020 Jan 16. pii: S0090-8258(20)30023.
    PubMed     Abstract available


  125. ACOSTA-TORRES S, Fader AN
    Laparoscopic splenectomy for secondary cytoreduction of ovarian cancer in a woman with localized splenic recurrence.
    Gynecol Oncol. 2020 Jan 16. pii: S0090-8258(19)31842.
    PubMed     Abstract available


  126. VERGOTE I, Powell MA, Teneriello MG, Miller DS, et al
    Second-line lenvatinib in patients with recurrent endometrial cancer.
    Gynecol Oncol. 2020 Jan 16. pii: S0090-8258(19)31869.
    PubMed     Abstract available


  127. CHO HW, Ouh YT, Min KJ, Lee NW, et al
    The impact of previous cesarean section (C/S) on the risk for post-molar gestational trophoblastic neoplasia (GTN).
    Gynecol Oncol. 2020 Jan 15. pii: S0090-8258(19)31683.
    PubMed     Abstract available


  128. MERIDETH MA, Harney LA, Vyas N, Bachi A, et al
    Gynecologic and reproductive health in patients with pathogenic germline variants in DICER1.
    Gynecol Oncol. 2020 Jan 15. pii: S0090-8258(19)31867.
    PubMed     Abstract available


  129. LLAURADO FERNANDEZ M, Dawson A, Kim H, Lam N, et al
    Hormone receptor expression and outcomes in low-grade serous ovarian carcinoma.
    Gynecol Oncol. 2020 Jan 14. pii: S0090-8258(19)31680.
    PubMed     Abstract available


  130. GHIRARDI V, Moruzzi MC, Bizzarri N, Vargiu V, et al
    Minimal residual disease at primary debulking surgery versus complete tumor resection at interval debulking surgery in advanced epithelial ovarian cancer: A survival analysis.
    Gynecol Oncol. 2020 Jan 14. pii: S0090-8258(20)30017.
    PubMed     Abstract available


  131. BEAVIS AL, Yen TT, Stone RL, Wethington SL, et al
    Adjuvant therapy for early stage, endometrial cancer with lymphovascular space invasion: Is there a role for chemotherapy?
    Gynecol Oncol. 2020 Jan 13. pii: S0090-8258(19)31849.
    PubMed     Abstract available


  132. BIXEL K, Vetter M, Davidson B, Berchuck A, et al
    Intraperitoneal chemotherapy following neoadjuvant chemotherapy and optimal interval tumor reductive surgery for advanced ovarian cancer.
    Gynecol Oncol. 2020 Jan 11. pii: S0090-8258(19)31837.
    PubMed     Abstract available


  133. MORGAN RD, Banerjee S, Hall M, Clamp AR, et al
    Pazopanib and Fosbretabulin in recurrent ovarian cancer (PAZOFOS): A multi-centre, phase 1b and open-label, randomised phase 2 trial.
    Gynecol Oncol. 2020 Jan 10. pii: S0090-8258(20)30005.
    PubMed     Abstract available


  134. WHITCOMB B, Lutman C, Pearl M, Medlin E, et al
    Use of cannabinoids in cancer patients: A Society of Gynecologic Oncology (SGO) clinical practice statement.
    Gynecol Oncol. 2020 Jan 10. pii: S0090-8258(19)31805.
    PubMed    


  135. RAFFONE A, Travaglino A, Mascolo M, Carotenuto C, et al
    Histopathological characterization of ProMisE molecular groups of endometrial cancer.
    Gynecol Oncol. 2020 Jan 10. pii: S0090-8258(20)30008.
    PubMed     Abstract available


  136. STALEY SA, Tucker K, Newton M, Ertel M, et al
    Sarcopenia as a predictor of survival and chemotoxicity in patients with epithelial ovarian cancer receiving platinum and taxane-based chemotherapy.
    Gynecol Oncol. 2020 Jan 10. pii: S0090-8258(20)30003.
    PubMed     Abstract available


  137. IIHARA H, Shimokawa M, Hayasaki Y, Fujita Y, et al
    Efficacy and safety of 5 mg olanzapine combined with aprepitant, granisetron and dexamethasone to prevent carboplatin-induced nausea and vomiting in patients with gynecologic cancer: A multi-institution phase II study.
    Gynecol Oncol. 2020 Jan 9. pii: S0090-8258(20)30004.
    PubMed     Abstract available


  138. WANG D, Zhu S, Jia C, Cao D, et al
    Diagnosis and management of growing teratoma syndrome after ovarian immature teratoma: A single center experience.
    Gynecol Oncol. 2020 Jan 9. pii: S0090-8258(19)31872.
    PubMed     Abstract available


  139. MONK BJ, Herzog TJ, Wang G, Triantos S, et al
    A phase 3 randomized, open-label, multicenter trial for safety and efficacy of combined trabectedin and pegylated liposomal doxorubicin therapy for recurrent ovarian cancer.
    Gynecol Oncol. 2020 Jan 8. pii: S0090-8258(19)31873.
    PubMed     Abstract available


  140. BRANDT B, Sioulas V, Basaran D, Kuhn T, et al
    Minimally invasive surgery versus laparotomy for radical hysterectomy in the management of early-stage cervical cancer: Survival outcomes.
    Gynecol Oncol. 2020 Jan 7. pii: S0090-8258(19)31868.
    PubMed     Abstract available


  141. SIAMAKPOUR-REIHANI S, Cobb LP, Jiang C, Zhang D, et al
    Differential expression of immune related genes in high-grade ovarian serous carcinoma.
    Gynecol Oncol. 2020 Jan 7. pii: S0090-8258(19)31840.
    PubMed     Abstract available


  142. SANTIN AD, Deng W, Frumovitz M, Buza N, et al
    Phase II evaluation of nivolumab in the treatment of persistent or recurrent cervical cancer (NCT02257528/NRG-GY002).
    Gynecol Oncol. 2020 Jan 7. pii: S0090-8258(19)31864.
    PubMed     Abstract available


  143. SCHAD MD, Patel AK, Glaser SM, Balasubramani GK, et al
    Declining brachytherapy utilization for cervical cancer patients - Have we reversed the trend?
    Gynecol Oncol. 2020 Jan 7. pii: S0090-8258(19)31863.
    PubMed     Abstract available


  144. CHEN LM, Blank SV, Burton E, Glass K, et al
    Corrigendum to "Reproductive and hormonal considerations in women at increased risk for hereditary gynecologic cancers: Society of Gynecologic Oncology and American Society for reproductive medicine evidence-based review" [Gynecol. Oncol. 155 (2019) 5
    Gynecol Oncol. 2020 Jan 7. pii: S0090-8258(19)31850.
    PubMed    


  145. FRAUNE C, Rosebrock J, Simon R, Hube-Magg C, et al
    High homogeneity of MMR deficiency in ovarian cancer.
    Gynecol Oncol. 2020 Jan 7. pii: S0090-8258(19)31861.
    PubMed     Abstract available


  146. PEIRETTI M, Candotti G, Fais ML, Ricciardi E, et al
    Comparison between laparoscopy and laparotomy in the surgical re-staging of granulosa cell tumors of the ovary.
    Gynecol Oncol. 2020 Jan 7. pii: S0090-8258(19)31870.
    PubMed     Abstract available


  147. LIANG MI, Aviki EM, Wright JD, Havrilesky LJ, et al
    Society of gynecologic oncology future of physician payment reform task force: Lessons learned in developing and implementing surgical alternative payment models.
    Gynecol Oncol. 2020 Jan 6. pii: S0090-8258(19)31866.
    PubMed    


  148. BREWER M, Angioli R, Scambia G, Lorusso D, et al
    Front-line chemo-immunotherapy with carboplatin-paclitaxel using oregovomab indirect immunization in advanced ovarian cancer: A randomized phase II study.
    Gynecol Oncol. 2020 Jan 6. pii: S0090-8258(19)31845.
    PubMed     Abstract available


  149. TURNER TB, Kushner DM, Winkel AF, Oldham J, et al
    The Society of Gynecologic Oncology wellness curriculum pilot: A groundbreaking initiative for fellowship training.
    Gynecol Oncol. 2020 Jan 3. pii: S0090-8258(19)31797.
    PubMed     Abstract available


  150. HERZOG TJ, Secord AA, Coleman RL, Naumann RW, et al
    European society of medical oncology (ESMO) 2019 meeting report features practice changing data in gynecologic malignancies.
    Gynecol Oncol. 2020 Jan 3. pii: S0090-8258(19)31639.
    PubMed     Abstract available


  151. MULTINU F, Chen J, Madison JD, Torres M, et al
    Analysis of DNA methylation in endometrial biopsies to predict risk of endometrial cancer.
    Gynecol Oncol. 2020 Jan 2. pii: S0090-8258(19)31844.
    PubMed     Abstract available


  152. GORRINGE KL, Cheasley D, Wakefield MJ, Ryland GL, et al
    Therapeutic options for mucinous ovarian carcinoma.
    Gynecol Oncol. 2020 Jan 2. pii: S0090-8258(19)31836.
    PubMed     Abstract available


  153. VARGHESE A, Shih IM
    Not All Peritoneal Implants Are Created Equal.
    Gynecol Oncol. 2020;156:1-2.
    PubMed    


  154. CHODAVADIA PA, Jacobs CD, Wang F, Havrilesky LJ, et al
    Off-study utilization of experimental therapies: Analysis of GOG249-eligible cohorts using real world data.
    Gynecol Oncol. 2020;156:154-161.
    PubMed     Abstract available


  155. FROEDING LP, Hogdall C, Kristensen E, Zobbe V, et al
    Recurrence and survival rates in node negative patients after sentinel node biopsy for early-stage vulva cancer - A nationwide study.
    Gynecol Oncol. 2020;156:124-130.
    PubMed     Abstract available


  156. MHAWECH-FAUCEGLIA P, Izevbaye I, Spindler T, Wang G, et al
    Genomic heterogeneity in peritoneal implants: A differential analysis of gene expression using nanostring Human Cancer Reference panel identifies a malignant signature.
    Gynecol Oncol. 2020;156:6-12.
    PubMed     Abstract available


    December 2019
  157. JORGE S, McFaddin AS, Doll KM, Pennington KP, et al
    Simultaneous germline and somatic sequencing in ovarian carcinoma: mutation rate and impact on clinical decision-making.
    Gynecol Oncol. 2019 Dec 27. pii: S0090-8258(19)31802.
    PubMed     Abstract available


  158. SALMINEN L, Nadeem N, Jain S, Grenman S, et al
    A longitudinal analysis of CA125 glycoforms in the monitoring and follow up of high grade serous ovarian cancer.
    Gynecol Oncol. 2019 Dec 27. pii: S0090-8258(19)31846.
    PubMed     Abstract available


  159. WAMBECKE A, Ahmad M, Lambert B, Joly F, et al
    The influence of long non-coding RNAs on the response to chemotherapy in ovarian cancer.
    Gynecol Oncol. 2019 Dec 26. pii: S0090-8258(19)31841.
    PubMed     Abstract available


  160. JONES NL, Xiu J, Rocconi RP, Herzog TJ, et al
    Immune checkpoint expression, microsatellite instability, and mutational burden: Identifying immune biomarker phenotypes in uterine cancer.
    Gynecol Oncol. 2019 Dec 24. pii: S0090-8258(19)31694.
    PubMed     Abstract available


  161. KAY AH, Venn M, Urban R, Gray HJ, et al
    Postoperative narcotic use in patients with ovarian cancer on an Enhanced Recovery After Surgery (ERAS) pathway.
    Gynecol Oncol. 2019 Dec 24. pii: S0090-8258(19)31839.
    PubMed     Abstract available


  162. CONNOR YD, Miao D, Lin DI, Hayne C, et al
    Germline mutations of SMARCA4 in small cell carcinoma of the ovary, hypercalcemic type and in SMARCA4-deficient undifferentiated uterine sarcoma: Clinical features of a single family and comparison of large cohorts.
    Gynecol Oncol. 2019 Dec 21. pii: S0090-8258(19)31618.
    PubMed     Abstract available


  163. AREND RC, Davis AM, Chimiczewski P, O'Malley DM, et al
    EMR 20006-012: A phase II randomized double-blind placebo controlled trial comparing the combination of pimasertib (MEK inhibitor) with SAR245409 (PI3K inhibitor) to pimasertib alone in patients with previously treated unresectable borderline or low g
    Gynecol Oncol. 2019 Dec 20. pii: S0090-8258(19)31786.
    PubMed     Abstract available


  164. CLARK KT, Trimble CL
    Current status of therapeutic HPV vaccines.
    Gynecol Oncol. 2019 Dec 20. pii: S0090-8258(19)31838.
    PubMed     Abstract available


  165. VAZ J, Tian C, Richardson MT, Chan JK, et al
    Impact of adjuvant treatment and prognostic factors in stage I uterine leiomyosarcoma patients treated in Commission on Cancer(R)-accredited facilities.
    Gynecol Oncol. 2019 Dec 19. pii: S0090-8258(19)31800.
    PubMed     Abstract available


  166. VARELA CAGETTI L, Zemmour C, Minsat M, Lambaudie E, et al
    Lessons from radiochemotherapy and modern image-guided adaptive brachytherapy followed by hysterectomy.
    Gynecol Oncol. 2019 Dec 18. pii: S0090-8258(19)31785.
    PubMed     Abstract available


  167. MATSUO K, Machida H, Matsuzaki S, Grubbs BH, et al
    Evolving population-based statistics for rare epithelial ovarian cancers.
    Gynecol Oncol. 2019 Dec 18. pii: S0090-8258(19)31781.
    PubMed     Abstract available


  168. NAUMANN RW, Coleman RL, Brown J, Moore KN, et al
    Corrigendum to "Phase III trials in ovarian cancer: The evolving landscape of front line therapy" [Gynecol. Oncol. 153 (2019) 436-444].
    Gynecol Oncol. 2019 Dec 16. pii: S0090-8258(19)31799.
    PubMed    


  169. NASIOUDIS D, Latif NA, Simpkins F, Cory L, et al
    Adjuvant chemotherapy for early stage endometrioid ovarian carcinoma: An analysis of the National Cancer Data Base.
    Gynecol Oncol. 2019 Dec 13. pii: S0090-8258(19)31784.
    PubMed     Abstract available


  170. KOHUT A, Earnhardt MC, Cuccolo NG, Kim CS, et al
    Evaluating unplanned readmission and prolonged length of stay following minimally invasive surgery for endometrial cancer.
    Gynecol Oncol. 2019 Dec 13. pii: S0090-8258(19)31475.
    PubMed     Abstract available


  171. YANG J, Delara R, Magrina J, Magtibay P, et al
    Comparing survival outcomes between surgical and radiographic lymph node assessment in locally advanced cervical cancer: A propensity score-matched analysis.
    Gynecol Oncol. 2019 Dec 13. pii: S0090-8258(19)31801.
    PubMed     Abstract available


  172. KRILL L, Deng W, Eskander R, Mutch D, et al
    Overexpression of enhance of Zeste homolog 2 (EZH2) in endometrial carcinoma: An NRG Oncology/Gynecologic Oncology Group Study.
    Gynecol Oncol. 2019 Dec 13. pii: S0090-8258(19)31795.
    PubMed     Abstract available


  173. ZHANG H, Wu X, Xu Z, Sun Z, et al
    Impact of perioperative red blood cell transfusion on postoperative recovery and long-term outcome in patients undergoing surgery for ovarian cancer: A propensity score-matched analysis.
    Gynecol Oncol. 2019 Dec 12. pii: S0090-8258(19)31798.
    PubMed     Abstract available


  174. BALAYA V, Bresset A, Guani B, Magaud L, et al
    Risk factors for failure of bilateral sentinel lymph node mapping in early-stage cervical cancer.
    Gynecol Oncol. 2019 Dec 12. pii: S0090-8258(19)31614.
    PubMed     Abstract available


  175. PERES LC, Sinha S, Townsend MK, Fridley BL, et al
    Predictors of survival trajectories among women with epithelial ovarian cancer.
    Gynecol Oncol. 2019 Dec 12. pii: S0090-8258(19)31803.
    PubMed     Abstract available


  176. ZHANG W, Tan C, Xu M, Wu X, et al
    Primary appendiceal mucinous neoplasm: Gynecological manifestations, management, and prognosis.
    Gynecol Oncol. 2019 Dec 12. pii: S0090-8258(19)31681.
    PubMed     Abstract available


  177. KRIMMEL-MORRISON JD, Ghezelayagh TS, Lian S, Zhang Y, et al
    Characterization of TP53 mutations in Pap test DNA of women with and without serous ovarian carcinoma.
    Gynecol Oncol. 2019 Dec 12. pii: S0090-8258(19)31783.
    PubMed     Abstract available


  178. KIM S, Park J, Chen Y, Rowe K, et al
    Long-term diabetes risk among endometrial cancer survivors in a population-based cohort study.
    Gynecol Oncol. 2019 Dec 12. pii: S0090-8258(19)31598.
    PubMed     Abstract available


  179. CARLSON JW, Kauderer J, Hutson A, Carter J, et al
    GOG 244-The lymphedema and gynecologic cancer (LEG) study: Incidence and risk factors in newly diagnosed patients.
    Gynecol Oncol. 2019 Dec 11. pii: S0090-8258(19)31566.
    PubMed     Abstract available


  180. RONCOLATO FT, O'Connell RL, Joly F, Lanceley A, et al
    Predictors of progression free survival, overall survival and early cessation of chemotherapy in women with potentially platinum sensitive (PPS) recurrent ovarian cancer (ROC) starting third or subsequent line(>/=3) chemotherapy - The GCIG symptom
    Gynecol Oncol. 2019 Dec 10. pii: S0090-8258(19)31558.
    PubMed     Abstract available


  181. GRAUL A, Haggerty A, Stickley C, Kumar P, et al
    Effect of patient education on palliative care knowledge and acceptability of outpatient palliative care services among gynecologic oncology patients: A randomized controlled trial.
    Gynecol Oncol. 2019 Dec 9. pii: S0090-8258(19)31674.
    PubMed     Abstract available


  182. VERGOTE I, Bergfeldt K, Franquet A, Lisyanskaya AS, et al
    A randomized phase III trial in patients with recurrent platinum sensitive ovarian cancer comparing efficacy and safety of paclitaxel micellar and Cremophor EL-paclitaxel.
    Gynecol Oncol. 2019 Dec 9. pii: S0090-8258(19)31685.
    PubMed     Abstract available


  183. VERGOTE IB, Lund B, Peen U, Umajuridze Z, et al
    Phase 2 study of the Exportin 1 inhibitor selinexor in patients with recurrent gynecological malignancies.
    Gynecol Oncol. 2019 Dec 7. pii: S0090-8258(19)31663.
    PubMed     Abstract available


  184. GITTO SB, Kim H, Rafail S, Omran DK, et al
    An autologous humanized patient-derived-xenograft platform to evaluate immunotherapy in ovarian cancer.
    Gynecol Oncol. 2019 Dec 6. pii: S0090-8258(19)31568.
    PubMed     Abstract available


  185. FORSSE D, Tangen IL, Fasmer KE, Halle MK, et al
    Blood steroid levels predict survival in endometrial cancer and reflect tumor estrogen signaling.
    Gynecol Oncol. 2019 Dec 5. pii: S0090-8258(19)31782.
    PubMed     Abstract available


  186. PERKINS V, Moore K, Vesely S, Matsuo K, et al
    Incorporation of whole pelvic radiation into treatment of stage IVB cervical cancer: A novel treatment strategy.
    Gynecol Oncol. 2019 Dec 3. pii: S0090-8258(19)31620.
    PubMed     Abstract available


  187. KLAPHEKE AK, Keegan THM, Ruskin R, Cress RD, et al
    Changes in health-related quality of life in older women after diagnosis with gynecologic cancer.
    Gynecol Oncol. 2019 Dec 2. pii: S0090-8258(19)31684.
    PubMed     Abstract available


  188. LIANG C, Liu P, Cui Z, Liang Z, et al
    Effect of laparoscopic versus abdominal radical hysterectomy on major surgical complications in women with stage IA-IIB cervical cancer in China, 2004-2015.
    Gynecol Oncol. 2019 Dec 2. pii: S0090-8258(19)31619.
    PubMed     Abstract available


  189. HINCHCLIFF E, Jazaeri AA
    Sunset, or dawn of a new age for ovarian cancer vaccine therapy?
    Gynecol Oncol. 2019;155:387-388.
    PubMed    


    November 2019
  190. MYSONA DP, Tran LKH, Tran PMH, Gehrig PA, et al
    Clinical calculator predictive of chemotherapy benefit in stage 1A uterine papillary serous cancers.
    Gynecol Oncol. 2019 Nov 30. pii: S0090-8258(19)31601.
    PubMed     Abstract available


  191. HAN C, Perrone E, Zeybek B, Bellone S, et al
    In vitro and in vivo activity of sacituzumab govitecan, an antibody-drug conjugate targeting trophoblast cell-surface antigen 2 (Trop-2) in uterine serous carcinoma.
    Gynecol Oncol. 2019 Nov 30. pii: S0090-8258(19)31669.
    PubMed     Abstract available


  192. VERGOTE I, Heitz F, Buderath P, Powell M, et al
    A randomized, double-blind, placebo-controlled phase 1b/2 study of ralimetinib, a p38 MAPK inhibitor, plus gemcitabine and carboplatin versus gemcitabine and carboplatin for women with recurrent platinum-sensitive ovarian cancer.
    Gynecol Oncol. 2019 Nov 29. pii: S0090-8258(19)31627.
    PubMed     Abstract available


  193. SANGTANI A, Wang C, Weaver A, Hoppman NL, et al
    Combining copy number, methylation markers, and mutations as a panel for endometrial cancer detection via intravaginal tampon collection.
    Gynecol Oncol. 2019 Nov 28. pii: S0090-8258(19)31679.
    PubMed     Abstract available


  194. TAKAYA H, Nakai H, Sakai K, Nishio K, et al
    Intratumor heterogeneity and homologous recombination deficiency of high-grade serous ovarian cancer are associated with prognosis and molecular subtype and change in treatment course.
    Gynecol Oncol. 2019 Nov 27. pii: S0090-8258(19)31664.
    PubMed     Abstract available


  195. NARASIMHULU DM, Bews KA, Hanson KT, Chang YH, et al
    Using evidence to direct quality improvement efforts: Defining the highest impact complications after complex cytoreductive surgery for ovarian cancer.
    Gynecol Oncol. 2019 Nov 27. pii: S0090-8258(19)31628.
    PubMed     Abstract available


  196. KANAO H, Omi M, Takeshima N
    Step-by-step demonstration of laparoscopic laterally extended endopelvic resection for a recurrent endometrial cancerous tumor at a sciatic foramen, with a detailed explanation of the pelvic sidewall anatomy.
    Gynecol Oncol. 2019 Nov 27. pii: S0090-8258(19)31666.
    PubMed     Abstract available


  197. MATSUO K, Machida H, Grubbs BH, Matsuzaki S, et al
    Diagnosis-shift between low-grade serous ovarian cancer and serous borderline ovarian tumor: A population-based study.
    Gynecol Oncol. 2019 Nov 27. pii: S0090-8258(19)31482.
    PubMed     Abstract available


  198. LUHRS O, Ekdahl L, Lonnerfors C, Geppert B, et al
    Combining Indocyanine Green and Tc(99)-nanocolloid does not increase the detection rate of sentinel lymph nodes in early stage cervical cancer compared to Indocyanine Green alone.
    Gynecol Oncol. 2019 Nov 26. pii: S0090-8258(19)31677.
    PubMed     Abstract available


  199. LEITAO MM JR, Zhou QC, Gomez-Hidalgo NR, Iasonos A, et al
    Patient-reported outcomes after surgery for endometrial carcinoma: Prevalence of lower-extremity lymphedema after sentinel lymph node mapping versus lymphadenectomy.
    Gynecol Oncol. 2019 Nov 25. pii: S0090-8258(19)31624.
    PubMed     Abstract available


  200. CASARIN J, Song C, Multinu F, Cappuccio S, et al
    Implementing robotic surgery for uterine cancer in the United States: Better outcomes without increased costs.
    Gynecol Oncol. 2019 Nov 25. pii: S0090-8258(19)31667.
    PubMed     Abstract available


  201. GRIFFIN NE, Buchanan TR, Smith SH, Leon AA, et al
    Low rates of cascade genetic testing among families with hereditary gynecologic cancer: An opportunity to improve cancer prevention.
    Gynecol Oncol. 2019 Nov 25. pii: S0090-8258(19)31626.
    PubMed     Abstract available


  202. KIM J, Cho YJ, Ryu JY, Hwang I, et al
    CDK7 is a reliable prognostic factor and novel therapeutic target in epithelial ovarian cancer.
    Gynecol Oncol. 2019 Nov 24. pii: S0090-8258(19)31625.
    PubMed     Abstract available


  203. NGUYEN JMV, Bouchard-Fortier G, Covens A
    Same-day discharge of Gynecologic Oncology patients following ileostomy closure is feasible and safe.
    Gynecol Oncol. 2019 Nov 24. pii: S0090-8258(19)31665.
    PubMed     Abstract available


  204. GENTRY ZL, Boitano TKL, Smith HJ, Eads DK, et al
    The financial impact of an enhanced recovery after surgery (ERAS) protocol in an academic gynecologic oncology practice.
    Gynecol Oncol. 2019 Nov 24. pii: S0090-8258(19)31668.
    PubMed     Abstract available


  205. SCHLAPPE BA, Weaver AL, McGree ME, Ducie J, et al
    Multicenter study comparing oncologic outcomes after lymph node assessment via a sentinel lymph node algorithm versus comprehensive pelvic and paraaortic lymphadenectomy in patients with serous and clear cell endometrial carcinoma.
    Gynecol Oncol. 2019 Nov 24. pii: S0090-8258(19)31623.
    PubMed     Abstract available


  206. LIANG MI, Pisu M, Summerlin SS, Boitano TKL, et al
    Extensive financial hardship among gynecologic cancer patients starting a new line of therapy.
    Gynecol Oncol. 2019 Nov 23. pii: S0090-8258(19)31673.
    PubMed     Abstract available


  207. MACHIDA H, Iwata T, Okugawa K, Matsuo K, et al
    Fertility-sparing trachelectomy for early-stage cervical cancer: A proposal of an ideal candidate.
    Gynecol Oncol. 2019 Nov 23. pii: S0090-8258(19)31672.
    PubMed     Abstract available


  208. OSTBY SA, Evans JG, Smith HJ, Boitano TKL, et al
    Reducing emergency department (ED) computed tomography (CT) utilization in women treated for gynecologic cancers.
    Gynecol Oncol. 2019 Nov 22. pii: S0090-8258(19)31675.
    PubMed     Abstract available


  209. COLLINS A, Miles GJ, Wood J, MacFarlane M, et al
    Patient-derived explants, xenografts and organoids: 3-dimensional patient-relevant pre-clinical models in endometrial cancer.
    Gynecol Oncol. 2019 Nov 22. pii: S0090-8258(19)31671.
    PubMed     Abstract available


  210. MAI PL, Huang HQ, Wenzel LB, Han PK, et al
    Prospective follow-up of quality of life for participants undergoing risk-reducing salpingo-oophorectomy or ovarian cancer screening in GOG-0199: An NRG Oncology/GOG study.
    Gynecol Oncol. 2019 Nov 21. pii: S0090-8258(19)31613.
    PubMed     Abstract available


  211. DONKERS H, Bekkers R, Massuger L, Galaal K, et al
    Socioeconomic deprivation and survival in endometrial cancer: The effect of BMI.
    Gynecol Oncol. 2019 Nov 20. pii: S0090-8258(19)31617.
    PubMed     Abstract available


  212. HIROSE S, Murakami N, Takahashi K, Kuno I, et al
    Genomic alterations in STK11 can predict clinical outcomes in cervical cancer patients.
    Gynecol Oncol. 2019 Nov 19. pii: S0090-8258(19)31606.
    PubMed     Abstract available


  213. STASENKO M, Tunnage I, Ashley CW, Rubinstein MM, et al
    Clinical outcomes of patients with POLE mutated endometrioid endometrial cancer.
    Gynecol Oncol. 2019 Nov 19. pii: S0090-8258(19)31615.
    PubMed     Abstract available


  214. LE PAGE C, Rahimi K, Rodrigues M, Heinzelmann-Schwarz V, et al
    Clinicopathological features of women with epithelial ovarian cancer and double heterozygosity for BRCA1 and BRCA2: A systematic review and case report analysis.
    Gynecol Oncol. 2019 Nov 18. pii: S0090-8258(19)31670.
    PubMed     Abstract available


  215. MCCOMAS KN, Torgeson AM, Ager BJ, Hellekson C, et al
    The variable impact of positive lymph nodes in cervical cancer: Implications of the new FIGO staging system.
    Gynecol Oncol. 2019 Nov 16. pii: S0090-8258(19)31609.
    PubMed     Abstract available


  216. RODRIGUEZ-FREIXINOS V, Farinas-Madrid L, Gil-Martin M, Barretina-Ginesta P, et al
    Corrigendum to 'Chemotherapy and PARP inhibitors in heavily pretreated BRCA1/2 mutation ovarian cancer (BMOC) patients' [Gynecologic Oncology 152 (2019) 270-277].
    Gynecol Oncol. 2019 Nov 16. pii: S0090-8258(19)31604.
    PubMed    


  217. BASARAN D, Bruce S, Aviki EM, Mueller JJ, et al
    Sentinel lymph node mapping alone compared to more extensive lymphadenectomy in patients with uterine serous carcinoma.
    Gynecol Oncol. 2019 Nov 15. pii: S0090-8258(19)31562.
    PubMed     Abstract available


  218. TAYLOR SE, Chu T, Elvin JA, Edwards RP, et al
    Phase II study of everolimus and bevacizumab in recurrent ovarian, peritoneal, and fallopian tube cancer.
    Gynecol Oncol. 2019 Nov 15. pii: S0090-8258(19)31616.
    PubMed     Abstract available


  219. NISHIKIMI K, Tate S, Matsuoka A, Shozu M, et al
    Learning curve of high-complexity surgery for advanced ovarian cancer.
    Gynecol Oncol. 2019 Nov 14. pii: S0090-8258(19)31621.
    PubMed     Abstract available


  220. CLARKE MA, Long BJ, Sherman ME, Lemens MA, et al
    A prospective clinical cohort study of women at increased risk for endometrial cancer.
    Gynecol Oncol. 2019 Nov 9. pii: S0090-8258(19)31534.
    PubMed     Abstract available


  221. GAGNO S, Poletto E, Bartoletti M, Quartuccio L, et al
    A TGF-beta associated genetic score to define prognosis and platinum sensitivity in advanced epithelial ovarian cancer.
    Gynecol Oncol. 2019 Nov 8. pii: S0090-8258(19)31603.
    PubMed     Abstract available


  222. MOORE KN, Miller A, Bell-McGuinn KM, Schilder RJ, et al
    A phase I study of intravenous or intraperitoneal platinum based chemotherapy in combination with veliparib and bevacizumab in newly diagnosed ovarian, primary peritoneal and fallopian tube cancer.
    Gynecol Oncol. 2019 Nov 7. pii: S0090-8258(19)31569.
    PubMed     Abstract available


  223. ALIMUJIANG A, Khoja L, Wiensch A, Pike MC, et al
    "I am not a statistic" ovarian cancer survivors' views of factors that influenced their long-term survival.
    Gynecol Oncol. 2019 Nov 6. pii: S0090-8258(19)31564.
    PubMed     Abstract available


  224. HARRIS KL, Maurer KA, Jarboe E, Werner TL, et al
    LVSI positive and NX in early endometrial cancer: Surgical restaging (and no further treatment if N0), or adjuvant ERT?
    Gynecol Oncol. 2019 Nov 5. pii: S0090-8258(19)31537.
    PubMed     Abstract available


  225. FEHNIGER JE, Berger AA, Juckett L, Elvin J, et al
    Comprehensive genomic sequencing of paired ovarian cancers reveals discordance in genes that determine clinical trial eligibility.
    Gynecol Oncol. 2019 Nov 5. pii: S0090-8258(19)31561.
    PubMed     Abstract available


  226. CECERE SC, Giannone G, Salutari V, Arenare L, et al
    Olaparib as maintenance therapy in patients with BRCA 1-2 mutated recurrent platinum sensitive ovarian cancer: Real world data and post progression outcome.
    Gynecol Oncol. 2019 Nov 4. pii: S0090-8258(19)31607.
    PubMed     Abstract available


  227. WORMALD BW, Doran SJ, Ind TE, D'Arcy J, et al
    Radiomic features of cervical cancer on T2-and diffusion-weighted MRI: Prognostic value in low-volume tumors suitable for trachelectomy.
    Gynecol Oncol. 2019 Nov 1. pii: S0090-8258(19)31567.
    PubMed     Abstract available


  228. FERRISS JS, Fader AN
    Enough already: Is this the end of comprehensive lymphadenectomy in endometrial cancer or are further trials needed?
    Gynecol Oncol. 2019;155:175-176.
    PubMed    


  229. MALAGON T, Louvanto K, Ramanakumar AV, Koushik A, et al
    Viral load of human papillomavirus types 16/18/31/33/45 as a predictor of cervical intraepithelial neoplasia and cancer by age.
    Gynecol Oncol. 2019;155:245-253.
    PubMed     Abstract available


  230. WANG W, Liu X, Hou X, Lian X, et al
    Posttreatment squamous cell carcinoma antigen predicts treatment failure in patients with cervical squamous cell carcinoma treated with concurrent chemoradiotherapy.
    Gynecol Oncol. 2019;155:224-228.
    PubMed     Abstract available


  231. BEIRNE JP, McArt DG, Roddy A, McDermott C, et al
    Defining the molecular evolution of extrauterine high grade serous carcinoma.
    Gynecol Oncol. 2019;155:305-317.
    PubMed     Abstract available


  232. ONG PY, Poon SL, Tan KT, Putti TC, et al
    Using next-generation sequencing (NGS) platform to diagnose pathogenic germline BRCA1/2 mutations from archival tumor specimens.
    Gynecol Oncol. 2019;155:275-279.
    PubMed     Abstract available


  233. BI J, Areecheewakul S, Li Y, Yang S, et al
    MTDH/AEG-1 downregulation using pristimerin-loaded nanoparticles inhibits Fanconi anemia proteins and increases sensitivity to platinum-based chemotherapy.
    Gynecol Oncol. 2019;155:349-358.
    PubMed     Abstract available


  234. KHADRAOUI W, Zeybek B, Mutlu L, Menderes G, et al
    Robotic type II B posterior exenteration for recurrent vaginal cancer.
    Gynecol Oncol. 2019;155:384-385.
    PubMed     Abstract available


    October 2019
  235. CARTER J, Huang HQ, Armer J, Carlson JW, et al
    GOG 244 - The LymphEdema and Gynecologic cancer (LEG) study: The association between the gynecologic cancer lymphedema questionnaire (GCLQ) and lymphedema of the lower extremity (LLE).
    Gynecol Oncol. 2019 Oct 31. pii: S0090-8258(19)31539.
    PubMed     Abstract available


  236. LORUSSO D, Ferrandina G, Colombo N, Pignata S, et al
    Carboplatin-paclitaxel compared to Carboplatin-Paclitaxel-Bevacizumab in advanced or recurrent endometrial cancer: MITO END-2 - A randomized phase II trial.
    Gynecol Oncol. 2019 Oct 30. pii: S0090-8258(19)31596.
    PubMed     Abstract available


  237. ZHOU JG, Zhao HT, Jin SH, Tian X, et al
    Identification of a RNA-seq-based signature to improve prognostics for uterine sarcoma.
    Gynecol Oncol. 2019 Oct 26. pii: S0090-8258(19)31485.
    PubMed     Abstract available


  238. O'CEARBHAILL RE, Deng W, Chen LM, Lucci JA 3rd, et al
    A phase II randomized, double-blind trial of a polyvalent Vaccine-KLH conjugate (NSC 748933 IND# 14384) + OPT-821 versus OPT-821 in patients with epithelial ovarian, fallopian tube, or peritoneal cancer who are in second or third complete remission: A
    Gynecol Oncol. 2019 Oct 22. pii: S0090-8258(19)31536.
    PubMed     Abstract available


  239. ALLDREDGE J, Serna-Gallegos T, Gallegos N, VanLeer JP, et al
    Evaluation of clear cell subtypes of ovarian and uterine malignancies with anti-PD-L1 and anti-PD1 immunohistochemical expression and their association with stage and survival.
    Gynecol Oncol. 2019 Oct 22. pii: S0090-8258(19)31565.
    PubMed    


  240. ISHIKAWA M, Kasamatsu T, Tsuda H, Fukunaga M, et al
    A multi-center retrospective study of neuroendocrine tumors of the uterine cervix: Prognosis according to the new 2018 staging system, comparing outcomes for different chemotherapeutic regimens and histopathological subtypes.
    Gynecol Oncol. 2019 Oct 18. pii: S0090-8258(19)31540.
    PubMed     Abstract available


  241. WESTIN SN, Sill MW, Coleman RL, Waggoner S, et al
    Safety lead-in of the MEK inhibitor trametinib in combination with GSK2141795, an AKT inhibitor, in patients with recurrent endometrial cancer: An NRG Oncology/GOG study.
    Gynecol Oncol. 2019 Oct 15. pii: S0090-8258(19)31548.
    PubMed     Abstract available


  242. TATEBE K, Hasan Y, Son CH
    Adjuvant vaginal brachytherapy and chemotherapy versus pelvic radiotherapy in early-stage endometrial cancer: Outcomes by risk factors.
    Gynecol Oncol. 2019 Oct 11. pii: S0090-8258(19)31541.
    PubMed     Abstract available


  243. BAIOCCHI G, Salani R
    Meeting report from the 19th meeting of the International Gynecologic Cancer Society (IGCS) 2019: Summary of selected abstracts and meeting highlights.
    Gynecol Oncol. 2019 Oct 10. pii: S0090-8258(19)31563.
    PubMed    


  244. MARCHETTI C, Rosati A, Scaletta G, Pietragalla A, et al
    Secondary cytoreductive surgery in platinum-sensitive recurrent ovarian cancer before olaparib maintenance: Still getting any benefit? A case-control study.
    Gynecol Oncol. 2019 Oct 9. pii: S0090-8258(19)31545.
    PubMed     Abstract available


  245. VAN KOL KGG, Vergeldt TFM, Bekkers RLM
    Abdominal radical trachelectomy versus chemotherapy followed by vaginal radical trachelectomy in stage 1B2 (FIGO 2018) cervical cancer. A systematic review on fertility and recurrence rates.
    Gynecol Oncol. 2019 Oct 9. pii: S0090-8258(19)31546.
    PubMed     Abstract available


  246. MULTINU F, Ducie JA, Eriksson AGZ, Schlappe BA, et al
    Role of lymphadenectomy in endometrial cancer with nonbulky lymph node metastasis: Comparison of comprehensive surgical staging and sentinel lymph node algorithm.
    Gynecol Oncol. 2019 Oct 8. pii: S0090-8258(19)31531.
    PubMed     Abstract available


  247. KURODA T, Ogiwara H, Sasaki M, Takahashi K, et al
    Therapeutic preferability of gemcitabine for ARID1A-deficient ovarian clear cell carcinoma.
    Gynecol Oncol. 2019 Oct 8. pii: S0090-8258(19)31559.
    PubMed     Abstract available


  248. LABIDI-GALY SI, de La Motte Rouge T, Derbel O, Wolfer A, et al
    Clinical factors associated with prolonged response and survival under olaparib as maintenance therapy in BRCA mutated ovarian cancers.
    Gynecol Oncol. 2019 Oct 8. pii: S0090-8258(19)31528.
    PubMed     Abstract available


  249. BERG T, Nottrup TJ, Roed H
    Gemcitabine for recurrent ovarian cancer - a systematic review and meta-analysis.
    Gynecol Oncol. 2019 Oct 8. pii: S0090-8258(19)31547.
    PubMed     Abstract available


  250. TAYLAN E, Oktay K
    Fertility preservation in gynecologic cancers.
    Gynecol Oncol. 2019 Oct 8. pii: S0090-8258(19)31532.
    PubMed     Abstract available


  251. WU P, Xiong H, Yang M, Li L, et al
    Co-infections of HPV16/18 with other high-risk HPV types and the risk of cervical carcinogenesis: A large population-based study.
    Gynecol Oncol. 2019 Oct 8. pii: S0090-8258(19)31560.
    PubMed     Abstract available


  252. CHO EJ, Chun SM, Park H, Sung CO, et al
    Whole transcriptome analysis of gestational trophoblastic neoplasms reveals altered PI3K signaling pathway in epithelioid trophoblastic tumor.
    Gynecol Oncol. 2019 Oct 8. pii: S0090-8258(19)31542.
    PubMed     Abstract available


  253. RAKOWSKI JA, Holloway RW, Ahmad S, Jeppson CN, et al
    A prospective randomized trial of intravenous ketorolac vs. acetaminophen administered with opioid patient-controlled analgesia in gynecologic surgery.
    Gynecol Oncol. 2019 Oct 7. pii: S0090-8258(19)31543.
    PubMed     Abstract available


  254. NOMURA H, Aoki D, Susumu N, Mizuno M, et al
    Analysis of the relapse patterns and risk factors of endometrial cancer following postoperative adjuvant chemotherapy in a phase III randomized clinical trial.
    Gynecol Oncol. 2019 Oct 7. pii: S0090-8258(19)31544.
    PubMed     Abstract available


  255. ELIAS KM, Berkowitz RS, Horowitz NS
    Continued hCG surveillance following chemotherapy for gestational trophoblastic neoplasia: When is enough enough?
    Gynecol Oncol. 2019;155:1-2.
    PubMed    


  256. NICA A, Covens A, Vicus D, Kupets R, et al
    Long term outcomes in patients with sentinel lymph nodes (SLNs) identified by injecting remaining scar after previously excised vulvar cancer.
    Gynecol Oncol. 2019;155:83-87.
    PubMed     Abstract available


  257. BUCHANAN TR, Zamorano AS, Massad LS, Liu J, et al
    Risk of cervical and vaginal dysplasia after surgery for vulvar intraepithelial neoplasia or cancer: A 6year follow-up study.
    Gynecol Oncol. 2019;155:88-92.
    PubMed     Abstract available


  258. GULERIA C, Suri V, Kapoor R, Minz RW, et al
    Human papillomavirus 16 infection alters the Toll-like receptors and downstream signaling cascade: A plausible early event in cervical squamous cell carcinoma development.
    Gynecol Oncol. 2019;155:151-160.
    PubMed     Abstract available


    September 2019
  259. HOFFMAN MS, Xiong Y, Apte S, Roberts W, et al
    Twenty-year surgical trends in a gynecologic oncology fellowship training program: Implications for practice.
    Gynecol Oncol. 2019 Sep 28. pii: S0090-8258(19)31533.
    PubMed     Abstract available


  260. DIOUN SM, Vilardo N, Goldberg GL, Gressel GM, et al
    Necessity of routine cardiac evaluation in patients receiving pegylated liposomal doxorubicin for gynecologic cancer.
    Gynecol Oncol. 2019 Sep 28. pii: S0090-8258(19)31529.
    PubMed     Abstract available


  261. WONG JWH, Killeen JL, Carney ME
    Completeness of salpingectomy intended for ovarian cancer risk reduction.
    Gynecol Oncol. 2019 Sep 12. pii: S0090-8258(19)31523.
    PubMed     Abstract available


  262. DOCKERY LE, Rubenstein AR, Ding K, Mashburn SG, et al
    Extending the platinum-free interval: The impact of omitting 2nd line platinum chemotherapy in intermediate platinum-sensitive ovarian cancer.
    Gynecol Oncol. 2019 Sep 12. pii: S0090-8258(19)31394.
    PubMed     Abstract available


  263. HIMOTO Y, Cybulska P, Shitano F, Sala E, et al
    Does the method of primary treatment affect the pattern of first recurrence in high-grade serous ovarian cancer?
    Gynecol Oncol. 2019 Sep 11. pii: S0090-8258(19)31462.
    PubMed     Abstract available


  264. VERGOTE I, du Bois A, Floquet A, Rau J, et al
    Overall survival results of AGO-OVAR16: A phase 3 study of maintenance pazopanib versus placebo in women who have not progressed after first-line chemotherapy for advanced ovarian cancer.
    Gynecol Oncol. 2019 Sep 10. pii: S0090-8258(19)31476.
    PubMed     Abstract available


  265. SCHLECHTWEG K, Chen L, St Clair CM, Tergas AI, et al
    Neuroendocrine carcinoma of the endometrium: Disease course, treatment, and outcomes.
    Gynecol Oncol. 2019 Sep 10. pii: S0090-8258(19)31522.
    PubMed     Abstract available


  266. SWAILES A, Gupta M, Chauhan SP, Kesterson J, et al
    Factors associated with the successful completion of randomized controlled trials in gynecological oncology.
    Gynecol Oncol. 2019 Sep 10. pii: S0090-8258(19)31527.
    PubMed     Abstract available


  267. OLAWAIYE AB, Leath CA 3rd
    Contemporary management of uterine clear cell carcinoma: A Society of Gynecologic Oncology (SGO) review and recommendation.
    Gynecol Oncol. 2019 Sep 6. pii: S0090-8258(19)31483.
    PubMed     Abstract available


  268. SIMS TT, Colbert LE, Zheng J, Delgado Medrano AY, et al
    Gut microbial diversity and genus-level differences identified in cervical cancer patients versus healthy controls.
    Gynecol Oncol. 2019 Sep 6. pii: S0090-8258(19)31489.
    PubMed     Abstract available


  269. GRONWALD J, Lubinski J, Huzarski T, Cybulski C, et al
    A comparison of ovarian cancer mortality in women with BRCA1 mutations undergoing annual ultrasound screening or preventive oophorectomy.
    Gynecol Oncol. 2019 Sep 6. pii: S0090-8258(19)31486.
    PubMed     Abstract available


  270. MICHELS KA, McNeel TS, Trabert B
    Metabolic syndrome and risk of ovarian and fallopian tube cancer in the United States: An analysis of linked SEER-Medicare data.
    Gynecol Oncol. 2019 Sep 5. pii: S0090-8258(19)31484.
    PubMed     Abstract available


  271. HOLLIS RL, Stanley B, Iida Y, Thomson J, et al
    Hormone receptor expression patterns define clinically meaningful subgroups of endometrioid ovarian carcinoma.
    Gynecol Oncol. 2019 Sep 5. pii: S0090-8258(19)31487.
    PubMed     Abstract available


  272. JOHANSEN G, Dahm-Kahler P, Staf C, Floter Radestad A, et al
    Fertility-sparing surgery for treatment of non-epithelial ovarian cancer: Oncological and reproductive outcomes in a prospective nationwide population-based cohort study.
    Gynecol Oncol. 2019 Sep 4. pii: S0090-8258(19)31469.
    PubMed     Abstract available


  273. MAKII C, Ikeda Y, Oda K, Uehara Y, et al
    Anti-tumor activity of dual inhibition of phosphatidylinositol 3-kinase and MDM2 against clear cell ovarian carcinoma.
    Gynecol Oncol. 2019 Sep 4. pii: S0090-8258(19)31480.
    PubMed     Abstract available


  274. AHMAD TR, Chen LM, Chapman JS, Chen LL, et al
    Medicaid and Medicare payer status are associated with worse surgical outcomes in gynecologic oncology.
    Gynecol Oncol. 2019 Sep 3. pii: S0090-8258(19)31465.
    PubMed     Abstract available


  275. KAY AH, Urban RR, Gray HJ
    Intraperitoneal ports placed at the time of bowel resection for treatment of ovarian cancer: Complications and surgical outcomes.
    Gynecol Oncol. 2019 Sep 3. pii: S0090-8258(19)31472.
    PubMed     Abstract available


  276. MCALPINE JN, Gilks CB
    Precision medicine in endometrial cancer.
    Gynecol Oncol. 2019;154:451-453.
    PubMed    


  277. WOELBER L, Eulenburg C, Kosse J, Neuser P, et al
    Predicting the course of disease in recurrent vulvar cancer - A subset analysis of the AGO-CaRE-1 study.
    Gynecol Oncol. 2019;154:571-576.
    PubMed     Abstract available


  278. CHAE SH, Shim SH, Chang M, Choi AY, et al
    Effect of adjuvant therapy on the risk of recurrence in early-stage leiomyosarcoma: A meta-analysis.
    Gynecol Oncol. 2019;154:638-650.
    PubMed     Abstract available


  279. PARRA SG, Rodriguez AM, Cherry KD, Schwarz RA, et al
    Low-cost, high-resolution imaging for detecting cervical precancer in medically-underserved areas of Texas.
    Gynecol Oncol. 2019;154:558-564.
    PubMed     Abstract available


  280. CAPOZZI VA, Ceni V, Sozzi G, Cianciolo A, et al
    Endoscopic near infrared and indocyanine green to verify the viability of the subcutaneous flap for vulvar cancer.
    Gynecol Oncol. 2019;154:653-654.
    PubMed     Abstract available


  281. KLAPDOR R, Wolber L, Hanker L, Schmalfeldt B, et al
    Predictive factors for lymph node metastases in vulvar cancer. An analysis of the AGO-CaRE-1 multicenter study.
    Gynecol Oncol. 2019;154:565-570.
    PubMed     Abstract available


    August 2019
  282. TOZZI R, Traill Z, Campanile RG, Kilic Y, et al
    Diagnostic flow-chart to identify bowel involvement in patients with stage IIIC-IV ovarian cancer: Can laparoscopy improve the accuracy of CT scan?
    Gynecol Oncol. 2019 Aug 31. pii: S0090-8258(19)31477.
    PubMed     Abstract available


  283. BJURBERG M, Holmberg E, Borgfeldt C, Floter-Radestad A, et al
    Primary treatment patterns and survival of cervical cancer in Sweden: A population-based Swedish Gynecologic Cancer Group Study.
    Gynecol Oncol. 2019 Aug 30. pii: S0090-8258(19)31474.
    PubMed     Abstract available


  284. ELZAKKERS JCJ, van der Aa MA, van Altena AM, de Hullu JA, et al
    Further insights into the role of tumour characteristics in survival of young women with epithelial ovarian cancer.
    Gynecol Oncol. 2019 Aug 30. pii: S0090-8258(19)31470.
    PubMed     Abstract available


  285. RADER JS, Pan A, Corbin B, Iden M, et al
    Identification and validation of a prognostic proteomic signature for cervical cancer.
    Gynecol Oncol. 2019 Aug 30. pii: S0090-8258(19)31473.
    PubMed     Abstract available


  286. HIRAO N, Iwata T, Tanaka K, Nishio H, et al
    Transcription factor homeobox D9 is involved in the malignant phenotype of cervical cancer through direct binding to the human papillomavirus oncogene promoter.
    Gynecol Oncol. 2019 Aug 30. pii: S0090-8258(19)31478.
    PubMed     Abstract available


  287. RAFFONE A, Travaglino A, Mascolo M, Carbone L, et al
    TCGA molecular groups of endometrial cancer: Pooled data about prognosis.
    Gynecol Oncol. 2019 Aug 29. pii: S0090-8258(19)31471.
    PubMed     Abstract available


  288. LONG ROCHE K, Gardner GJ
    State of the science: Evolving role of surgery for the treatment of ovarian cancer.
    Gynecol Oncol. 2019 Aug 28. pii: S0090-8258(19)31468.
    PubMed    


  289. CHEN LM, Blank SV, Burton E, Glass K, et al
    Reproductive and Hormonal Considerations in Women at Increased Risk for Hereditary Gynecologic Cancers: Society of Gynecologic Oncology and American Society for Reproductive Medicine Evidence-Based Review.
    Gynecol Oncol. 2019 Aug 22. pii: S0090-8258(19)31333.
    PubMed     Abstract available


  290. SHUKLA V, Varghese VK, Kabekkodu SP, Mallya S, et al
    Enumeration of deregulated miRNAs in liquid and tissue biopsies of cervical cancer.
    Gynecol Oncol. 2019 Aug 18. pii: S0090-8258(19)31463.
    PubMed     Abstract available


  291. BIANCHI A, Lopez S, Altwerger G, Bellone S, et al
    PARP-1 activity (PAR) determines the sensitivity of cervical cancer to olaparib.
    Gynecol Oncol. 2019 Aug 18. pii: S0090-8258(19)31461.
    PubMed     Abstract available


  292. MATSUO K, Cripe JC, Kurnit KC, Kaneda M, et al
    Recurrence, death, and secondary malignancy after ovarian conservation for young women with early-stage low-grade endometrial cancer.
    Gynecol Oncol. 2019 Aug 16. pii: S0090-8258(19)31458.
    PubMed     Abstract available


  293. LITTELL RD, Kumar A, Einstein MH, Karam A, et al
    Advanced communication: A critical component of high quality gynecologic cancer care: A Society of Gynecologic Oncology evidence based review and guide.
    Gynecol Oncol. 2019 Aug 16. pii: S0090-8258(19)31450.
    PubMed     Abstract available


  294. LIU YL, Zhou Q, Iasonos A, Emengo VN, et al
    Subsequent therapies and survival after immunotherapy in recurrent ovarian cancer.
    Gynecol Oncol. 2019 Aug 14. pii: S0090-8258(19)31457.
    PubMed     Abstract available


  295. WEBBER K, Carolus E, Mileshkin L, Sommeijer D, et al
    OVQUEST - Life after the diagnosis and treatment of ovarian cancer - An international survey of symptoms and concerns in ovarian cancer survivors.
    Gynecol Oncol. 2019 Aug 12. pii: S0090-8258(19)31460.
    PubMed     Abstract available


  296. KILTS TP, Glaser GE, Langstraat CL, Kumar A, et al
    Comparing risk stratification criteria for predicting lymphatic dissemination in endometrial cancer.
    Gynecol Oncol. 2019 Aug 10. pii: S0090-8258(19)31456.
    PubMed     Abstract available


  297. WADE KNS, Brady MF, Thai T, Wang Y, et al
    Measurements of adiposity as prognostic biomarkers for survival with anti-angiogenic treatment in epithelial ovarian cancer: An NRG Oncology/Gynecologic Oncology Group ancillary data analysis of GOG 218.
    Gynecol Oncol. 2019 Aug 10. pii: S0090-8258(19)31409.
    PubMed     Abstract available


  298. WESTON E, Raker C, Huang D, Parker A, et al
    Opioid use after minimally invasive hysterectomy in gynecologic oncology patients.
    Gynecol Oncol. 2019 Aug 9. pii: S0090-8258(19)31453.
    PubMed     Abstract available


  299. TORTORELLA L, Casarin J, Multinu F, Cappuccio S, et al
    Sentinel lymph node biopsy with cervical injection of indocyanine green in apparent early-stage endometrial cancer: predictors of unsuccessful mapping.
    Gynecol Oncol. 2019 Aug 8. pii: S0090-8258(19)31459.
    PubMed     Abstract available


  300. NARASIMHULU DM, Kumar A, Weaver AL, McGree ME, et al
    Using an evidence-based triage algorithm to reduce 90-day mortality after primary debulking surgery for advanced epithelial ovarian cancer.
    Gynecol Oncol. 2019 Aug 8. pii: S0090-8258(19)31455.
    PubMed     Abstract available


  301. LATHAM AH, Chen L, Hou JY, Tergas AI, et al
    Sequencing of therapy in women with stage III endometrial carcinoma receiving adjuvant combination chemotherapy and radiation.
    Gynecol Oncol. 2019 Aug 6. pii: S0090-8258(19)31410.
    PubMed     Abstract available


  302. ZAMORANO AS, Hagemann AR, Morrison L, Lee JA, et al
    Pre-diagnosis body mass index, physical activity and ovarian cancer mortality.
    Gynecol Oncol. 2019 Aug 2. pii: S0090-8258(19)31449.
    PubMed     Abstract available


  303. KIM SI, Lee M, Lee S, Suh DH, et al
    Impact of laparoscopic radical hysterectomy on survival outcome in patients with FIGO stage IB cervical cancer: A matching study of two institutional hospitals in Korea.
    Gynecol Oncol. 2019 Aug 2. pii: S0090-8258(19)31408.
    PubMed     Abstract available


  304. PUECHL AM, Chino F, Havrilesky LJ, Davidson BA, et al
    Place of death by region and urbanization among gynecologic cancer patients: 2006-2016.
    Gynecol Oncol. 2019 Aug 1. pii: S0090-8258(19)31402.
    PubMed     Abstract available


  305. KAHR HS, Christiansen OB, Hogdall C, Grove A, et al
    Endometrial cancer does not increase the 30-day risk of venous thromboembolism following hysterectomy compared to benign disease. A Danish National Cohort Study.
    Gynecol Oncol. 2019 Aug 1. pii: S0090-8258(19)31411.
    PubMed     Abstract available


  306. DUDLEY S, Viswanathan A
    Margins in vulvar cancer: challenges to classical clinicopathologic vulvar recurrence risk factors.
    Gynecol Oncol. 2019;154:253-254.
    PubMed    


  307. BEDELL SM, Hedberg C, Griffin A, Pearson H, et al
    Role of adjuvant radiation or re-excision for early stage vulvar squamous cell carcinoma with positive or close surgical margins.
    Gynecol Oncol. 2019;154:276-279.
    PubMed     Abstract available


  308. SALYER C, Kobelka C, Barrie A, Weintraub MR, et al
    Clinical characteristics and outcomes in elderly women with BRCA1 and BRCA2 mutations.
    Gynecol Oncol. 2019;154:374-378.
    PubMed     Abstract available


  309. TE GROOTENHUIS NC, Pouwer AW, de Bock GH, Hollema H, et al
    Margin status revisited in vulvar squamous cell carcinoma.
    Gynecol Oncol. 2019;154:266-275.
    PubMed     Abstract available


    July 2019
  310. BALACHANDRAN K, Salawu A, Ghorani E, Kaur B, et al
    When to stop human chorionic gonadotrophin (hCG) surveillance after treatment with chemotherapy for gestational trophoblastic neoplasia (GTN): A national analysis on over 4,000 patients.
    Gynecol Oncol. 2019 Jul 30. pii: S0090-8258(19)31448.
    PubMed     Abstract available


  311. RANDALL LM, Wenham RM, Low PS, Dowdy SC, et al
    A phase II, multicenter, open-label trial of OTL38 injection for the intra-operative imaging of folate receptor-alpha positive ovarian cancer.
    Gynecol Oncol. 2019 Jul 27. pii: S0090-8258(19)31396.
    PubMed     Abstract available


  312. RAMONDETTA LM, Hu W, Thaker PH, Urbauer DL, et al
    Prospective pilot trial with combination of propranolol with chemotherapy in patients with epithelial ovarian cancer and evaluation on circulating immune cell gene expression.
    Gynecol Oncol. 2019 Jul 25. pii: S0090-8258(19)31353.
    PubMed     Abstract available


  313. KATO K, Omi M, Fusegi A, Takeshima N, et al
    Modified posterior pelvic exenteration with pelvic side-wall resection requiring both intestinal and urinary reconstruction during surgery for ovarian cancer.
    Gynecol Oncol. 2019 Jul 24. pii: S0090-8258(19)31404.
    PubMed     Abstract available


  314. WISSING M, Mitric C, Amajoud Z, Abitbol J, et al
    Risk factors for lymph nodes involvement in obese women with endometrial carcinomas.
    Gynecol Oncol. 2019 Jul 24. pii: S0090-8258(19)31405.
    PubMed     Abstract available


  315. BARTELS HC, Rogers AC, McSharry V, McVey R, et al
    A meta-analysis of morbidity and mortality in primary cytoreductive surgery compared to neoadjuvant chemotherapy in advanced ovarian malignancy.
    Gynecol Oncol. 2019 Jul 23. pii: S0090-8258(19)31397.
    PubMed     Abstract available


  316. IGNATOV A, Lebius C, Ignatov T, Ivros S, et al
    Lymph node micrometastases and outcome of endometrial cancer.
    Gynecol Oncol. 2019 Jul 22. pii: S0090-8258(19)31407.
    PubMed     Abstract available


  317. CYBULSKA P, Paula ADC, Tseng J, Leitao MM Jr, et al
    Molecular profiling and molecular classification of endometrioid ovarian carcinomas.
    Gynecol Oncol. 2019 Jul 21. pii: S0090-8258(19)31398.
    PubMed     Abstract available


  318. XIANG L, Ye S, Yang H
    Total pelvic peritonectomy for ovarian cancer with extensive peritoneal carcinomatosis in pelvic cavity.
    Gynecol Oncol. 2019 Jul 17. pii: S0090-8258(19)31352.
    PubMed     Abstract available


  319. GADDUCCI A, Zannoni GF
    Uterine smooth muscle tumors of unknown malignant potential: A challenging question.
    Gynecol Oncol. 2019 Jul 17. pii: S0090-8258(19)31351.
    PubMed     Abstract available


  320. ZANFAGNIN V, Huang Y, Mc Gree ME, Weaver AL, et al
    Predictors of extensive lymphatic dissemination and recurrences in node-positive endometrial cancer.
    Gynecol Oncol. 2019 Jul 16. pii: S0090-8258(19)31391.
    PubMed     Abstract available


  321. SAMUEL D, Vilardo N, Isani SS, Kuo DYS, et al
    Readability assessment of online gynecologic oncology patient education materials from major governmental, non-profit and pharmaceutical organizations.
    Gynecol Oncol. 2019 Jul 16. pii: S0090-8258(19)31347.
    PubMed     Abstract available


  322. LIU B, Li L, Wang M, Wei L, et al
    Health-related quality of life in locally advanced cervical cancer patients treated with neoadjuvant therapy followed by radical surgery: A single-institutional retrospective study from a prospective database.
    Gynecol Oncol. 2019 Jul 12. pii: S0090-8258(19)31354.
    PubMed     Abstract available


  323. LIM SL, Puechl AM, Broadwater G, Ehrisman JA, et al
    Gender variation in Medicare utilization and payments in gynecologic oncology.
    Gynecol Oncol. 2019 Jul 11. pii: S0090-8258(19)31318.
    PubMed     Abstract available


  324. HUBBARD AK, Poynter JN
    Global incidence comparisons and trends in ovarian germ cell tumors by geographic region in girls, adolescents and young women: 1988-2012.
    Gynecol Oncol. 2019 Jul 11. pii: S0090-8258(19)31348.
    PubMed     Abstract available


  325. ALIMENA S, Yang DD, Melamed A, Mahal BA, et al
    Racial disparities in brachytherapy administration and survival in women with locally advanced cervical cancer.
    Gynecol Oncol. 2019 Jul 7. pii: S0090-8258(19)31338.
    PubMed     Abstract available


  326. KUMAR A, Martin DP, Dhanorker SR, Brandt SR, et al
    Improving the rate of surgical normothermia in gynecologic surgery.
    Gynecol Oncol. 2019 Jul 5. pii: S0090-8258(19)31349.
    PubMed     Abstract available


  327. SUZUKI K, Nagao S, Shibutani T, Yamamoto K, et al
    Phase II trial of paclitaxel, carboplatin, and bevacizumab for advanced or recurrent cervical cancer.
    Gynecol Oncol. 2019 Jul 5. pii: S0090-8258(19)31262.
    PubMed     Abstract available


  328. MATSUO K, Huang Y, Zivanovic O, Shimada M, et al
    Effectiveness of postoperative chemotherapy for stage IC mucinous ovarian cancer.
    Gynecol Oncol. 2019 Jul 3. pii: S0090-8258(19)31337.
    PubMed     Abstract available


  329. PAIK ES, Lim MC, Kim MH, Kim YH, et al
    Comparison of laparoscopic and abdominal radical hysterectomy in early stage cervical cancer patients without adjuvant treatment: Ancillary analysis of a Korean Gynecologic Oncology Group Study (KGOG 1028).
    Gynecol Oncol. 2019 Jul 1. pii: S0090-8258(19)31339.
    PubMed     Abstract available


  330. KUMAR A, Sheedy S, Kim B, Suidan R, et al
    Models to predict outcomes after primary debulking surgery: Independent validation of models to predict suboptimal cytoreduction and gross residual disease.
    Gynecol Oncol. 2019;154:72-76.
    PubMed     Abstract available


    June 2019
  331. XIANG M, English DP, Kidd EA
    Defining the survival benefit of adjuvant pelvic radiotherapy and chemotherapy versus chemotherapy alone in stages III-IVA endometrial carcinoma.
    Gynecol Oncol. 2019 Jun 27. pii: S0090-8258(19)31336.
    PubMed     Abstract available


  332. PRENDERGAST EN, Holman LL, Liu AY, Lai TS, et al
    Comprehensive genomic profiling of recurrent endometrial cancer: Implications for selection of systemic therapy.
    Gynecol Oncol. 2019 Jun 27. pii: S0090-8258(19)31332.
    PubMed     Abstract available


  333. ABDULFATAH E, Wakeling E, Sakr S, Al-Obaidy K, et al
    Molecular classification of endometrial carcinoma applied to endometrial biopsy specimens: Towards early personalized patient management.
    Gynecol Oncol. 2019 Jun 24. pii: S0090-8258(19)31323.
    PubMed     Abstract available


  334. LI W, Meng Y, Wang Y, Cheng X, et al
    Association of age and viral factors with high-risk HPV persistence: A retrospective follow-up study.
    Gynecol Oncol. 2019 Jun 24. pii: S0090-8258(19)31270.
    PubMed     Abstract available


  335. KRANAWETTER M, Ataseven B, Grimm C, Schneider S, et al
    Low anterior resection syndrome (LARS) in patients with epithelial ovarian cancer after primary debulking surgery.
    Gynecol Oncol. 2019 Jun 21. pii: S0090-8258(19)31331.
    PubMed     Abstract available


  336. CANAZ E, Grabowski JP, Richter R, Braicu EI, et al
    Survival and prognostic factors in patients with recurrent low-grade epithelial ovarian cancer: An analysis of five prospective phase II/III trials of NOGGO metadata base.
    Gynecol Oncol. 2019 Jun 20. pii: S0090-8258(19)31327.
    PubMed     Abstract available


  337. HENGEVELD EM, Zusterzeel PLM, Lajer H, Hogdall CK, et al
    The value of surgical staging in patients with apparent early stage epithelial ovarian carcinoma.
    Gynecol Oncol. 2019 Jun 20. pii: S0090-8258(19)31317.
    PubMed     Abstract available


  338. FUH KC, Java JJ, Chan JK, Kapp DS, et al
    Differences in presentation and survival of Asians compared to Caucasians with ovarian cancer: An NRG Oncology/GOG Ancillary study of 7914 patients.
    Gynecol Oncol. 2019 Jun 19. pii: S0090-8258(19)31257.
    PubMed     Abstract available


  339. ARMBRUSTER SD, Previs R, Soliman PT, Westin SN, et al
    Clinicopathologic features and treatment in patients with early stage uterine clear cell carcinoma: A 16-year experience.
    Gynecol Oncol. 2019 Jun 18. pii: S0090-8258(19)31278.
    PubMed     Abstract available


  340. TANG M, O'Connell RL, Amant F, Beale P, et al
    PARAGON: A Phase II study of anastrozole in patients with estrogen receptor-positive recurrent/metastatic low-grade ovarian cancers and serous borderline ovarian tumors.
    Gynecol Oncol. 2019 Jun 18. pii: S0090-8258(19)31322.
    PubMed     Abstract available


  341. DOTTINO JA, He W, Sun CC, Zhao H, et al
    Centers for Medicare and Medicaid Services' Hospital Consumer Assessment of Healthcare Providers and Systems (HCAHPS) scores and gynecologic oncology surgical outcomes.
    Gynecol Oncol. 2019 Jun 14. pii: S0090-8258(19)31280.
    PubMed     Abstract available


  342. MARIANI A, Wang C, Oberg AL, Riska SM, et al
    Genes associated with bowel metastases in ovarian cancer.
    Gynecol Oncol. 2019 Jun 14. pii: S0090-8258(19)31321.
    PubMed     Abstract available


  343. LIU JF, Gordon M, Veneris J, Braiteh F, et al
    Safety, clinical activity and biomarker assessments of atezolizumab from a Phase I study in advanced/recurrent ovarian and uterine cancers.
    Gynecol Oncol. 2019 Jun 13. pii: S0090-8258(19)31265.
    PubMed     Abstract available


  344. PACHE B, Joliat GR, Hubner M, Grass F, et al
    Cost-analysis of Enhanced Recovery After Surgery (ERAS) program in gynecologic surgery.
    Gynecol Oncol. 2019 Jun 13. pii: S0090-8258(19)31281.
    PubMed     Abstract available


  345. CYBULSKA P, Sioulas V, Orfanelli T, Zivanovic O, et al
    Secondary surgical resection for patients with recurrent uterine leiomyosarcoma.
    Gynecol Oncol. 2019 Jun 12. pii: S0090-8258(19)31259.
    PubMed     Abstract available


  346. HORNER W, Peng K, Pleasant V, Brackmann M, et al
    Trends in surgical complexity and treatment modalities utilized in the management of ovarian cancer in an era of neoadjuvant chemotherapy.
    Gynecol Oncol. 2019 Jun 11. pii: S0090-8258(19)31267.
    PubMed     Abstract available


  347. BOITANO TKL, Barrington DA, Batra S, McGwin G Jr, et al
    Differences in referral patterns based on race for women at high-risk for ovarian cancer in the southeast: Results from a Gynecologic Cancer Risk Assessment Clinic.
    Gynecol Oncol. 2019 Jun 10. pii: S0090-8258(19)31275.
    PubMed     Abstract available


  348. BERGAMINI A, Cormio G, Ferrandina G, Lorusso D, et al
    Conservative surgery in stage I adult type granulosa cells tumors of the ovary: Results from the MITO-9 study.
    Gynecol Oncol. 2019 Jun 10. pii: S0090-8258(19)31273.
    PubMed     Abstract available


  349. DICK S, Kremer WW, De Strooper LMA, Lissenberg-Witte BI, et al
    Long-term CIN3+ risk of HPV positive women after triage with FAM19A4/miR124-2 methylation analysis.
    Gynecol Oncol. 2019 Jun 7. pii: S0090-8258(19)31279.
    PubMed     Abstract available


  350. HARDING BN, Delaney JA, Urban RR, Weiss NS, et al
    Post-diagnosis use of antihypertensive medications and the risk of death from ovarian cancer.
    Gynecol Oncol. 2019 Jun 6. pii: S0090-8258(19)31274.
    PubMed     Abstract available


  351. KIM JS, Turbov J, Rosales R, Thaete LG, et al
    Combination simvastatin and metformin synergistically inhibits endometrial cancer cell growth.
    Gynecol Oncol. 2019 Jun 6. pii: S0090-8258(19)31266.
    PubMed     Abstract available


  352. FRAZER JL, Hook CE, Addley HC, Jackson CR, et al
    Recurrent ovarian immature teratoma in a 12-year-old girl: Implications for management.
    Gynecol Oncol. 2019 Jun 5. pii: S0090-8258(19)31277.
    PubMed     Abstract available


  353. KORSHOLM M, Gyrd-Hansen D, Mogensen O, Moller S, et al
    Long term resource consequences of a nationwide introduction of robotic surgery for women with early stage endometrial cancer.
    Gynecol Oncol. 2019 Jun 5. pii: S0090-8258(19)31271.
    PubMed     Abstract available


  354. ARO K, Nieminen P, Louvanto K, Jakobsson M, et al
    Age-specific HPV type distribution in high-grade cervical disease in screened and unvaccinated women.
    Gynecol Oncol. 2019 Jun 5. pii: S0090-8258(19)31268.
    PubMed     Abstract available


  355. MOORE KN, Gunderson CC, Sabbatini P, McMeekin DS, et al
    A phase 1b dose escalation study of ipafricept (OMP54F28) in combination with paclitaxel and carboplatin in patients with recurrent platinum-sensitive ovarian cancer.
    Gynecol Oncol. 2019 Jun 4. pii: S0090-8258(19)30496.
    PubMed     Abstract available


  356. WRIGHT JD, Chen L, Buskwofie A, Tergas AI, et al
    Regionalization of care for women with ovarian cancer.
    Gynecol Oncol. 2019 Jun 3. pii: S0090-8258(19)31269.
    PubMed     Abstract available


  357. WILLOWS K, Kupets R, Diong C, Vicus D, et al
    Rates over time and regional variation of radical minimally invasive surgery for cervical cancer: A population based study.
    Gynecol Oncol. 2019 Jun 3. pii: S0090-8258(19)31263.
    PubMed     Abstract available


  358. WETHINGTON SL, Fader AN
    ProMisE on the horizon: molecular classification of endometrial cancer in young women.
    Gynecol Oncol. 2019;153:465-466.
    PubMed    


  359. BACKES FJ, Cohen D, Salani R, Cohn DE, et al
    Prospective clinical trial of robotic sentinel lymph node assessment with isosulfane blue (ISB) and indocyanine green (ICG) in endometrial cancer and the impact of ultrastaging (NCT01818739).
    Gynecol Oncol. 2019;153:496-499.
    PubMed     Abstract available


  360. GUAN Y, Luan Y, Xie Y, Zhou H, et al
    Chloride channel-3 is required for efficient tumour cell migration and invasion in human cervical squamous cell carcinoma.
    Gynecol Oncol. 2019;153:661-669.
    PubMed     Abstract available


  361. SHERMAN-SAMIS M, Onallah H, Holth A, Reich R, et al
    SOX2 and SOX9 are markers of clinically aggressive disease in metastatic high-grade serous carcinoma.
    Gynecol Oncol. 2019;153:651-660.
    PubMed     Abstract available


  362. ZIGRAS T, Kupets R, Barbera L, Covens A, et al
    Uptake of sentinel lymph node procedures in women with vulvar cancer over time in a population based study.
    Gynecol Oncol. 2019;153:574-579.
    PubMed     Abstract available


    May 2019
  363. NASIOUDIS D, Kahn R, Chapman-Davis E, Frey MK, et al
    Impact of hospital surgical volume on complete gross resection (CGR) rates following primary debulking surgery for advanced stage epithelial ovarian carcinoma.
    Gynecol Oncol. 2019 May 31. pii: S0090-8258(19)31260.
    PubMed     Abstract available


  364. GRETTE K, Long B, Finan MA, Rocconi RP, et al
    Intraperitoneal (IP) port cytology after completion of primary therapy for advanced stage ovarian cancer: A novel approach to a "second look".
    Gynecol Oncol. 2019 May 31. pii: S0090-8258(19)31236.
    PubMed     Abstract available


  365. WRIGHT TC JR, Stoler MH, Parvu V, Yanson K, et al
    Risk detection for high-grade cervical disease using Onclarity HPV extended genotyping in women, >/=21years of age, with ASC-US or LSIL cytology.
    Gynecol Oncol. 2019 May 31. pii: S0090-8258(19)31256.
    PubMed     Abstract available


  366. NASIOUDIS D, Haggerty AF, Giuntoli RL 2nd, Burger RA, et al
    Adjuvant chemotherapy is not associated with a survival benefit for patients with early stage mucinous ovarian carcinoma.
    Gynecol Oncol. 2019 May 30. pii: S0090-8258(19)31233.
    PubMed     Abstract available


  367. MILESHKIN L, Edmondson R, O'Connell RL, Sjoquist KM, et al
    Phase 2 study of anastrozole in recurrent estrogen (ER)/progesterone (PR) positive endometrial cancer: The PARAGON trial - ANZGOG 0903.
    Gynecol Oncol. 2019 May 23. pii: S0090-8258(19)31232.
    PubMed     Abstract available


  368. GUDGEON JM, Varner MW, Hashibe M, Williams MS, et al
    Is immunohistochemistry-based screening for Lynch syndrome in endometrial cancer effective? The consent's the thing.
    Gynecol Oncol. 2019 May 23. pii: S0090-8258(19)31231.
    PubMed     Abstract available


  369. MATSUO K, Mandelbaum RS, Machida H, Yoshihara K, et al
    Decreasing secondary primary uterine cancer after breast cancer: A population-based analysis.
    Gynecol Oncol. 2019 May 23. pii: S0090-8258(19)31258.
    PubMed     Abstract available


  370. MULTINU F, Casarin J, Cappuccio S, Keeney GL, et al
    Ultrastaging of negative pelvic lymph nodes to decrease the true prevalence of isolated paraaortic dissemination in endometrial cancer.
    Gynecol Oncol. 2019 May 22. pii: S0090-8258(19)31234.
    PubMed     Abstract available


  371. LIU JF, Gray KP, Wright AA, Campos S, et al
    Results from a single arm, single stage phase II trial of trametinib and GSK2141795 in persistent or recurrent cervical cancer.
    Gynecol Oncol. 2019 May 20. pii: S0090-8258(19)31228.
    PubMed     Abstract available


  372. COHEN PA, Powell A, Bohm S, Gilks CB, et al
    Pathological chemotherapy response score is prognostic in tubo-ovarian high-grade serous carcinoma: A systematic review and meta-analysis of individual patient data.
    Gynecol Oncol. 2019 May 19. pii: S0090-8258(19)31181.
    PubMed     Abstract available


  373. STASENKO M, Cybulska P, Feit N, Makker V, et al
    Brain metastasis in epithelial ovarian cancer by BRCA1/2 mutation status.
    Gynecol Oncol. 2019 May 18. pii: S0090-8258(19)31229.
    PubMed     Abstract available


  374. BROWN CL
    50th Annual Meeting of the Society of Gynecologic Oncology.
    Gynecol Oncol. 2019 May 18. pii: S0090-8258(19)31148.
    PubMed    


  375. CHAPMAN BV, Swanick CW, Ning MS, Allen PK, et al
    Adjuvant combined-modality therapy for stage IIIC endometrioid and non-endometrioid endometrial cancer.
    Gynecol Oncol. 2019 May 17. pii: S0090-8258(19)31227.
    PubMed     Abstract available


  376. GIL KM, Pugh SL, Klopp AH, Yeung AR, et al
    Expanded validation of the EPIC bowel and urinary domains for use in women with gynecologic cancer undergoing postoperative radiotherapy.
    Gynecol Oncol. 2019 May 16. pii: S0090-8258(19)31184.
    PubMed     Abstract available


  377. GRANDI G, Perrone AM, Chiossi G, Friso S, et al
    Increasing BMI is associated with both endometrioid and serous histotypes among endometrial rather than ovarian cancers: a case-to-case study.
    Gynecol Oncol. 2019 May 16. pii: S0090-8258(19)31186.
    PubMed     Abstract available


  378. MARU Y, Tanaka N, Itami M, Hippo Y, et al
    Efficient use of patient-derived organoids as a preclinical model for gynecologic tumors.
    Gynecol Oncol. 2019 May 14. pii: S0090-8258(19)31230.
    PubMed     Abstract available


  379. ANDERSEN B, Christensen BS, Christensen J, Ejersbo D, et al
    HPV-prevalence in elderly women in Denmark.
    Gynecol Oncol. 2019 May 11. pii: S0090-8258(19)31182.
    PubMed     Abstract available


  380. TOMAO F, Musacchio L, Di Mauro F, Boccia SM, et al
    Is BRCA mutational status a predictor of platinum-based chemotherapy related hematologic toxicity in high-grade serous ovarian cancer patients?
    Gynecol Oncol. 2019 May 9. pii: S0090-8258(19)30504.
    PubMed     Abstract available


  381. FILIPPOVA OT, Chi DS, Long Roche K, Sonoda Y, et al
    Geriatric co-management leads to safely performed cytoreductive surgery in older women with advanced stage ovarian cancer treated at a tertiary care cancer center.
    Gynecol Oncol. 2019 May 8. pii: S0090-8258(19)31185.
    PubMed     Abstract available


  382. VAN ARSDALE A, Miller DT, Kuo DY, Isani S, et al
    Association of obesity with survival in patients with endometrial cancer.
    Gynecol Oncol. 2019 May 3. pii: S0090-8258(19)30493.
    PubMed     Abstract available


  383. HOPPENOT C, Peters P, Cowan M, Moore ED, et al
    Malignant bowel obstruction due to uterine or ovarian cancer: Are there differences in outcome?
    Gynecol Oncol. 2019 May 2. pii: S0090-8258(19)31183.
    PubMed     Abstract available


  384. LEDERMANN JA
    Do increased tumor infiltrating lymphocytes co-existing with Homologous Recombination Deficiency provide clues to enhance immunotherapy of ovarian cancer?
    Gynecol Oncol. 2019;153:213-214.
    PubMed    


  385. BLOK F, Dasgupta S, Dinjens WNM, Roes EM, et al
    Retrospective study of a 16year cohort of BRCA1 and BRCA2 carriers presenting for RRSO: Prevalence of invasive and in-situ carcinoma, with follow-up.
    Gynecol Oncol. 2019;153:326-334.
    PubMed     Abstract available


  386. AVIKI EM, Abu-Rustum NR
    When surgical innovation and payment systems collide: The sentinel lymph node story.
    Gynecol Oncol. 2019;153:215-216.
    PubMed    


  387. FOKOM DOMGUE J, Messick C, Milbourne A, Guo M, et al
    Prevalence of high-grade anal dysplasia among women with high-grade lower genital tract dysplasia or cancer: Results of a pilot study.
    Gynecol Oncol. 2019;153:266-270.
    PubMed     Abstract available


  388. SYKES P, Eva L, van der Griend R, McNally O, et al
    Pathological process has a crucial role in sentinel node biopsy for vulvar cancer.
    Gynecol Oncol. 2019;153:292-296.
    PubMed     Abstract available


  389. KRASNER CN, Castro C, Penson RT, Roche M, et al
    Final report on serial phase II trials of all-intraperitoneal chemotherapy with or without bevacizumab for women with newly diagnosed, optimally cytoreduced carcinoma of Mullerian origin.
    Gynecol Oncol. 2019;153:223-229.
    PubMed     Abstract available


  390. POLTERAUER S, Schwameis R, Grimm C, Hillemanns P, et al
    Lymph node ratio in inguinal lymphadenectomy for squamous cell vulvar cancer: Results from the AGO-CaRE-1 study.
    Gynecol Oncol. 2019;153:286-291.
    PubMed     Abstract available


    April 2019
  391. SPIRTOS NM, Enserro D, Homesley HD, Gibbons SK, et al
    The addition of paclitaxel to doxorubicin and cisplatin and volume-directed radiation does not improve overall survival (OS) or long-term recurrence-free survival (RFS) in advanced endometrial cancer (EC): A randomized phase III NRG/Gynecologic Oncolo
    Gynecol Oncol. 2019 Apr 30. pii: S0090-8258(19)30433.
    PubMed     Abstract available


  392. BOUBERHAN S, Shea M, Kennedy A, Erlinger A, et al
    Financial toxicity in gynecologic oncology.
    Gynecol Oncol. 2019 Apr 30. pii: S0090-8258(19)30498.
    PubMed     Abstract available


  393. MOHANKUMAR K, Li X, Sridharan S, Karki K, et al
    Nuclear receptor 4A1 (NR4A1) antagonists induce ROS-dependent inhibition of mTOR signaling in endometrial cancer.
    Gynecol Oncol. 2019 Apr 30. pii: S0090-8258(19)31180.
    PubMed     Abstract available


  394. ANGIOLO G, Silvestro C, Guerrieri ME, Damiano AG, et al
    Placental site trophoblastic tumor and epithelioid trophoblastic tumor: Clinical and pathological features, prognostic variables and treatment strategy.
    Gynecol Oncol. 2019 Apr 29. pii: S0090-8258(19)30184.
    PubMed     Abstract available


  395. MANDELBAUM RS, Chen L, Shoupe D, Paulson RJ, et al
    Patterns of utilization and outcome of ovarian conservation for young women with minimal-risk endometrial cancer.
    Gynecol Oncol. 2019 Apr 26. pii: S0090-8258(19)31151.
    PubMed     Abstract available


  396. DANIELE G, Arenare L, Scambia G, Pisano C, et al
    Prognostic role of chemotherapy-induced neutropenia in first-line treatment of advanced ovarian cancer. A pooled analysis of MITO2 and MITO7 trials.
    Gynecol Oncol. 2019 Apr 24. pii: S0090-8258(19)30507.
    PubMed     Abstract available


  397. FRANCIS SR, Ager BJ, Do OA, Huang YJ, et al
    Recurrent early stage endometrial cancer: Patterns of recurrence and results of salvage therapy.
    Gynecol Oncol. 2019 Apr 24. pii: S0090-8258(19)31174.
    PubMed     Abstract available


  398. POLCHER M, Rottmann M, Brugger S, Mahner S, et al
    Lymph node dissection in endometrial cancer and clinical outcome: A population-based study in 5546 patients.
    Gynecol Oncol. 2019 Apr 23. pii: S0090-8258(19)30497.
    PubMed     Abstract available


  399. KENNARD JA, Stephens AJ, Ahmad S, Zhu X, et al
    Sentinel lymph nodes (SLN) in endometrial cancer: The relationship between primary tumor histology, SLN metastasis size, and non-sentinel node metastasis.
    Gynecol Oncol. 2019 Apr 23. pii: S0090-8258(19)31152.
    PubMed     Abstract available


  400. ENGLISH DP, Huang M
    Highlights from the Society of Gynecologic Oncology's 50th Annual Meeting on Women's Cancer.
    Gynecol Oncol. 2019 Apr 22. pii: S0090-8258(19)31150.
    PubMed    


  401. MA S, Wang J, Han Y, Guo F, et al
    Platinum single-agent vs. platinum-based doublet agent concurrent chemoradiotherapy for locally advanced cervical cancer: A meta-analysis of randomized controlled trials.
    Gynecol Oncol. 2019 Apr 18. pii: S0090-8258(19)30508.
    PubMed     Abstract available


  402. GORE M, Hackshaw A, Brady WE, Penson RT, et al
    An international, phase III randomized trial in patients with mucinous epithelial ovarian cancer (mEOC/GOG 0241) with long-term follow-up: and experience of conducting a clinical trial in a rare gynecological tumor.
    Gynecol Oncol. 2019 Apr 17. pii: S0090-8258(19)30491.
    PubMed     Abstract available


  403. BOGANI G, Chiappa V, Vinti D, Somigliana E, et al
    Long-term results of fertility-sparing treatment for early-stage cervical cancer.
    Gynecol Oncol. 2019 Apr 16. pii: S0090-8258(19)30502.
    PubMed     Abstract available


  404. LUCIDO CT, Wynja E, Madeo M, Williamson CS, et al
    Innervation of cervical carcinoma is mediated by cancer-derived exosomes.
    Gynecol Oncol. 2019 Apr 16. pii: S0090-8258(19)31149.
    PubMed     Abstract available


  405. BALAYA V, Mathevet P, Magaud L, Bonsang-Kitzis H, et al
    Predictive factors of unexpected lymphatic drainage pathways in early-stage cervical cancer.
    Gynecol Oncol. 2019 Apr 16. pii: S0090-8258(19)30503.
    PubMed     Abstract available


  406. ALHILLI MM, Elson P, Rybicki L, Khorana AA, et al
    Delay in time to surgery and impact on survival in patients with endometrial cancer: A National Cancer Database Analysis.
    Gynecol Oncol. 2019 Apr 15. pii: S0090-8258(19)30437.
    PubMed     Abstract available


  407. SWAILES AL, Hossler CE, Kesterson JP
    Pathway to the Papanicolaou smear: The development of cervical cytology in twentieth-century America and implications in the present day.
    Gynecol Oncol. 2019 Apr 14. pii: S0090-8258(19)30499.
    PubMed     Abstract available


  408. LEE L, Matulonis U
    Immunotherapy and radiation combinatorial trials in gynecologic cancer: A potential synergy?
    Gynecol Oncol. 2019 Apr 14. pii: S0090-8258(19)30490.
    PubMed     Abstract available


  409. MOORE RG, Blackman A, Miller MC, Robison K, et al
    Multiple biomarker algorithms to predict epithelial ovarian cancer in women with a pelvic mass: Can additional makers improve performance?
    Gynecol Oncol. 2019 Apr 13. pii: S0090-8258(19)30501.
    PubMed     Abstract available


  410. GAILLARD SL, Andreano KJ, Gay LM, Steiner M, et al
    Constitutively active ESR1 mutations in gynecologic malignancies and clinical response to estrogen-receptor directed therapies.
    Gynecol Oncol. 2019 Apr 13. pii: S0090-8258(19)30505.
    PubMed     Abstract available


  411. GIULIANO AR, Joura EA, Garland SM, Huh WK, et al
    Nine-valent HPV vaccine efficacy against related diseases and definitive therapy: comparison with historic placebo population.
    Gynecol Oncol. 2019 Apr 11. pii: S0090-8258(19)30488.
    PubMed     Abstract available


  412. LEFKOWITS C, Bevis K, Carey EC, Sheeder J, et al
    Gynecologic oncology providers endorse practice-changing impact of communication skills training.
    Gynecol Oncol. 2019 Apr 9. pii: S0090-8258(19)30435.
    PubMed     Abstract available


  413. PIGNATA S, Scambia G, Lorusso D, De Giorgi U, et al
    The MITO CERV-2 trial: A randomized phase II study of cetuximab plus carboplatin and paclitaxel, in advanced or recurrent cervical cancer.
    Gynecol Oncol. 2019 Apr 9. pii: S0090-8258(19)30495.
    PubMed     Abstract available


  414. XU X, Kong X, Liu T, Zhou L, et al
    Metastasis-associated protein 1, modulated by miR-30c, promotes endometrial cancer progression through AKT/mTOR/4E-BP1 pathway.
    Gynecol Oncol. 2019 Apr 9. pii: S0090-8258(19)30500.
    PubMed     Abstract available


  415. HORSBOEL TA, Kjaer SK, Johansen C, Suppli NP, et al
    Increased risk for depression persists for years among women treated for gynecological cancers - a register-based cohort study with up to 19years of follow-up.
    Gynecol Oncol. 2019 Apr 8. pii: S0090-8258(19)30494.
    PubMed     Abstract available


  416. REIJNEN C, Kusters-Vandevelde HVN, Prinsen CF, Massuger LFAG, et al
    Mismatch repair deficiency as a predictive marker for response to adjuvant radiotherapy in endometrial cancer.
    Gynecol Oncol. 2019 Apr 3. pii: S0090-8258(19)30270.
    PubMed     Abstract available


  417. BOGANI G, Murgia F, Ditto A, Raspagliesi F, et al
    Sentinel node mapping vs. lymphadenectomy in endometrial cancer: A systematic review and meta-analysis.
    Gynecol Oncol. 2019 Apr 2. pii: S0090-8258(19)30489.
    PubMed     Abstract available


  418. LAGO V, Fotopoulou C, Chiantera V, Minig L, et al
    Risk factors for anastomotic leakage after colorectal resection in ovarian cancer surgery: A multi-centre study.
    Gynecol Oncol. 2019 Apr 2. pii: S0090-8258(19)30434.
    PubMed     Abstract available


  419. HARPER DM, Nieminen P, Donders G, Einstein MH, et al
    The efficacy and safety of Tipapkinogen Sovacivec therapeutic HPV vaccine in cervical intraepithelial neoplasia grades 2 and 3: Randomized controlled phase II trial with 2.5years of follow-up.
    Gynecol Oncol. 2019 Apr 2. pii: S0090-8258(19)30484.
    PubMed     Abstract available


  420. LEITAO MM JR
    The change in landscape after a new landmark is constructed: Radical hysterectomy for early cervical cancer and Minimally Invasive Surgery.
    Gynecol Oncol. 2019;153:1-2.
    PubMed    


  421. VAN BAAL JOAM, Van de Vijver KK, Algera MD, van der A MA, et al
    The effect of adjuvant chemotherapy on survival in patients with FIGO stage I high-grade serous ovarian cancer.
    Gynecol Oncol. 2019 Apr 1. pii: S0090-8258(19)30492.
    PubMed     Abstract available


  422. PUECHL AM, Edwards J, Suri A, Nakayama J, et al
    The association between progesterone receptor expression and survival in women with adult granulosa cell tumors.
    Gynecol Oncol. 2019;153:74-79.
    PubMed     Abstract available


  423. MANNING-GEIST BL, Alimena S, Del Carmen MG, Goodman A, et al
    Infection, thrombosis, and oncologic outcome after interval debulking surgery: Does perioperative blood transfusion matter?
    Gynecol Oncol. 2019;153:63-67.
    PubMed     Abstract available


    March 2019
  424. COSGROVE CM, Cohn DE, Rhoades J, Felix AS, et al
    The prognostic significance of aortic lymph node metastasis in endometrial cancer: Potential implications for selective aortic lymph node assessment.
    Gynecol Oncol. 2019 Mar 30. pii: S0090-8258(19)30486.
    PubMed     Abstract available


  425. VENERIS JT, Lee EK, Goebel EA, Nucci MR, et al
    Diagnosis and management of a recurrent polymerase-epsilon (POLE)-mutated endometrial cancer.
    Gynecol Oncol. 2019 Mar 29. pii: S0090-8258(19)30482.
    PubMed     Abstract available


  426. DE ARRUDA FN, Oonk MHM, Mourits MJE, de Graeff P, et al
    Determinants of health-related quality of life in elderly ovarian cancer patients: The role of frailty and dependence.
    Gynecol Oncol. 2019 Mar 29. pii: S0090-8258(19)30485.
    PubMed     Abstract available


  427. LAAKSONEN MA, Arriaga ME, Canfell K, MacInnis RJ, et al
    The preventable burden of endometrial and ovarian cancers in Australia: A pooled cohort study.
    Gynecol Oncol. 2019 Mar 29. pii: S0090-8258(19)30275.
    PubMed     Abstract available


  428. LEE EK, Liu JF
    Antibody-drug conjugates in gynecologic malignancies.
    Gynecol Oncol. 2019 Mar 28. pii: S0090-8258(19)30438.
    PubMed     Abstract available


  429. SECORD AA, McCollum M, Davidson BA, Broadwater G, et al
    Phase II trial of nintedanib in patients with bevacizumab-resistant recurrent epithelial ovarian, tubal, and peritoneal cancer.
    Gynecol Oncol. 2019 Mar 28. pii: S0090-8258(19)30441.
    PubMed     Abstract available


  430. GUO Y, Cui W, Pei Y, Xu D, et al
    Platelets promote invasion and induce epithelial to mesenchymal transition in ovarian cancer cells by TGF-beta signaling pathway.
    Gynecol Oncol. 2019 Mar 27. pii: S0090-8258(19)30136.
    PubMed     Abstract available


  431. BRITTON H, Huang L, Lum A, Leung S, et al
    Molecular classification defines outcomes and opportunities in young women with endometrial carcinoma.
    Gynecol Oncol. 2019 Mar 25. pii: S0090-8258(19)30271.
    PubMed     Abstract available


  432. MORONEY MR, Davies KD, Wilberger AC, Sheeder J, et al
    Molecular markers in recurrent stage I, grade 1 endometrioid endometrial cancers.
    Gynecol Oncol. 2019 Mar 22. pii: S0090-8258(19)30273.
    PubMed     Abstract available


  433. DISILVESTRO PA
    Shaping the standard of care in ovarian cancer management: A review of Gynecologic Oncology Group (GOG)/NRG oncology clinical trials of the past twenty years.
    Gynecol Oncol. 2019 Mar 22. pii: S0090-8258(19)30130.
    PubMed     Abstract available


  434. MACHIDA H, Matsuo K, Yamagami W, Ebina Y, et al
    Trends and characteristics of epithelial ovarian cancer in Japan between 2002 and 2015: A JSGO-JSOG joint study.
    Gynecol Oncol. 2019 Mar 21. pii: S0090-8258(19)30436.
    PubMed     Abstract available


  435. LIN AJ, Ma S, Markovina S, Schwarz J, et al
    Clinical outcomes after isolated pelvic failure in cervical cancer patients treated with definitive radiation.
    Gynecol Oncol. 2019 Mar 21. pii: S0090-8258(19)30297.
    PubMed     Abstract available


  436. HEILMANN T, Pfisterer J, Hempel AM, Sass S, et al
    Early treatment modifications improve chemotherapy adherence in ovarian cancer patients >/=70years.
    Gynecol Oncol. 2019 Mar 21. pii: S0090-8258(19)30125.
    PubMed     Abstract available


  437. LAWRENSON K, Song F, Hazelett DJ, Kar SP, et al
    Genome-wide association studies identify susceptibility loci for epithelial ovarian cancer in east Asian women.
    Gynecol Oncol. 2019 Mar 19. pii: S0090-8258(19)30133.
    PubMed     Abstract available


  438. HILLMAN RT, Sanchez-Migallon A, Meyer LA, Iniesta MD, et al
    Patient characteristics and opioid use prior to discharge after open gynecologic surgery in an enhanced recovery after surgery (ERAS) program.
    Gynecol Oncol. 2019 Mar 19. pii: S0090-8258(19)30274.
    PubMed     Abstract available


  439. ROZENHOLC A, Samouelian V, Warkus T, Gauthier P, et al
    Green versus blue: Randomized controlled trial comparing indocyanine green with methylene blue for sentinel lymph node detection in endometrial cancer.
    Gynecol Oncol. 2019 Mar 19. pii: S0090-8258(19)30296.
    PubMed     Abstract available


  440. HUANG M, Kamath P, Schlumbrecht M, Miao F, et al
    Identifying disparities in germline and somatic testing for ovarian cancer.
    Gynecol Oncol. 2019 Mar 16. pii: S0090-8258(19)30155.
    PubMed     Abstract available


  441. WATSON CH, Lopez-Acevedo M, Broadwater G, Kim AH, et al
    A pilot study of lower extremity lymphedema, lower extremity function, and quality of life in women after minimally invasive endometrial cancer staging surgery.
    Gynecol Oncol. 2019 Mar 15. pii: S0090-8258(19)30131.
    PubMed     Abstract available


  442. RATNER E, Bala M, Louie-Gao M, Aydin E, et al
    Increased risk of brain metastases in ovarian cancer patients with BRCA mutations.
    Gynecol Oncol. 2019 Mar 12. pii: S0090-8258(19)30152.
    PubMed     Abstract available


  443. LAVIE O, Chetrit A, Novikov I, Sadetzki S, et al
    Fifteen-year survival of invasive epithelial ovarian cancer in women with BRCA1/2 mutations - the National Israeli Study of Ovarian Cancer.
    Gynecol Oncol. 2019 Mar 11. pii: S0090-8258(19)30132.
    PubMed     Abstract available


  444. PRESCOTT LS, Taylor JS, Enbaya A, Marten CA, et al
    Choosing Wisely: Decreasing the incidence of perioperative blood transfusions in gynecologic oncology.
    Gynecol Oncol. 2019 Mar 11. pii: S0090-8258(19)30156.
    PubMed     Abstract available


  445. RUENGKHACHORN I, Phithakwatchara N, Viriyapak B, Sangkarat S, et al
    Comparison of oncologic outcomes of unanticipated cervical carcinoma in women undergoing inadvertent simple hysterectomy and those undergoing surgical treatment after preoperative diagnosis.
    Gynecol Oncol. 2019 Mar 11. pii: S0090-8258(19)30135.
    PubMed     Abstract available


  446. MORA PAR, Sun SY, Velarde GC, Filho JR, et al
    Can carboplatin or etoposide replace actinomycin-d for second-line treatment of methotrexate resistant low-risk gestational trophoblastic neoplasia?
    Gynecol Oncol. 2019 Mar 8. pii: S0090-8258(19)30153.
    PubMed     Abstract available


  447. MURAKAMI R, Matsumura N, Michimae H, Tanabe H, et al
    The mesenchymal transition subtype more responsive to dose dense taxane chemotherapy combined with carboplatin than to conventional taxane and carboplatin chemotherapy in high grade serous ovarian carcinoma: A survey of Japanese Gynecologic Oncology G
    Gynecol Oncol. 2019 Mar 7. pii: S0090-8258(19)30120.
    PubMed     Abstract available


  448. FELIP I, Moiola CP, Megino-Luque C, Lopez-Gil C, et al
    Therapeutic potential of the new TRIB3-mediated cell autophagy anticancer drug ABTL0812 in endometrial cancer.
    Gynecol Oncol. 2019 Mar 7. pii: S0090-8258(19)30150.
    PubMed     Abstract available


  449. WRIGHT TC JR, Parvu V, Stoler MH, Kodsi S, et al
    HPV infections and cytologic abnormalities in vaccinated women 21-34years of age: Results from the baseline phase of the Onclarity trial.
    Gynecol Oncol. 2019 Mar 7. pii: S0090-8258(19)30126.
    PubMed     Abstract available


  450. DOO DW, Kirkland CT, Griswold LH, McGwin G, et al
    Comparative outcomes between robotic and abdominal radical hysterectomy for IB1 cervical cancer: Results from a single high volume institution.
    Gynecol Oncol. 2019 Mar 6. pii: S0090-8258(19)30149.
    PubMed     Abstract available


  451. SON JH, Kim J, Shim J, Kong TW, et al
    Comparison of posterior rectal dissection techniques during rectosigmoid colon resection as part of cytoreductive surgery in patients with epithelial ovarian cancer: Close rectal dissection versus total mesorectal excision.
    Gynecol Oncol. 2019 Mar 4. pii: S0090-8258(19)30139.
    PubMed     Abstract available


  452. MERT I, Kumar A, Torres D, Huang Y, et al
    Should mucosal bowel invasion in ovarian cancer be assigned to FIGO stage IV disease?
    Gynecol Oncol. 2019 Mar 2. pii: S0090-8258(19)30128.
    PubMed     Abstract available


  453. BOGANI G, Mariani A, Paolini B, Ditto A, et al
    Low-volume disease in endometrial cancer: The role of micrometastasis and isolated tumor cells.
    Gynecol Oncol. 2019 Mar 1. pii: S0090-8258(19)30137.
    PubMed     Abstract available


  454. MOSS HA, Melamed A, Wright JD
    Measuring cause-and-effect relationships without randomized clinical trials: Quasi-experimental methods for gynecologic oncology research.
    Gynecol Oncol. 2019;152:533-539.
    PubMed     Abstract available


  455. CALO C, Elliott JO, Clements A, Reid G, et al
    Cervical cancer radiation therapy compliance rates based on location of radiation therapy.
    Gynecol Oncol. 2019;152:528-532.
    PubMed     Abstract available


  456. ZAKEM SJ, Robin TP, Smith DE, Amini A, et al
    Evolving trends in the management of high-intermediate risk endometrial cancer in the United States.
    Gynecol Oncol. 2019;152:522-527.
    PubMed     Abstract available


  457. GRESSEL GM, Dioun SM, Richley M, Lounsbury DW, et al
    Utilizing the Patient Reported Outcomes Measurement Information System (PROMIS(R)) to increase referral to ancillary support services for severely symptomatic patients with gynecologic cancer.
    Gynecol Oncol. 2019;152:509-513.
    PubMed     Abstract available


  458. MEYER LA, Shi Q, Lasala J, Iniesta MD, et al
    Comparison of patient reported symptom burden on an enhanced recovery after surgery (ERAS) care pathway in patients with ovarian cancer undergoing primary vs. interval tumor reductive surgery.
    Gynecol Oncol. 2019;152:501-508.
    PubMed     Abstract available


  459. WANG XS, Shi Q, Williams LA, Cleeland CS, et al
    Validation and application of a module of the MD Anderson Symptom Inventory for measuring perioperative symptom burden in patients with gynecologic cancer (the MDASI-PeriOp-GYN).
    Gynecol Oncol. 2019;152:492-500.
    PubMed     Abstract available


  460. KUMAR A, Nesbitt KM, Bakkum-Gamez JN
    Quality improvement in gynecologic oncology: Current successes and future promise.
    Gynecol Oncol. 2019;152:486-491.
    PubMed     Abstract available


  461. NGUYEN JMV, Sadeghi M, Gien LT, Covens A, et al
    Impact of a preventive bundle to reduce surgical site infections in gynecologic oncology.
    Gynecol Oncol. 2019;152:480-485.
    PubMed     Abstract available


  462. VELENTZIS LS, Smith MA, Simms KT, Lew JB, et al
    Pathways to a cancer-free future: A protocol for modelled evaluations to maximize the future impact of interventions on cervical cancer in Australia.
    Gynecol Oncol. 2019;152:465-471.
    PubMed     Abstract available


  463. KWON JS, Tinker AV, Hanley GE, Pansegrau G, et al
    BRCA mutation testing for first-degree relatives of women with high-grade serous ovarian cancer.
    Gynecol Oncol. 2019;152:459-464.
    PubMed     Abstract available


  464. TAYLOR JS, Zhang N, Rajan SS, Chavez-MacGregor M, et al
    How we use hospice: Hospice enrollment patterns and costs in elderly ovarian cancer patients.
    Gynecol Oncol. 2019;152:452-458.
    PubMed     Abstract available


  465. FOOTE JR, Secord AA, Liang MI, Ehrisman JA, et al
    Targeted composite value-based endpoints in platinum-sensitive recurrent ovarian cancer.
    Gynecol Oncol. 2019;152:445-451.
    PubMed     Abstract available


  466. SUIDAN RS, He W, Sun CC, Zhao H, et al
    National trends, outcomes, and costs of radiation therapy in the management of low- and high-intermediate risk endometrial cancer.
    Gynecol Oncol. 2019;152:439-444.
    PubMed     Abstract available


  467. HALL MT, Smith MA, Lew JB, O'Hallahan J, et al
    The combined impact of implementing HPV immunisation and primary HPV screening in New Zealand: Transitional and long-term benefits, costs and resource utilisation implications.
    Gynecol Oncol. 2019;152:472-479.
    PubMed     Abstract available


  468. FELDER M, Kapur A, Rakhmilevich AL, Qu X, et al
    MUC16 suppresses human and murine innate immune responses.
    Gynecol Oncol. 2019;152:618-628.
    PubMed     Abstract available


  469. SHEU J, Palileo A, Chen MY, Hoepner L, et al
    Hospice utilization in advanced cervical malignancies: An analysis of the National Inpatient Sample.
    Gynecol Oncol. 2019;152:594-598.
    PubMed     Abstract available


    February 2019
  470. BROOKS RA, Tritchler DS, Darcy KM, Lankes HA, et al
    GOG 8020/210: Risk stratification of lymph node metastasis, disease progression and survival using single nucleotide polymorphisms in endometrial cancer: An NRG oncology/gynecologic oncology group study.
    Gynecol Oncol. 2019 Feb 28. pii: S0090-8258(19)30138.
    PubMed     Abstract available


  471. TIMMERMANS M, van der Hel O, Sonke GS, Van de Vijver KK, et al
    The prognostic value of residual disease after neoadjuvant chemotherapy in advanced ovarian cancer; A systematic review.
    Gynecol Oncol. 2019 Feb 27. pii: S0090-8258(19)30129.
    PubMed     Abstract available


  472. ARQUIETTE JM, Moss HA, Truong T, Pieper CF, et al
    Impact of a documentation intervention on health-assessment metrics on an inpatient gynecologic oncology service.
    Gynecol Oncol. 2019 Feb 27. pii: S0090-8258(19)30119.
    PubMed     Abstract available


  473. BARRINGTON DA, Dilley SE, Smith HJ, Straughn JM Jr, et al
    Pembrolizumab in advanced recurrent endometrial cancer: A cost-effectiveness analysis.
    Gynecol Oncol. 2019 Feb 24. pii: S0090-8258(19)30123.
    PubMed     Abstract available


  474. JORGENSEN SL, Mogensen O, Petersen MA, Wu CS, et al
    New insights into early recovery after robotic surgery for endometrial cancer.
    Gynecol Oncol. 2019 Feb 23. pii: S0090-8258(19)30111.
    PubMed     Abstract available


  475. MORSE CB, Toukatly MN, Kilgore MR, Agnew KJ, et al
    Tumor infiltrating lymphocytes and homologous recombination deficiency are independently associated with improved survival in ovarian carcinoma.
    Gynecol Oncol. 2019 Feb 22. pii: S0090-8258(19)30121.
    PubMed     Abstract available


  476. HUEPENBECKER SP, Cusworth SE, Kuroki LM, Lu P, et al
    Continuous epidural infusion in gynecologic oncology patients undergoing exploratory laparotomy: The new standard for decreased postoperative pain and opioid use.
    Gynecol Oncol. 2019 Feb 21. pii: S0090-8258(19)30127.
    PubMed     Abstract available


  477. MCGUIRE S, Kara B, Hart PC, Montag A, et al
    Inhibition of fascin in cancer and stromal cells blocks ovarian cancer metastasis.
    Gynecol Oncol. 2019 Feb 20. pii: S0090-8258(19)30059.
    PubMed     Abstract available


  478. MESQUITA KA, Alabdullah M, Griffin M, Toss MS, et al
    ERCC1-XPF deficiency is a predictor of olaparib induced synthetic lethality and platinum sensitivity in epithelial ovarian cancers.
    Gynecol Oncol. 2019 Feb 20. pii: S0090-8258(19)30124.
    PubMed     Abstract available


  479. MATSUO K, Machida H, Mandelbaum RS, Grubbs BH, et al
    Mucinous borderline ovarian tumor versus invasive well-differentiated mucinous ovarian cancer: Difference in characteristics and outcomes.
    Gynecol Oncol. 2019 Feb 20. pii: S0090-8258(19)30106.
    PubMed     Abstract available


  480. MATSUO K, Mandelbaum RS, Adams CL, Roman LD, et al
    Performance and outcome of pelvic exenteration for gynecologic malignancies: A population-based study.
    Gynecol Oncol. 2019 Feb 18. pii: S0090-8258(19)30105.
    PubMed     Abstract available


  481. RODRIGUEZ-FREIXINOS V, Lheureux S, Mandilaras V, Clarke B, et al
    Impact of somatic molecular profiling on clinical trial outcomes in rare epithelial gynecologic cancer patients.
    Gynecol Oncol. 2019 Feb 18. pii: S0090-8258(19)30108.
    PubMed     Abstract available


  482. EINSTEIN MH, Ndlovu N, Lee J, Stier EA, et al
    Cisplatin and radiation therapy in HIV-positive women with locally advanced cervical cancer in sub-Saharan Africa: A phase II study of the AIDS malignancy consortium.
    Gynecol Oncol. 2019 Feb 15. pii: S0090-8258(19)30065.
    PubMed     Abstract available


  483. VAN WALREE IC, Hamaker ME, van de Poll-Franse LV, Vos MC, et al
    Older ovarian cancer survivors report lower long-term health-related quality of life than younger survivors: A study from the population-based profiles registry.
    Gynecol Oncol. 2019 Feb 13. pii: S0090-8258(19)30104.
    PubMed     Abstract available


  484. NAUMANN RW, Coleman RL, Brown J, Moore KN, et al
    Phase III trials in ovarian cancer: The evolving landscape of front line therapy.
    Gynecol Oncol. 2019 Feb 12. pii: S0090-8258(19)30113.
    PubMed     Abstract available


  485. LIANG J, Wolsiefer K, Zestcott CA, Chase D, et al
    Implicit bias toward cervical cancer: Provider and training differences.
    Gynecol Oncol. 2019 Feb 7. pii: S0090-8258(19)30055.
    PubMed     Abstract available


  486. SUSZYNSKA M, Klonowska K, Jasinska AJ, Kozlowski P, et al
    Large-scale meta-analysis of mutations identified in panels of breast/ovarian cancer-related genes - Providing evidence of cancer predisposition genes.
    Gynecol Oncol. 2019 Feb 4. pii: S0090-8258(19)30069.
    PubMed     Abstract available


  487. HUTCHCRAFT ML, Smith B, McLaughlin EM, Hade EM, et al
    Conization pathologic features as a predictor of intermediate and high risk features on radical hysterectomy specimens in early stage cervical cancer.
    Gynecol Oncol. 2019 Feb 2. pii: S0090-8258(19)30068.
    PubMed     Abstract available


  488. LIM SL, Havrilesky LJ, Habib AS, Secord AA, et al
    Cost-effectiveness of hyperthermic intraperitoneal chemotherapy (HIPEC) at interval debulking of epithelial ovarian cancer following neoadjuvant chemotherapy.
    Gynecol Oncol. 2019 Feb 1. pii: S0090-8258(19)30067.
    PubMed     Abstract available


  489. VOGEL RI, Niendorf K, Petzel S, Lee H, et al
    A patient-centered mobile health application to motivate use of genetic counseling among women with ovarian cancer: A pilot randomized controlled trial.
    Gynecol Oncol. 2019 Feb 1. pii: S0090-8258(19)30062.
    PubMed     Abstract available


  490. VASSILAKOS P, Poncet A, Catarino R, Viviano M, et al
    Cost-effectiveness evaluation of HPV self-testing offered to non-attendees in cervical cancer screening in Switzerland.
    Gynecol Oncol. 2019 Feb 1. pii: S0090-8258(19)30064.
    PubMed     Abstract available


  491. ORSULIC S, Karlan BY
    Can molecular subtyping be used to triage women with advanced ovarian cancer to Primary Debulking Surgery or Neoadjuvant Chemotherapy?
    Gynecol Oncol. 2019;152:221-222.
    PubMed    


  492. SOONG TR, Howitt BE, Horowitz N, Nucci MR, et al
    The fallopian tube, "precursor escape" and narrowing the knowledge gap to the origins of high-grade serous carcinoma.
    Gynecol Oncol. 2019;152:426-433.
    PubMed     Abstract available


  493. XIN W, Hua K, Ding J
    The way to display the chylous tubes and to prevent chylous leakage in laparoscopic para-aortic lymphadenectomy.
    Gynecol Oncol. 2019;152:434-435.
    PubMed    


  494. SMITH JA, Le T, Martin GA, Gaikwad A, et al
    Identifying the need to refine the potential patient risk factors for niraparib-induced thrombocytopenia.
    Gynecol Oncol. 2019;152:265-269.
    PubMed     Abstract available


  495. FLEM KARLSEN K, McFadden E, Florenes VA, Davidson B, et al
    Soluble AXL is ubiquitously present in malignant serous effusions.
    Gynecol Oncol. 2019;152:408-415.
    PubMed     Abstract available


  496. XIA P, Huang M, Zhang Y, Xiong X, et al
    NCK1 promotes the angiogenesis of cervical squamous carcinoma via Rac1/PAK1/MMP2 signal pathway.
    Gynecol Oncol. 2019;152:387-395.
    PubMed     Abstract available


    January 2019
  497. HINCHCLIFF EM, Bednar EM, Lu KH, Rauh-Hain JA, et al
    Disparities in gynecologic cancer genetics evaluation.
    Gynecol Oncol. 2019 Jan 30. pii: S0090-8258(19)30066.
    PubMed     Abstract available


  498. NISHIO S, Mikami Y, Tokunaga H, Yaegashi N, et al
    Analysis of gastric-type mucinous carcinoma of the uterine cervix - An aggressive tumor with a poor prognosis: A multi-institutional study.
    Gynecol Oncol. 2019 Jan 29. pii: S0090-8258(19)30063.
    PubMed     Abstract available


  499. HOSKINS P, Eccleston A, Hurry M, Dyer M, et al
    Targeted surgical prevention of epithelial ovarian cancer is cost effective and saves money in BRCA mutation carrying family members of women with epithelial ovarian cancer. A Canadian model.
    Gynecol Oncol. 2019 Jan 28. pii: S0090-8258(19)30061.
    PubMed     Abstract available


  500. MODUGNO F, Goughnour SL, Wallack D, Edwards RP, et al
    Breastfeeding factors and risk of epithelial ovarian cancer.
    Gynecol Oncol. 2019 Jan 25. pii: S0090-8258(19)30060.
    PubMed     Abstract available


  501. CHOI HJ, Heo JH, Park JY, Jeong JY, et al
    A novel PI3K/mTOR dual inhibitor, CMG002, overcomes the chemoresistance in ovarian cancer.
    Gynecol Oncol. 2019 Jan 25. pii: S0090-8258(19)30045.
    PubMed     Abstract available


  502. HURLEY RM, Wahner Hendrickson AE, Visscher DW, Ansell P, et al
    53BP1 as a potential predictor of response in PARP inhibitor-treated homologous recombination-deficient ovarian cancer.
    Gynecol Oncol. 2019 Jan 24. pii: S0090-8258(19)30058.
    PubMed     Abstract available


  503. YANG B, Xu Y, Zhu Q, Xie L, et al
    Treatment efficiency of comprehensive hysteroscopic evaluation and lesion resection combined with progestin therapy in young women with endometrial atypical hyperplasia and endometrial cancer.
    Gynecol Oncol. 2019 Jan 21. pii: S0090-8258(19)30056.
    PubMed     Abstract available


  504. HOLSCHNEIDER CH, Petereit DG, Chu C, Hsu IC, et al
    Brachytherapy: A critical component of primary radiation therapy for cervical cancer: For the Society of Gynecologic Oncology (SGO) and the American Brachytherapy Society (ABS).
    Gynecol Oncol. 2019 Jan 17. pii: S0090-8258(18)31297.
    PubMed     Abstract available


  505. GOODMAN CR, Hatoum S, Seagle BL, Donnelly ED, et al
    Association of chemotherapy and radiotherapy sequence with overall survival in locoregionally advanced endometrial cancer.
    Gynecol Oncol. 2019 Jan 16. pii: S0090-8258(19)30040.
    PubMed     Abstract available


  506. PRODROMIDOU A, Iavazzo C, Fotiou A, Psomiadou V, et al
    The application of fibrin sealant for the prevention of lymphocele after lymphadenectomy in patients with gynecological malignancies: A systematic review and meta-analysis of randomized controlled trials.
    Gynecol Oncol. 2019 Jan 16. pii: S0090-8258(19)30044.
    PubMed     Abstract available


  507. UPPENDAHL LD, Felices M, Bendzick L, Ryan C, et al
    Cytokine-induced memory-like natural killer cells have enhanced function, proliferation, and in vivo expansion against ovarian cancer cells.
    Gynecol Oncol. 2019 Jan 15. pii: S0090-8258(19)30039.
    PubMed     Abstract available


  508. DING J, Cheng XY, Liu S, Ji HY, et al
    Apatinib exerts anti-tumour effects on ovarian cancer cells.
    Gynecol Oncol. 2019 Jan 14. pii: S0090-8258(19)30043.
    PubMed     Abstract available


  509. CRIPE JC, Buchanan TR Jr, Kuroki LM, Wan L, et al
    Association between body mass index and surgical menopausal symptoms in patients with early stage endometrial cancer.
    Gynecol Oncol. 2019 Jan 14. pii: S0090-8258(19)30042.
    PubMed     Abstract available


  510. BREGAR A, Mojtahed A, Kilcoyne A, Kurra V, et al
    CT prediction of surgical outcome in patients with advanced epithelial ovarian carcinoma undergoing neoadjuvant chemotherapy.
    Gynecol Oncol. 2019 Jan 11. pii: S0090-8258(18)31476.
    PubMed     Abstract available


  511. KIM SI, Cho JH, Seol A, Kim YI, et al
    Comparison of survival outcomes between minimally invasive surgery and conventional open surgery for radical hysterectomy as primary treatment in patients with stage IB1-IIA2 cervical cancer.
    Gynecol Oncol. 2019 Jan 11. pii: S0090-8258(19)30041.
    PubMed     Abstract available


  512. OH SH, Park SJ, Lee EJ, Yim GW, et al
    Pelvic lymphadenectomy by vaginal natural orifice transluminal endoscopic surgery (vNOTES) for early-stage endometrial cancer.
    Gynecol Oncol. 2019 Jan 10. pii: S0090-8258(19)30002.
    PubMed    


  513. MCCUAIG JM, Tone AA, Maganti M, Romagnuolo T, et al
    Modified panel-based genetic counseling for ovarian cancer susceptibility: A randomized non-inferiority study.
    Gynecol Oncol. 2019 Jan 10. pii: S0090-8258(18)31541.
    PubMed     Abstract available


  514. FABBRO M, Moore KN, Dorum A, Tinker AV, et al
    Efficacy and safety of niraparib as maintenance treatment in older patients (>/=70years) with recurrent ovarian cancer: Results from the ENGOT-OV16/NOVA trial.
    Gynecol Oncol. 2019 Jan 9. pii: S0090-8258(18)31473.
    PubMed     Abstract available


  515. STOLER MH, Wright TC Jr, Parvu V, Yanson K, et al
    Stratified risk of high-grade cervical disease using onclarity HPV extended genotyping in women, >/=25years of age, with NILM cytology.
    Gynecol Oncol. 2019 Jan 9. pii: S0090-8258(18)31538.
    PubMed     Abstract available


  516. WAGNER P, Kommoss FKF, Kommoss S, Hartkopf AD, et al
    Unexpected malignant uterine pathology: Incidence, characteristics and outcome in a large single-center series of hysterectomies for presumed benign uterine disease.
    Gynecol Oncol. 2019 Jan 8. pii: S0090-8258(18)31540.
    PubMed     Abstract available


  517. BONAZZOLI E, Cocco E, Lopez S, Bellone S, et al
    PI3K oncogenic mutations mediate resistance to afatinib in HER2/neu overexpressing gynecological cancers.
    Gynecol Oncol. 2019 Jan 7. pii: S0090-8258(19)30004.
    PubMed     Abstract available


  518. WANG J, Du Y, Dong J, Zhou Y, et al
    Clinical significance of genotyping for human papillomavirus (HPV) 16 18/45 combined with cytology in cervical exfoliated cells in HPV oncogenic mRNA-positive women.
    Gynecol Oncol. 2019 Jan 7. pii: S0090-8258(18)31542.
    PubMed     Abstract available


  519. MATSUO K, Hom MS, Yabuno A, Shida M, et al
    Association of statins, aspirin, and venous thromboembolism in women with endometrial cancer.
    Gynecol Oncol. 2019 Jan 4. pii: S0090-8258(18)31534.
    PubMed     Abstract available


  520. JERZAK KJ, Duska L, MacKay HJ
    Endocrine therapy in endometrial cancer: An old dog with new tricks.
    Gynecol Oncol. 2019 Jan 4. pii: S0090-8258(18)31518.
    PubMed     Abstract available


  521. YAO T, DeJong SR, McGree ME, Weaver AL, et al
    Frailty in ovarian cancer identified the need for increased postoperative care requirements following cytoreductive surgery.
    Gynecol Oncol. 2019 Jan 3. pii: S0090-8258(18)31539.
    PubMed     Abstract available


  522. FULK K, Milam MR, Li S, Yussuf A, et al
    Women with breast and uterine cancer are more likely to harbor germline mutations than women with breast or uterine cancer alone: A case for expanded gene testing.
    Gynecol Oncol. 2019 Jan 3. pii: S0090-8258(18)31535.
    PubMed     Abstract available


  523. LONG B, Lilyquist J, Weaver A, Hu C, et al
    Cancer susceptibility gene mutations in type I and II endometrial cancer.
    Gynecol Oncol. 2019;152:20-25.
    PubMed     Abstract available


  524. RUSH CM, Goodfellow PJ
    Diverse mutational signatures in endometrial cancer: implications for tumor etiology and evolution.
    Gynecol Oncol. 2019;152:1-2.
    PubMed    


  525. PARK SJ, Kim HS
    Laterally extended endopelvic resection with nephrectomy for vaginal cancer.
    Gynecol Oncol. 2019;152:218-219.
    PubMed    


  526. NICA A, Covens A, Vicus D, Kupets R, et al
    Sentinel lymph nodes in vulvar cancer: Management dilemmas in patients with positive nodes and larger tumors.
    Gynecol Oncol. 2019;152:94-100.
    PubMed     Abstract available


  527. SAND FL, Nielsen DMB, Frederiksen MH, Rasmussen CL, et al
    The prognostic value of p16 and p53 expression for survival after vulvar cancer: A systematic review and meta-analysis.
    Gynecol Oncol. 2019;152:208-217.
    PubMed     Abstract available


  528. LOOPIK DL, Bekkers RLM, Massuger LFAG, Melchers WJG, et al
    Justifying conservative management of CIN2 in women younger than 25years - A population-based study.
    Gynecol Oncol. 2019;152:82-86.
    PubMed     Abstract available


  529. SALCEDO MP, Sood AK, Dos Reis R, Ramalingam P, et al
    Perineural invasion (PNI) in vulvar carcinoma: A review of 421 cases.
    Gynecol Oncol. 2019;152:101-105.
    PubMed     Abstract available


  530. SULLIVAN MW, Camacho FT, Mills AM, Modesitt SC, et al
    Missing information in statewide and national cancer databases: Correlation with health risk factors, geographic disparities, and outcomes.
    Gynecol Oncol. 2019;152:119-126.
    PubMed     Abstract available


    December 2018
  531. LING DC, Vargo JA, Glaser SM, Kim H, et al
    Outcomes after definitive re-irradiation with 3D brachytherapy with or without external beam radiation therapy for vaginal recurrence of endometrial cancer.
    Gynecol Oncol. 2018 Dec 29. pii: S0090-8258(18)31536.
    PubMed     Abstract available


  532. MATULONIS UA, Sill MW, Makker V, Mutch DG, et al
    A randomized phase II study of cabozantinib versus weekly paclitaxel in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer: An NRG Oncology/Gynecologic Oncology Group study.
    Gynecol Oncol. 2018 Dec 23. pii: S0090-8258(18)31460.
    PubMed     Abstract available


  533. ZHANG L, Jiang Y, Lu X, Zhao H, et al
    Genomic characterization of cervical cancer based on human papillomavirus status.
    Gynecol Oncol. 2018 Dec 20. pii: S0090-8258(18)31516.
    PubMed     Abstract available


  534. ROSS JGC, Escamilla V, Lee NK, Diane Yamada S, et al
    Geospatial patterns of access to self-care resources for obesity among endometrial cancer survivors in a high poverty urban community.
    Gynecol Oncol. 2018 Dec 20. pii: S0090-8258(18)31470.
    PubMed     Abstract available


  535. RAUH-HAIN JA, Hidrue MK, Gaccione P, Melamed A, et al
    Variation in resource utilization associated with the surgical management of ovarian cancer.
    Gynecol Oncol. 2018 Dec 19. pii: S0090-8258(18)31513.
    PubMed     Abstract available


  536. MYSONA D, Pyrzak A, Purohit S, Zhi W, et al
    A combined score of clinical factors and serum proteins can predict time to recurrence in high grade serous ovarian cancer.
    Gynecol Oncol. 2018 Dec 18. pii: S0090-8258(18)31515.
    PubMed     Abstract available


  537. CEPPI L, Galli F, Lamanna M, Magni S, et al
    Ovarian function, fertility, and menopause occurrence after fertility-sparing surgery and chemotherapy for ovarian neoplasms.
    Gynecol Oncol. 2018 Dec 18. pii: S0090-8258(18)31452.
    PubMed     Abstract available


  538. BULLS HW, Hoogland AI, Kennedy B, James BW, et al
    A longitudinal examination of associations between age and chemotherapy-induced peripheral neuropathy in patients with gynecologic cancer.
    Gynecol Oncol. 2018 Dec 14. pii: S0090-8258(18)31458.
    PubMed     Abstract available


  539. NIE D, Gong H, Mao X, Li Z, et al
    Systemic immune-inflammation index predicts prognosis in patients with epithelial ovarian cancer: A retrospective study.
    Gynecol Oncol. 2018 Dec 14. pii: S0090-8258(18)31454.
    PubMed     Abstract available


  540. ANGELES MA, Martinez-Gomez C, Martinez A, Ferron G, et al
    En bloc pelvic resection for ovarian carcinomatosis: Hudson procedure in 10 steps.
    Gynecol Oncol. 2018 Dec 14. pii: S0090-8258(18)31471.
    PubMed    


  541. DAVIDSON BA, Broadwater G, Crim A, Boccacio R, et al
    Surgical complexity score and role of laparoscopy in women with advanced ovarian cancer treated with neoadjuvant chemotherapy.
    Gynecol Oncol. 2018 Dec 14. pii: S0090-8258(18)31475.
    PubMed     Abstract available


  542. RODRIGUEZ-FREIXINOS V, Farinas-Madrid L, Gil-Martin M, Barretina-Ginesta P, et al
    Chemotherapy and PARP inhibitors in heavily pretreated BRCA1/2 mutation ovarian cancer (BMOC) patients.
    Gynecol Oncol. 2018 Dec 12. pii: S0090-8258(18)31456.
    PubMed     Abstract available


  543. XIANG M, English DP, Kidd EA
    National patterns of care and cancer-specific outcomes of adjuvant treatment in patients with serous and clear cell endometrial carcinoma.
    Gynecol Oncol. 2018 Dec 12. pii: S0090-8258(18)31472.
    PubMed     Abstract available


  544. NORQUIST BM
    Challenges in the identification of inherited risk of ovarian cancer: where should we go from here?
    Gynecol Oncol. 2018 Dec 8. pii: S0090-8258(18)31459.
    PubMed    


  545. BEDNAR EM, Sun CC, Camacho B, Terrell J, et al
    Disseminating universal genetic testing to a diverse, indigent patient population at a county hospital gynecologic oncology clinic.
    Gynecol Oncol. 2018 Dec 8. pii: S0090-8258(18)31457.
    PubMed     Abstract available


  546. LAW KE, Hildebrand EA, Hawthorne HJ, Hallbeck MS, et al
    A pilot study of non-routine events in gynecological surgery: Type, impact, and effect.
    Gynecol Oncol. 2018 Dec 6. pii: S0090-8258(18)31455.
    PubMed     Abstract available


  547. VARGA A, Piha-Paul S, Ott PA, Mehnert JM, et al
    Pembrolizumab in patients with programmed death ligand 1-positive advanced ovarian cancer: Analysis of KEYNOTE-028.
    Gynecol Oncol. 2018 Dec 3. pii: S0090-8258(18)31418.
    PubMed     Abstract available


  548. DUSKA LR
    Evolving times and paradigms in endometrial cancer: Incorporating and interpreting new data and technologic advances.
    Gynecol Oncol. 2018;151:393-394.
    PubMed    


  549. GAFFNEY DK, Hashibe M, Kepka D, Maurer KA, et al
    Too many women are dying from cervix cancer: Problems and solutions.
    Gynecol Oncol. 2018;151:547-554.
    PubMed     Abstract available


  550. VAN DER LINDEN M, van Esch E, Bulten J, Dreef E, et al
    The immune cell infiltrate in the microenvironment of vulvar Paget disease.
    Gynecol Oncol. 2018;151:453-459.
    PubMed     Abstract available


    November 2018
  551. TORRES D, Kumar A, Bakkum-Gamez JN, Weaver AL, et al
    Mesenchymal molecular subtype is an independent predictor of severe postoperative complications after primary debulking surgery for advanced ovarian cancer.
    Gynecol Oncol. 2018 Nov 28. pii: S0090-8258(18)31420.
    PubMed     Abstract available


  552. HAY CM, Donovan HS, Campbell GB, Taylor SE, et al
    Chemotherapy in older adult gynecologic oncology patients: Can a phenotypic frailty score predict tolerance?
    Gynecol Oncol. 2018 Nov 28. pii: S0090-8258(18)31451.
    PubMed     Abstract available


  553. STANLEY B, Hollis RL, Nunes H, Towler JD, et al
    Endocrine treatment of high grade serous ovarian carcinoma; quantification of efficacy and identification of response predictors.
    Gynecol Oncol. 2018 Nov 27. pii: S0090-8258(18)31450.
    PubMed     Abstract available


  554. PENN CA, Kamdar NS, Morgan DM, Spencer RJ, et al
    Preoperatively predicting non-home discharge after surgery for gynecologic malignancy.
    Gynecol Oncol. 2018 Nov 26. pii: S0090-8258(18)31449.
    PubMed     Abstract available


  555. SUBRAMANIAM A, Einerson BD, Blanchard CT, Erickson BK, et al
    The cost-effectiveness of opportunistic salpingectomy versus standard tubal ligation at the time of cesarean delivery for ovarian cancer risk reduction.
    Gynecol Oncol. 2018 Nov 23. pii: S0090-8258(18)31405.
    PubMed     Abstract available


  556. ALBEESH R, Turgeon GA, Alfieri J, Mansure JJ, et al
    Adjuvant therapy in stage III endometrial cancer confined to the pelvis.
    Gynecol Oncol. 2018 Nov 22. pii: S0090-8258(18)31364.
    PubMed     Abstract available


  557. FRIJSTEIN MM, Lok CAR, van Trommel NE, Ten Kate-Booij MJ, et al
    Management and prognostic factors of epithelioid trophoblastic tumors: Results from the International Society for the Study of Trophoblastic Diseases database.
    Gynecol Oncol. 2018 Nov 22. pii: S0090-8258(18)31416.
    PubMed     Abstract available


  558. WISWELL S, Bell JG, McHale J, Elliott JO, et al
    The effect of art therapy on the quality of life in patients with a gynecologic cancer receiving chemotherapy.
    Gynecol Oncol. 2018 Nov 22. pii: S0090-8258(18)31446.
    PubMed     Abstract available


  559. WAGNER BE, Langstraat CL, McGree ME, Weaver AL, et al
    Beyond prophylaxis: Extended risk of venous thromboembolism following primary debulking surgery for ovarian cancer.
    Gynecol Oncol. 2018 Nov 21. pii: S0090-8258(18)31422.
    PubMed     Abstract available


  560. JAVELLANA M, Hoppenot C, Lengyel E
    The road to long-term survival: Surgical approach and longitudinal treatments of long-term survivors of advanced-stage serous ovarian cancer.
    Gynecol Oncol. 2018 Nov 21. pii: S0090-8258(18)31404.
    PubMed     Abstract available


  561. BOLAND JL, Zhou Q, Martin M, Callahan MK, et al
    Early disease progression and treatment discontinuation in patients with advanced ovarian cancer receiving immune checkpoint blockade.
    Gynecol Oncol. 2018 Nov 20. pii: S0090-8258(18)31445.
    PubMed     Abstract available


  562. SANJIDA S, Janda M, McPhail SM, Kissane D, et al
    How many patients enter endometrial cancer surgery with psychotropic medication prescriptions, and how many receive a new prescription perioperatively?
    Gynecol Oncol. 2018 Nov 19. pii: S0090-8258(18)31419.
    PubMed     Abstract available


  563. ZHU B, Pan Y, Zheng X, Zhang Q, et al
    A clinical, biologic and mechanistic analysis of the role of ZNF692 in cervical cancer.
    Gynecol Oncol. 2018 Nov 19. pii: S0090-8258(18)31423.
    PubMed     Abstract available


  564. HEITZ F, Harter P, Avall-Lundqvist E, Reuss A, et al
    Early tumor regrowth is a contributor to impaired survival in patients with completely resected advanced ovarian cancer. An exploratory analysis of the Intergroup trial AGO-OVAR 12.
    Gynecol Oncol. 2018 Nov 19. pii: S0090-8258(18)31406.
    PubMed     Abstract available


  565. PRADER S, Vollmar N, du Bois A, Heitz F, et al
    Pattern and impact of metastatic cardiophrenic lymph nodes in advanced epithelial ovarian cancer.
    Gynecol Oncol. 2018 Nov 18. pii: S0090-8258(18)31363.
    PubMed     Abstract available


  566. GONZALEZ MARTIN A, Oza AM, Embleton AC, Pfisterer J, et al
    Exploratory outcome analyses according to stage and/or residual disease in the ICON7 trial of carboplatin and paclitaxel with or without bevacizumab for newly diagnosed ovarian cancer.
    Gynecol Oncol. 2018 Nov 15. pii: S0090-8258(18)31166.
    PubMed     Abstract available


  567. ZHANG Q, Wang C, Cliby WA
    Cancer-associated stroma significantly contributes to the mesenchymal subtype signature of serous ovarian cancer.
    Gynecol Oncol. 2018 Nov 15. pii: S0090-8258(18)31415.
    PubMed     Abstract available


  568. ROMEO C, Joly F, Ray-Coquard I, El Kouri C, et al
    Non-pegylated liposomal doxorubicin (NPLD, Myocet(R))+carboplatin in patients with platinum sensitive ovarian cancers: A ARCAGY-GINECO phase IB-II trial.
    Gynecol Oncol. 2018 Nov 14. pii: S0090-8258(18)31358.
    PubMed     Abstract available


  569. KOTOULA V, Lakis S, Tikas I, Giannoulatou E, et al
    Pathogenic BRCA1 mutations may be necessary but not sufficient for tissue genomic heterogeneity: Deep sequencing data from ovarian cancer patients.
    Gynecol Oncol. 2018 Nov 14. pii: S0090-8258(18)31417.
    PubMed     Abstract available


  570. SIN STK, Li Y, Liu M, Ma S, et al
    TROP-2 exhibits tumor suppressive functions in cervical cancer by dual inhibition of IGF-1R and ALK signaling.
    Gynecol Oncol. 2018 Nov 12. pii: S0090-8258(18)31354.
    PubMed     Abstract available


  571. SPEES LP, Wheeler SB, Varia M, Weinberger M, et al
    Evaluating the urban-rural paradox: The complicated relationship between distance and the receipt of guideline-concordant care among cervical cancer patients.
    Gynecol Oncol. 2018 Nov 12. pii: S0090-8258(18)31407.
    PubMed     Abstract available


  572. UPPAL S, Rebecca Liu J, Kevin Reynolds R, Rice LW, et al
    Trends and comparative effectiveness of inpatient radical hysterectomy for cervical cancer in the United States (2012-2015).
    Gynecol Oncol. 2018 Nov 10. pii: S0090-8258(18)31246.
    PubMed     Abstract available


  573. BUCKINGHAM L, Haggerty A, Graul A, Morgan M, et al
    Sexual function following hysterectomy for endometrial cancer: A five-year follow up investigation.
    Gynecol Oncol. 2018 Nov 9. pii: S0090-8258(18)31308.
    PubMed     Abstract available


  574. TORTORELLA L, Casarin J, Mara KC, Weaver AL, et al
    Prediction of short-term surgical complications in women undergoing pelvic exenteration for gynecological malignancies.
    Gynecol Oncol. 2018 Nov 8. pii: S0090-8258(18)31350.
    PubMed     Abstract available


  575. KURNIT KC, Previs RA, Soliman PT, Westin SN, et al
    Prognostic factors impacting survival in early stage uterine carcinosarcoma.
    Gynecol Oncol. 2018 Nov 8. pii: S0090-8258(18)31317.
    PubMed     Abstract available


  576. ASHLEY CW, Da Cruz Paula A, Kumar R, Mandelker D, et al
    Analysis of mutational signatures in primary and metastatic endometrial cancer reveals distinct patterns of DNA repair defects and shifts during tumor progression.
    Gynecol Oncol. 2018 Nov 8. pii: S0090-8258(18)31316.
    PubMed     Abstract available


  577. HALL E, Finch A, Jacobson M, Rosen B, et al
    Effects of bilateral salpingo-oophorectomy on menopausal symptoms and sexual functioning among women with a BRCA1 or BRCA2 mutation.
    Gynecol Oncol. 2018 Nov 7. pii: S0090-8258(18)31355.
    PubMed     Abstract available


  578. ZHONG Q, Hu Z, Li Q, Yi T, et al
    Cyclin D1 silencing impairs DNA double strand break repair, sensitizes BRCA1 wildtype ovarian cancer cells to olaparib.
    Gynecol Oncol. 2018 Nov 7. pii: S0090-8258(18)31310.
    PubMed     Abstract available


  579. TURASHVILI G, Gomez-Hidalgo NR, Flynn J, Gonen M, et al
    Risk-based stratification of carcinomas concurrently involving the endometrium and ovary.
    Gynecol Oncol. 2018 Nov 6. pii: S0090-8258(18)31315.
    PubMed     Abstract available


  580. LEE JY, Park JY, Park SY, Lee JW, et al
    Real-world effectiveness of bevacizumab based on AURELIA in platinum-resistant recurrent ovarian cancer (REBECA): A Korean Gynecologic Oncology Group study (KGOG 3041).
    Gynecol Oncol. 2018 Nov 5. pii: S0090-8258(18)31314.
    PubMed     Abstract available


  581. MULLEN MM, Kuroki LM, Thaker PH
    Novel treatment options in platinum-sensitive recurrent ovarian cancer: A review.
    Gynecol Oncol. 2018 Nov 5. pii: S0090-8258(18)31306.
    PubMed     Abstract available


  582. SPENCER RJ, Rice LW, Ye C, Woo K, et al
    Disparities in the allocation of research funding to gynecologic cancers by Funding to Lethality scores.
    Gynecol Oncol. 2018 Nov 4. pii: S0090-8258(18)31302.
    PubMed     Abstract available


  583. SELLA T, Stone RM
    The impact of new drugs for breast and ovarian cancer on the occurrence of therapy-related myeloid neoplasms: Understanding the baseline incidence.
    Gynecol Oncol. 2018;151:187-189.
    PubMed    


  584. LEEMAN A, Ebisch RMF, Kasius A, Bosgraaf RP, et al
    Defining hrHPV genotypes in cervical intraepithelial neoplasia by laser capture microdissection supports reflex triage of self-samples using HPV16/18 and FAM19A4/miR124-2 methylation.
    Gynecol Oncol. 2018;151:311-318.
    PubMed     Abstract available


  585. FIANO V, Trevisan M, Fasanelli F, Grasso C, et al
    Methylation in host and viral genes as marker of aggressiveness in cervical lesions: Analysis in 543 unscreened women.
    Gynecol Oncol. 2018;151:319-326.
    PubMed     Abstract available


  586. SPAANS VM, Scheunhage DA, Barzaghi B, de Kroon CD, et al
    Independent validation of the prognostic significance of invasion patterns in endocervical adenocarcinoma: Pattern A predicts excellent survival.
    Gynecol Oncol. 2018;151:196-201.
    PubMed     Abstract available


    October 2018
  587. MATSUO K, Machida H, Mandelbaum RS, Konishi I, et al
    Validation of the 2018 FIGO cervical cancer staging system.
    Gynecol Oncol. 2018 Oct 30. pii: S0090-8258(18)31309.
    PubMed     Abstract available


  588. WANG Y, Jiang J, He L, Gong G, et al
    Effect of lamin-A expression on migration and nuclear stability of ovarian cancer cells.
    Gynecol Oncol. 2018 Oct 29. pii: S0090-8258(18)31313.
    PubMed     Abstract available


  589. DUSKA LR, Suh DH, Wilson M, Diane Yamada S, et al
    International Gynecologic Cancer Society (IGCS) 2018: Meeting report.
    Gynecol Oncol. 2018 Oct 27. pii: S0090-8258(18)31301.
    PubMed    


  590. TANGEN IL, Fasmer KE, Konings GF, Jochems A, et al
    Blood steroids are associated with prognosis and fat distribution in endometrial cancer.
    Gynecol Oncol. 2018 Oct 26. pii: S0090-8258(18)31307.
    PubMed     Abstract available


  591. DING L, Ding Y, Kong X, Wu J, et al
    Dysregulation of Kruppel-like factor 12 in the development of endometrial cancer.
    Gynecol Oncol. 2018 Oct 25. pii: S0090-8258(18)31311.
    PubMed     Abstract available


  592. HANSEN JM, Sood AK, Coleman RL, Westin SN, et al
    Concordance of a laparoscopic scoring algorithm with primary surgery findings in advanced stage ovarian cancer.
    Gynecol Oncol. 2018 Oct 23. pii: S0090-8258(18)31299.
    PubMed     Abstract available


  593. HINCHCLIFF E, Hong D, Le H, Chisholm G, et al
    Characteristics and outcomes of patients with recurrent ovarian cancer undergoing early phase immune checkpoint inhibitor clinical trials.
    Gynecol Oncol. 2018 Oct 23. pii: S0090-8258(18)31287.
    PubMed     Abstract available


  594. OLAWAIYE AB, Java JJ, Krivak TC, Friedlander M, et al
    Corrigendum to "Does adjuvant chemotherapy dose modification have an impact on the outcome of patients diagnosed with advanced stage ovarian cancer? An NRG Oncology/Gynecologic Oncology Group study" [Gynecol. Oncol. 151 (2018) 18-23].
    Gynecol Oncol. 2018 Oct 22. pii: S0090-8258(18)31303.
    PubMed    


  595. CIBULA D, Abu-Rustum NR, Fischerova D, Pather S, et al
    Surgical treatment of "intermediate risk" lymph node negative cervical cancer patients without adjuvant radiotherapy-A retrospective cohort study and review of the literature.
    Gynecol Oncol. 2018 Oct 20. pii: S0090-8258(18)31298.
    PubMed     Abstract available


  596. TA RM, Hecht JL, Lin DI
    Discordant loss of mismatch repair proteins in advanced endometrial endometrioid carcinoma compared to paired primary uterine tumors.
    Gynecol Oncol. 2018 Oct 16. pii: S0090-8258(18)31291.
    PubMed     Abstract available


  597. HUANG C, Lu H, Li J, Xie X, et al
    SOX2 regulates radioresistance in cervical cancer via the hedgehog signaling pathway.
    Gynecol Oncol. 2018 Oct 15. pii: S0090-8258(18)31284.
    PubMed     Abstract available


  598. TANNER EJ, Filippova OT, Gardner GJ, Long Roche KC, et al
    A prospective trial of acute normovolemic hemodilution in patients undergoing primary cytoreductive surgery for advanced ovarian cancer.
    Gynecol Oncol. 2018 Oct 15. pii: S0090-8258(18)31285.
    PubMed     Abstract available


  599. SAPIENZA LG, Jhingran A, Kollmeier MA, Lin LL, et al
    Decrease in uterine perforations with ultrasound image-guided applicator insertion in intracavitary brachytherapy for cervical cancer: A systematic review and meta-analysis.
    Gynecol Oncol. 2018 Oct 14. pii: S0090-8258(18)31290.
    PubMed     Abstract available


  600. CARTER NJ, Marshall ML, Susswein LR, Zorn KK, et al
    Germline pathogenic variants identified in women with ovarian tumors.
    Gynecol Oncol. 2018 Oct 12. pii: S0090-8258(18)31249.
    PubMed     Abstract available


  601. CIBULA D, McCluggage WG
    Sentinel lymph node (SLN) concept in cervical cancer: Current limitations and unanswered questions.
    Gynecol Oncol. 2018 Oct 11. pii: S0090-8258(18)31286.
    PubMed     Abstract available


  602. SALINARO JR, Puechl AM, Havrilesky LJ, Davidson BA, et al
    Gender trends in gynecologic oncology authorship: Implications for the critical evaluation of gender distribution in academic rank and leadership positions.
    Gynecol Oncol. 2018 Oct 9. pii: S0090-8258(18)31288.
    PubMed     Abstract available


  603. KIM HS, Kim JY, Lee YJ, Kim SH, et al
    Expression of programmed cell death ligand 1 and immune checkpoint markers in residual tumors after neoadjuvant chemotherapy for advanced high-grade serous ovarian cancer.
    Gynecol Oncol. 2018 Oct 9. pii: S0090-8258(18)31153.
    PubMed     Abstract available


  604. NAUMANN RW, Morris JC, Tait DL, Higgins RV, et al
    Patients with BRCA mutations have superior outcomes after intraperitoneal chemotherapy in optimally resected high grade ovarian cancer.
    Gynecol Oncol. 2018 Oct 8. pii: S0090-8258(18)31282.
    PubMed     Abstract available


  605. MONK BJ, Kauderer JT, Moxley KM, Bonebrake AJ, et al
    A phase II evaluation of elesclomol sodium and weekly paclitaxel in the treatment of recurrent or persistent platinum-resistant ovarian, fallopian tube or primary peritoneal cancer: An NRG oncology/gynecologic oncology group study.
    Gynecol Oncol. 2018 Oct 8. pii: S0090-8258(18)31281.
    PubMed     Abstract available


  606. BELUR NAGARAJ A, Joseph P, Kovalenko O, Wang Q, et al
    Evaluating class III antiarrhythmic agents as novel MYC targeting drugs in ovarian cancer.
    Gynecol Oncol. 2018 Oct 6. pii: S0090-8258(18)31238.
    PubMed     Abstract available


  607. WANG J, Dean DC, Hornicek FJ, Shi H, et al
    RNA sequencing (RNA-Seq) and its application in ovarian cancer.
    Gynecol Oncol. 2018 Oct 5. pii: S0090-8258(18)31283.
    PubMed     Abstract available


  608. RASH JK, Lyle KD, Jairam-Thodla A, Ioffe Y, et al
    Delivery of gynecologic oncology care: Optimizing scope of advanced practice providers to enhance patient care: A Society of Gynecologic Oncology Position Paper.
    Gynecol Oncol. 2018 Oct 4. pii: S0090-8258(18)31237.
    PubMed    


  609. WANG W, Zou W, Liu JR
    Tumor-infiltrating T cells in epithelial ovarian cancer: predictors of prognosis and biological basis of immunotherapy.
    Gynecol Oncol. 2018;151:1-3.
    PubMed    


  610. ALOISI A, Casanova JM, Tseng JH, Seader KA, et al
    Patterns of FIRST recurrence of stage IIIC1 endometrial cancer with no PARAAORTIC nodal assessment.
    Gynecol Oncol. 2018 Oct 1. pii: S0090-8258(18)31240.
    PubMed     Abstract available


  611. MARTINEZ-GOMEZ C, Angeles MA, Martinez A, Ferron G, et al
    Creation of a Miami Pouch in 10 logical steps.
    Gynecol Oncol. 2018;151:178-179.
    PubMed    


  612. MATSUOKA A, Tate S, Nishikimi K, Shozu M, et al
    Successful retroperitoneal lymphadenectomy for double inferior vena cava with preoperative assessment using contrast-enhanced and three-dimensional computed tomography.
    Gynecol Oncol. 2018;151:180-181.
    PubMed    


  613. RODRIGUES LLS, Morgado MG, Sahasrabuddhe VV, De Paula VS, et al
    Cervico-vaginal self-collection in HIV-infected and uninfected women from Tapajos region, Amazon, Brazil: High acceptability, hrHPV diversity and risk factors.
    Gynecol Oncol. 2018;151:102-110.
    PubMed     Abstract available


  614. HORNE ZD, Dohopolski MJ, Pradhan D, Bhargava R, et al
    Human papillomavirus infection mediates response and outcome of vulvar squamous cell carcinomas treated with radiation therapy.
    Gynecol Oncol. 2018;151:96-101.
    PubMed     Abstract available


    September 2018
  615. ELNAGGAR AC, Hade EM, O'Malley DM, Liang MI, et al
    Time to chemotherapy in ovarian cancer: Compliance with ovarian cancer quality indicators at a National Cancer Institute-designated Comprehensive Cancer Center.
    Gynecol Oncol. 2018 Sep 30. pii: S0090-8258(18)31233.
    PubMed     Abstract available


  616. NASSER S, Lathouras K, Nixon K, Campbell J, et al
    Impact of right upper quadrant cytoreductive techniques with extensive liver mobilization on postoperative hepatic function and risk of liver failure in patients with advanced ovarian cancer.
    Gynecol Oncol. 2018 Sep 29. pii: S0090-8258(18)31247.
    PubMed     Abstract available


  617. MATSUOKA A, Tate S, Nishikimi K, Shozu M, et al
    Left cardiophrenic lymph node resection for advanced ovarian cancer with adhesion to the thoracic cavity.
    Gynecol Oncol. 2018 Sep 27. pii: S0090-8258(18)31241.
    PubMed    


  618. ZHANG L, Xu XQ, Hu SY, Chen F, et al
    Durability of clinical performance afforded by self-collected HPV testing: A 15-year cohort study in China.
    Gynecol Oncol. 2018 Sep 27. pii: S0090-8258(18)31231.
    PubMed     Abstract available


  619. SHENOLIKAR R, Durden E, Meyer N, Lenhart G, et al
    Incidence of secondary myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) in patients with ovarian or breast cancer in a real-world setting in the United States.
    Gynecol Oncol. 2018 Sep 26. pii: S0090-8258(18)31176.
    PubMed     Abstract available


  620. MANGILI G, Cioffi R, Danese S, Frigerio L, et al
    Does methotrexate (MTX) dosing in a 8-day MTX/FA regimen for the treatment of low-risk gestational trophoblastic neoplasia affect outcomes? The MITO-9 study.
    Gynecol Oncol. 2018 Sep 26. pii: S0090-8258(18)31244.
    PubMed     Abstract available


  621. WANG W, Zhang F, Hu K, Hou X, et al
    Image-guided, intensity-modulated radiation therapy in definitive radiotherapy for 1433 patients with cervical cancer.
    Gynecol Oncol. 2018 Sep 25. pii: S0090-8258(18)31243.
    PubMed     Abstract available


  622. LIM SL, Moss HA, Secord AA, Lee PS, et al
    Hysterectomy with sentinel lymph node biopsy in the setting of pre-operative diagnosis of endometrial intraepithelial neoplasia: A cost-effectiveness analysis.
    Gynecol Oncol. 2018 Sep 23. pii: S0090-8258(18)31239.
    PubMed     Abstract available


  623. NIEMI RJ, Roine AN, Eraviita E, Kumpulainen PS, et al
    FAIMS analysis of urine gaseous headspace is capable of differentiating ovarian cancer.
    Gynecol Oncol. 2018 Sep 23. pii: S0090-8258(18)31235.
    PubMed     Abstract available


  624. TAYLOR JS, He W, Harrison R, Zhao H, et al
    Disparities in treatment and survival among elderly ovarian cancer patients.
    Gynecol Oncol. 2018 Sep 22. pii: S0090-8258(18)31171.
    PubMed     Abstract available


  625. HANNIBAL CG, Dehlendorff C, Kjaer SK
    Use of paracetamol, low-dose aspirin, or non-aspirin non-steroidal anti-inflammatory drugs and risk of ovarian borderline tumors in Denmark.
    Gynecol Oncol. 2018 Sep 21. pii: S0090-8258(18)31242.
    PubMed     Abstract available


  626. ZIVANOVIC O, Chi DS, Filippova O, Randall LM, et al
    It's time to warm up to hyperthermic intraperitoneal chemotherapy for patients with ovarian cancer.
    Gynecol Oncol. 2018 Sep 21. pii: S0090-8258(18)31218.
    PubMed     Abstract available


  627. HUA W, Zhao Y, Jin X, Yu D, et al
    METTL3 promotes ovarian carcinoma growth and invasion through the regulation of AXL translation and epithelial to mesenchymal transition.
    Gynecol Oncol. 2018 Sep 21. pii: S0090-8258(18)31234.
    PubMed     Abstract available


  628. BOITANO TKL, Smith HJ, Rushton T, Johnston MC, et al
    Impact of enhanced recovery after surgery (ERAS) protocol on gastrointestinal function in gynecologic oncology patients undergoing laparotomy.
    Gynecol Oncol. 2018 Sep 20. pii: S0090-8258(18)31220.
    PubMed     Abstract available


  629. ROBERTS ME, Aynardi JT, Chu CS
    Uterine leiomyosarcoma: A review of the literature and update on management options.
    Gynecol Oncol. 2018 Sep 20. pii: S0090-8258(18)31221.
    PubMed     Abstract available


  630. DOWDY SC, Cliby WA, Famuyide AO
    Quality indicators in gynecologic oncology.
    Gynecol Oncol. 2018 Sep 13. pii: S0090-8258(18)31175.
    PubMed    


  631. WANG D, Cao D, Jia C, Huang H, et al
    Analysis of oncologic and reproductive outcomes after fertility-sparing surgery in apparent stage I adult ovarian granulosa cell tumors.
    Gynecol Oncol. 2018 Sep 12. pii: S0090-8258(18)31214.
    PubMed     Abstract available


  632. ODA K, Hamanishi J, Matsuo K, Hasegawa K, et al
    Genomics to immunotherapy of ovarian clear cell carcinoma: Unique opportunities for management.
    Gynecol Oncol. 2018 Sep 11. pii: S0090-8258(18)31174.
    PubMed     Abstract available


  633. JAZAERI A, Coleman RL, Sood AK, Frumovitz MM, et al
    A practical guide for the safe implementation of early phase drug development and immunotherapy program in gynecologic oncology practice.
    Gynecol Oncol. 2018 Sep 10. pii: S0090-8258(18)31167.
    PubMed     Abstract available


  634. AZIZ D, Etemadmoghadam D, Caldon CE, Au-Yeung G, et al
    19q12 amplified and non-amplified subsets of high grade serous ovarian cancer with overexpression of cyclin E1 differ in their molecular drivers and clinical outcomes.
    Gynecol Oncol. 2018 Sep 9. pii: S0090-8258(18)31169.
    PubMed     Abstract available


  635. ZHAO H, Yu H, Zheng J, Ning N, et al
    Lowly-expressed lncRNA GAS5 facilitates progression of ovarian cancer through targeting miR-196-5p and thereby regulating HOXA5.
    Gynecol Oncol. 2018 Sep 7. pii: S0090-8258(18)31162.
    PubMed     Abstract available


  636. CONNOR JP, O'Shea A, McCool K, Sampene E, et al
    Peri-operative allogeneic blood transfusion is associated with poor overall survival in advanced epithelial ovarian Cancer; potential impact of patient blood management on Cancer outcomes.
    Gynecol Oncol. 2018 Sep 7. pii: S0090-8258(18)31170.
    PubMed     Abstract available


  637. MATSUO K, Machida H, Mandelbaum RS, Ragab OM, et al
    Tumor-specific outcome of metachronous uterine malignancy after pelvic irradiation for cervical cancer.
    Gynecol Oncol. 2018 Sep 6. pii: S0090-8258(18)31165.
    PubMed     Abstract available


  638. RAJKUMAR S, Polson A, Nath R, Lane G, et al
    Prognostic implications of histological tumor regression (Bohm's score) in patients receiving neoadjuvant chemotherapy for high grade serous tubal & ovarian carcinoma.
    Gynecol Oncol. 2018 Sep 6. pii: S0090-8258(18)31172.
    PubMed     Abstract available


  639. GHELARDI A, Parazzini F, Martella F, Pieralli A, et al
    SPERANZA project: HPV vaccination after treatment for CIN2.
    Gynecol Oncol. 2018 Sep 6. pii: S0090-8258(18)31163.
    PubMed    


  640. KIM HJ, Chang JS, Koom WS, Lee KC, et al
    Radiotherapy is a safe and effective salvage treatment for recurrent cervical cancer.
    Gynecol Oncol. 2018 Sep 5. pii: S0090-8258(18)31158.
    PubMed     Abstract available


  641. SCURRY J, van Zyl B, Gulliver D, Otton G, et al
    Nucleotide excision repair protein ERCC1 and tumour-infiltrating lymphocytes are potential biomarkers of neoadjuvant platinum resistance in high grade serous ovarian cancer.
    Gynecol Oncol. 2018 Sep 4. pii: S0090-8258(18)31160.
    PubMed     Abstract available


  642. SIMONDS HM, Botha MH, Neugut AI, Van Der Merwe FH, et al
    Five-year overall survival following chemoradiation among HIV-positive and HIV-negative patients with locally advanced cervical carcinoma in a South African cohort.
    Gynecol Oncol. 2018 Sep 4. pii: S0090-8258(18)31168.
    PubMed     Abstract available


  643. LIU Y, Weber Z, San Lucas FA, Deshpande A, et al
    Assessing inter-component heterogeneity of biphasic uterine carcinosarcomas.
    Gynecol Oncol. 2018 Sep 4. pii: S0090-8258(18)31173.
    PubMed     Abstract available


  644. MILLS KA, Roach ST, Quinn JM, Guo L, et al
    SQ1274, a novel microtubule inhibitor, inhibits ovarian and uterine cancer cell growth.
    Gynecol Oncol. 2018 Sep 3. pii: S0090-8258(18)31097.
    PubMed     Abstract available


  645. TSENG JH, Cowan RA, Afonso AM, Zhou Q, et al
    Perioperative epidural use and survival outcomes in patients undergoing primary debulking surgery for advanced ovarian cancer.
    Gynecol Oncol. 2018 Sep 2. pii: S0090-8258(18)31154.
    PubMed     Abstract available


  646. YEN TT, Miyamoto T, Asaka S, Chui MH, et al
    Loss of ARID1A expression in endometrial samplings is associated with the risk of endometrial carcinoma.
    Gynecol Oncol. 2018;150:426-431.
    PubMed     Abstract available


  647. DE VINCENZO R, Tortorella L, Ricci C, Cavaliere AF, et al
    Locally advanced cervical cancer complicating pregnancy: A case of competing risks from the Catholic University of the Sacred Heart in Rome.
    Gynecol Oncol. 2018;150:398-405.
    PubMed     Abstract available


  648. DEL CARMEN MG, Pareja R, Melamed A, Rodriguez J, et al
    Isolated para-aortic lymph node metastasis in FIGO stage IA2-IB2 carcinoma of the cervix: Revisiting the role of surgical assessment.
    Gynecol Oncol. 2018;150:406-411.
    PubMed     Abstract available


  649. ZIEBA S, Kowalik A, Zalewski K, Rusetska N, et al
    Somatic mutation profiling of vulvar cancer: Exploring therapeutic targets.
    Gynecol Oncol. 2018;150:552-561.
    PubMed     Abstract available


    August 2018
  650. TEW WP, Sill MW, Walker JL, Secord AA, et al
    Randomized phase II trial of bevacizumab plus everolimus versus bevacizumab alone for recurrent or persistent ovarian, fallopian tube or peritoneal carcinoma: An NRG oncology/gynecologic oncology group study.
    Gynecol Oncol. 2018 Aug 31. pii: S0090-8258(18)31157.
    PubMed     Abstract available


  651. SCHLAPPE BA, Weaver AL, Ducie JA, Eriksson AGZ, et al
    Multicenter study comparing oncologic outcomes between two nodal assessment methods in patients with deeply invasive endometrioid endometrial carcinoma: A sentinel lymph node algorithm versus a comprehensive pelvic and paraaortic lymphadenectomy.
    Gynecol Oncol. 2018 Aug 31. pii: S0090-8258(18)31152.
    PubMed     Abstract available


  652. BOARDMAN CH, Brady WE, Dizon DS, Kunos CA, et al
    A Phase I Evaluation of Extended Field Radiation Therapy With Concomitant Cisplatin Chemotherapy Followed by Paclitaxel and Carboplatin Chemotherapy in Women With Cervical Carcinoma Metastatic to the Para-aortic Lymph Nodes: An NRG Oncology/Gynecologi
    Gynecol Oncol. 2018 Aug 31. pii: S0090-8258(18)31095.
    PubMed     Abstract available


  653. KIM SR, Pina A, Albert A, McAlpine J, et al
    Does MMR status in endometrial cancer influence response to adjuvant therapy?
    Gynecol Oncol. 2018 Aug 29. pii: S0090-8258(18)31151.
    PubMed     Abstract available


  654. SHINDE A, Li R, Amini A, Chen YJ, et al
    Improved survival with adjuvant brachytherapy in stage IA endometrial cancer of unfavorable histology.
    Gynecol Oncol. 2018 Aug 28. pii: S0090-8258(18)31159.
    PubMed     Abstract available


  655. VAN NIEUWENHUYSEN E, Busschaert P, Neven P, Han SN, et al
    The genetic landscape of 87 ovarian germ cell tumors.
    Gynecol Oncol. 2018 Aug 28. pii: S0090-8258(18)31130.
    PubMed     Abstract available


  656. LYCKE M, Kristjansdottir B, Sundfeldt K
    A multicenter clinical trial validating the performance of HE4, CA125, risk of ovarian malignancy algorithm and risk of malignancy index.
    Gynecol Oncol. 2018 Aug 24. pii: S0090-8258(18)31155.
    PubMed     Abstract available


  657. DIOUN S, Jorgensen JR, Miller EM, Tymon-Rosario J, et al
    Unplanned hospitalizations in a racially and ethnically diverse population of women receiving chemotherapy for epithelial ovarian cancer.
    Gynecol Oncol. 2018 Aug 24. pii: S0090-8258(18)31150.
    PubMed     Abstract available


  658. YUK JS, Lee JH
    Six-year survival of patients with unsuspected uterine malignancy after laparoscopic versus laparotomic myomectomy: An 11-year national retrospective cohort study.
    Gynecol Oncol. 2018 Aug 24. pii: S0090-8258(18)31156.
    PubMed     Abstract available


  659. RAUH-HAIN JA, Brewster WR, Behbakht K
    Society of Gynecologic Oncology 2018 Annual Meeting on Women's Cancer: Meeting report.
    Gynecol Oncol. 2018 Aug 24. pii: S0090-8258(18)31149.
    PubMed    


  660. CHANG JS, Kim SW, Kim YJ, Kim JY, et al
    Involved-field radiation therapy for recurrent ovarian cancer: Results of a multi-institutional prospective phase II trial.
    Gynecol Oncol. 2018 Aug 24. pii: S0090-8258(18)31129.
    PubMed     Abstract available


  661. NISHIKIMI K, Tate S, Matsuoka A, Shozu M, et al
    Resection of a metastatic bulky subphrenic tumor for the treatment of advanced ovarian cancer using liver mobilization and the Pringle maneuver.
    Gynecol Oncol. 2018 Aug 20. pii: S0090-8258(18)31134.
    PubMed     Abstract available


  662. OLAWAIYE AB, Java JJ, Krivak TC, Friedlander M, et al
    Does adjuvant chemotherapy dose modification have an impact on the outcome of patients diagnosed with advanced stage ovarian cancer? An NRG Oncology/Gynecologic Oncology Group study.
    Gynecol Oncol. 2018 Aug 19. pii: S0090-8258(18)31085.
    PubMed     Abstract available


  663. TSENG JH, Cowan RA, Zhou Q, Iasonos A, et al
    Continuous improvement in primary Debulking surgery for advanced ovarian cancer: Do increased complete gross resection rates independently lead to increased progression-free and overall survival?
    Gynecol Oncol. 2018 Aug 17. pii: S0090-8258(18)31131.
    PubMed     Abstract available


  664. SON JH, Lee JH, Jung JA, Kong TW, et al
    Risk factors for septic adverse events and their impact on survival in advanced ovarian cancer patients treated with neoadjuvant chemotherapy and interval debulking surgery.
    Gynecol Oncol. 2018 Aug 16. pii: S0090-8258(18)31098.
    PubMed     Abstract available


  665. BARBER EL, Rossi EC, Alexander A, Bilimoria K, et al
    Benign hysterectomy performed by gynecologic oncologists: Is selection bias altering our ability to measure surgical quality?
    Gynecol Oncol. 2018 Aug 15. pii: S0090-8258(18)31127.
    PubMed     Abstract available


  666. PERES LC, Cushing-Haugen KL, Anglesio M, Wicklund K, et al
    Histotype classification of ovarian carcinoma: A comparison of approaches.
    Gynecol Oncol. 2018 Aug 15. pii: S0090-8258(18)31133.
    PubMed     Abstract available


  667. ULM MA, ElNaggar AC, Tillmanns TD
    Celecoxib versus ketorolac following robotic hysterectomy for the management of postoperative pain: An open-label randomized control trial.
    Gynecol Oncol. 2018 Aug 15. pii: S0090-8258(18)31132.
    PubMed     Abstract available


  668. CONNOR EV, Newlin EM, Jelovsek JE, AlHilli MM, et al
    Predicting non-home discharge in epithelial ovarian cancer patients: External validation of a predictive model.
    Gynecol Oncol. 2018 Aug 11. pii: S0090-8258(18)31128.
    PubMed     Abstract available


  669. BISCH SP, Wells T, Gramlich L, Faris P, et al
    Enhanced Recovery After Surgery (ERAS) in gynecologic oncology: System-wide implementation and audit leads to improved value and patient outcomes.
    Gynecol Oncol. 2018 Aug 9. pii: S0090-8258(18)31096.
    PubMed     Abstract available


  670. WINTERHOFF BJ, Maile M, Mitra AK, Sebe A, et al
    Corrigendum to "Single cell sequencing reveals heterogeneity within ovarian cancer epithelium and cancer associated stromal cells" [Gyncol. Oncol. 144 (2017) 598-606].
    Gynecol Oncol. 2018 Aug 7. pii: S0090-8258(18)31079.
    PubMed    


  671. MOORE KN, O'Malley DM, Vergote I, Martin LP, et al
    Safety and activity findings from a phase 1b escalation study of mirvetuximab soravtansine, a folate receptor alpha (FRalpha)-targeting antibody-drug conjugate (ADC), in combination with carboplatin in patients with platinum-sensitive ovarian cancer.
    Gynecol Oncol. 2018 Aug 6. pii: S0090-8258(18)31081.
    PubMed     Abstract available


  672. MALLEN A, Soong TR, Townsend MK, Wenham RM, et al
    Surgical prevention strategies in ovarian cancer.
    Gynecol Oncol. 2018 Aug 4. pii: S0090-8258(18)31094.
    PubMed     Abstract available


  673. LI A, Xie R, Zhi Q, Deng Y, et al
    BRCA germline mutations in an unselected nationwide cohort of Chinese patients with ovarian cancer and healthy controls.
    Gynecol Oncol. 2018 Aug 2. pii: S0090-8258(18)31088.
    PubMed     Abstract available


  674. WORTMAN BG, Bosse T, Nout RA, Lutgens LCHW, et al
    Molecular-integrated risk profile to determine adjuvant radiotherapy in endometrial cancer: Evaluation of the pilot phase of the PORTEC-4a trial.
    Gynecol Oncol. 2018 Aug 2. pii: S0090-8258(18)31084.
    PubMed     Abstract available


  675. PINTO MP, Balmaceda C, Bravo ML, Kato S, et al
    Patient inflammatory status and CD4+/CD8+ intraepithelial tumor lymphocyte infiltration are predictors of outcomes in high-grade serous ovarian cancer.
    Gynecol Oncol. 2018 Aug 2. pii: S0090-8258(18)31089.
    PubMed     Abstract available


  676. WILFORD J, Osann K, Hsieh S, Monk B, et al
    Validation of PROMIS emotional distress short form scales for cervical cancer.
    Gynecol Oncol. 2018 Aug 2. pii: S0090-8258(18)31086.
    PubMed     Abstract available


  677. LEE J, Gubernick LR, Brodsky AL, Fehniger JE, et al
    Missed opportunities: Genetic counseling and testing among an ethnically diverse cohort of women with endometrial cancer.
    Gynecol Oncol. 2018 Aug 1. pii: S0090-8258(18)31087.
    PubMed     Abstract available


  678. LEVINE DA
    The limits of aggressive surgical cytoreduction.
    Gynecol Oncol. 2018;150:205-206.
    PubMed    


  679. ANGELES MA, Martinez-Gomez C, Martinez A, Ferron G, et al
    Laparoscopic hand-assisted Miami Pouch after pelvic exenteration in 10 steps.
    Gynecol Oncol. 2018;150:389-390.
    PubMed     Abstract available


  680. MANNING-GEIST BL, Hicks-Courant K, Gockley AA, Clark RM, et al
    Moving beyond "complete surgical resection" and "optimal": Is low-volume residual disease another option for primary debulking surgery?
    Gynecol Oncol. 2018;150:233-238.
    PubMed     Abstract available


  681. SHAH R, Xia C, Krailo M, Amatruda JF, et al
    Is carboplatin-based chemotherapy as effective as cisplatin-based chemotherapy in the treatment of advanced-stage dysgerminoma in children, adolescents and young adults?
    Gynecol Oncol. 2018;150:253-260.
    PubMed     Abstract available


    July 2018
  682. BEHBAKHT K, Cohn DE, Straughn JM Jr
    Hyperthermic intraperitoneal chemotherapy (HIPEC) is cost-effective in the management of primary ovarian cancer.
    Gynecol Oncol. 2018 Jul 30. pii: S0090-8258(18)31083.
    PubMed    


  683. SONG M, Kumaran MN, Gounder M, Gibbon DG, et al
    Phase I trial of selenium plus chemotherapy in gynecologic cancers.
    Gynecol Oncol. 2018 Jul 29. pii: S0090-8258(18)31014.
    PubMed     Abstract available


  684. VERGOTE I, von Moos R, Manso L, Van Nieuwenhuysen E, et al
    Tumor Treating Fields in combination with paclitaxel in recurrent ovarian carcinoma: Results of the INNOVATE pilot study.
    Gynecol Oncol. 2018 Jul 27. pii: S0090-8258(18)31082.
    PubMed     Abstract available


  685. MATSUO K, Blake EA, Machida H, Mandelbaum RS, et al
    Incidences and risk factors of metachronous vulvar, vaginal, and anal cancers after cervical cancer diagnosis.
    Gynecol Oncol. 2018 Jul 24. pii: S0090-8258(18)31080.
    PubMed     Abstract available


  686. MEAGHER NS, Schuster K, Voss A, Budden T, et al
    Does the primary site really matter? Profiling mucinous ovarian cancers of uncertain primary origin (MO-CUP) to personalise treatment and inform the design of clinical trials.
    Gynecol Oncol. 2018 Jul 24. pii: S0090-8258(18)31077.
    PubMed     Abstract available


  687. WEBSTER EM, Burke WM, Ware HM, Jones BA, et al
    Patient reported outcomes in evaluation of chemotherapy toxicity in women with gynecologic malignancies: A pilot study.
    Gynecol Oncol. 2018 Jul 20. pii: S0090-8258(18)31064.
    PubMed     Abstract available


  688. NISHIO S, Shimokawa M, Tasaki K, Nasu H, et al
    A phase II trial of irinotecan in patients with advanced or recurrent endometrial cancer and correlation with biomarker analysis.
    Gynecol Oncol. 2018 Jul 20. pii: S0090-8258(18)31078.
    PubMed     Abstract available


  689. CHAN JK, Gardner AB, Mann AK, Kapp DS, et al
    Hospital-acquired conditions after surgery for gynecologic cancer - An analysis of 82,304 patients.
    Gynecol Oncol. 2018 Jul 20. pii: S0090-8258(18)31065.
    PubMed     Abstract available


  690. NISHIKIMI K, Tate S, Matsuoka A, Shozu M, et al
    Metastatic cardiophrenic lymph node resection following full-thickness resection of right diaphragm for advanced ovarian carcinoma.
    Gynecol Oncol. 2018 Jul 19. pii: S0090-8258(18)31067.
    PubMed     Abstract available


  691. GREEN RW, Valentin L, Alcazar JL, Chiappa V, et al
    Endometrial cancer off-line staging using two-dimensional transvaginal ultrasound and three-dimensional volume contrast imaging: Intermethod agreement, interrater reliability and diagnostic accuracy.
    Gynecol Oncol. 2018 Jul 17. pii: S0090-8258(18)31009.
    PubMed     Abstract available


  692. BI Y, Verginadis II, Dey S, Lin L, et al
    Radiosensitization by the PARP inhibitor olaparib in BRCA1-proficient and deficient high-grade serous ovarian carcinomas.
    Gynecol Oncol. 2018 Jul 16. pii: S0090-8258(18)31015.
    PubMed     Abstract available


  693. TIWARI R, Narayanan GS, Jayakumar V, Narayanan S, et al
    The promise of image-guided brachytherapy of better clinical outcomes in treatment of cervical cancer: Does it deliver? An Indian scenario.
    Gynecol Oncol. 2018 Jul 14. pii: S0090-8258(18)31068.
    PubMed     Abstract available


  694. GALINDO LJ, Hernandez-Beeftink T, Salas A, Jung Y, et al
    HMGA2 and MED12 alterations frequently co-occur in uterine leiomyomas.
    Gynecol Oncol. 2018 Jul 12. pii: S0090-8258(18)31063.
    PubMed     Abstract available


  695. BARNARD ME, Pyden A, Rice MS, Linares M, et al
    Inter-pathologist and pathology report agreement for ovarian tumor characteristics in the Nurses' Health Studies.
    Gynecol Oncol. 2018 Jul 9. pii: S0090-8258(18)31016.
    PubMed     Abstract available


  696. TIMMERMANS M, van der Aa MA, Lalisang RI, Witteveen PO, et al
    Interval between debulking surgery and adjuvant chemotherapy is associated with overall survival in patients with advanced ovarian cancer.
    Gynecol Oncol. 2018 Jul 9. pii: S0090-8258(18)31017.
    PubMed     Abstract available


  697. DENG K, Yang C, Tan Q, Song W, et al
    Sites of distant metastases and overall survival in ovarian cancer: A study of 1481 patients.
    Gynecol Oncol. 2018 Jul 9. pii: S0090-8258(18)31004.
    PubMed     Abstract available


  698. XUE R, Cai X, Xu H, Wu S, et al
    The efficacy of concurrent weekly carboplatin with radiotherapy in the treatment of cervical cancer: A meta-analysis.
    Gynecol Oncol. 2018 Jul 8. pii: S0090-8258(18)31018.
    PubMed     Abstract available


  699. BURGER RA, Deng W, Makker V, Collins Y, et al
    Phase II evaluation of dalantercept in the treatment of persistent or recurrent epithelial ovarian cancer: An NRG Oncology/Gynecologic Oncology Group study.
    Gynecol Oncol. 2018 Jul 2. pii: S0090-8258(18)30999.
    PubMed     Abstract available


  700. SECORD AA, Previs RA, Nixon AB
    Cabozantinib in ovarian clear cell cancers: UnMET expectations.
    Gynecol Oncol. 2018;150:1-2.
    PubMed    


  701. CIUCCI A, Ferrandina G, Mascilini F, Filippetti F, et al
    Estrogen receptor beta: Potential target for therapy in adult granulosa cell tumors?
    Gynecol Oncol. 2018;150:158-165.
    PubMed     Abstract available


  702. NALDINI A, Vizzielli G, Perrone E, Gallotta V, et al
    Robotic video endoscopic inguinal lymphadenectomy (R-VEIL) for vulvar cancer with sentinel node mapping using indocyanine green and near-infrared fluorescence imaging technology.
    Gynecol Oncol. 2018;150:203-204.
    PubMed     Abstract available


  703. MARTINEZ-GOMEZ C, Angeles MA, Martinez A, Ferron G, et al
    Laparoscopic anterior pelvic exenteration in 10 steps.
    Gynecol Oncol. 2018;150:201-202.
    PubMed    


  704. LEES BF, Stewart TP, Rash JK, Baron SR, et al
    Abuse, cancer and sexual dysfunction in women: A potentially vicious cycle.
    Gynecol Oncol. 2018;150:166-172.
    PubMed     Abstract available


  705. CHARAKORN C, Thadanipon K, Chaijindaratana S, Rattanasiri S, et al
    The association between serum squamous cell carcinoma antigen and recurrence and survival of patients with cervical squamous cell carcinoma: A systematic review and meta-analysis.
    Gynecol Oncol. 2018;150:190-200.
    PubMed     Abstract available


    June 2018
  706. MEYER LA, He W, Sun CC, Zhao H, et al
    Neoadjuvant chemotherapy in elderly women with ovarian cancer: Rates of use and effectiveness.
    Gynecol Oncol. 2018 Jun 29. pii: S0090-8258(18)31002.
    PubMed     Abstract available


  707. ROGERI CD, Silveira HCS, Causin RL, Villa LL, et al
    Methylation of the hsa-miR-124, SOX1, TERT, and LMX1A genes as biomarkers for precursor lesions in cervical cancer.
    Gynecol Oncol. 2018 Jun 27. pii: S0090-8258(18)30990.
    PubMed     Abstract available


  708. ZHANG XS, Zhang YM, Li B, Fan B, et al
    Risk reduction of endometrial and ovarian cancer after bisphosphonates use: A meta-analysis.
    Gynecol Oncol. 2018 Jun 27. pii: S0090-8258(18)30988.
    PubMed     Abstract available


  709. VERDOODT F, Dehlendorff C, Friis S, Kjaer SK, et al
    Non-aspirin NSAID use and ovarian cancer mortality.
    Gynecol Oncol. 2018 Jun 27. pii: S0090-8258(18)31000.
    PubMed     Abstract available


  710. LEATH CA 3RD, Monk BJ
    Twenty-first century cervical cancer management: A historical perspective of the gynecologic oncology group/NRG oncology over the past twenty years.
    Gynecol Oncol. 2018 Jun 26. pii: S0090-8258(18)31005.
    PubMed     Abstract available


  711. GOCKLEY AA, Kolin DL, Awtrey CS, Lindeman NI, et al
    Durable response in a woman with recurrent low-grade endometrioid endometrial cancer and a germline BRCA2 mutation treated with a PARP inhibitor.
    Gynecol Oncol. 2018 Jun 21. pii: S0090-8258(18)30937.
    PubMed     Abstract available


  712. RAUH LA, Saks EJ, Nakad-Rodriguez D, Showalter TN, et al
    Cervical cancer care in rural Virginia: The impact of distance from an academic medical center on outcomes & the role of non-specialized radiation centers.
    Gynecol Oncol. 2018 Jun 20. pii: S0090-8258(18)31001.
    PubMed     Abstract available


  713. NIEVES-NEIRA W, Kim JJ, Matei D
    Hormonal strategies in gynecologic cancer: Bridging biology and therapy.
    Gynecol Oncol. 2018 Jun 20. pii: S0090-8258(18)30947.
    PubMed    


  714. GEBHARDT BJ, Vargo JA, Kim H, Houser CJ, et al
    Image-based multichannel vaginal cylinder brachytherapy for the definitive treatment of gynecologic malignancies in the vagina.
    Gynecol Oncol. 2018 Jun 18. pii: S0090-8258(18)30987.
    PubMed     Abstract available


  715. ROSS MS, Burriss ME, Winger DG, Edwards RP, et al
    Unplanned postoperative intensive care unit admission for ovarian cancer cytoreduction is associated with significant decrease in overall survival.
    Gynecol Oncol. 2018 Jun 18. pii: S0090-8258(18)30984.
    PubMed     Abstract available


  716. CLARK RM, Rice LW, Del Carmen MG
    Thirty-day unplanned hospital readmission in ovarian cancer patients undergoing primary or interval cytoreductive surgery: systematic literature review.
    Gynecol Oncol. 2018 Jun 18. pii: S0090-8258(18)30985.
    PubMed     Abstract available


  717. URBAN RR, Pappas TC, Bullock RG, Munroe DG, et al
    Combined symptom index and second-generation multivariate biomarker test for prediction of ovarian cancer in patients with an adnexal mass.
    Gynecol Oncol. 2018 Jun 18. pii: S0090-8258(18)30946.
    PubMed     Abstract available


  718. TORRES D, Wang C, Kumar A, Bakkum-Gamez JN, et al
    Factors that influence survival in high-grade serous ovarian cancer: A complex relationship between molecular subtype, disease dissemination, and operability.
    Gynecol Oncol. 2018 Jun 17. pii: S0090-8258(18)30944.
    PubMed     Abstract available


  719. CHAN JK, Brady W, Monk BJ, Brown J, et al
    A phase II evaluation of sunitinib in the treatment of persistent or recurrent clear cell ovarian carcinoma: An NRG Oncology/Gynecologic Oncology Group Study (GOG-254).
    Gynecol Oncol. 2018 Jun 16. pii: S0090-8258(18)30941.
    PubMed     Abstract available


  720. LI N, Zhan X, Zhan X
    The lncRNA SNHG3 regulates energy metabolism of ovarian cancer by an analysis of mitochondrial proteomes.
    Gynecol Oncol. 2018 Jun 16. pii: S0090-8258(18)30989.
    PubMed     Abstract available


  721. BODY N, Gregoire J, Renaud MC, Sebastianelli A, et al
    Tips and tricks to improve sentinel lymph node mapping with Indocyanin green in endometrial cancer.
    Gynecol Oncol. 2018 Jun 14. pii: S0090-8258(18)30943.
    PubMed     Abstract available


  722. GRAETZ I, Anderson JN, McKillop CN, Stepanski EJ, et al
    Use of a web-based app to improve postoperative outcomes for patients receiving gynecological oncology care: A randomized controlled feasibility trial.
    Gynecol Oncol. 2018 Jun 11. pii: S0090-8258(18)30983.
    PubMed     Abstract available


  723. BOLZE PA, Mathe M, Hajri T, You B, et al
    First-line hysterectomy for women with low-risk non-metastatic gestational trophoblastic neoplasia no longer wishing to conceive.
    Gynecol Oncol. 2018 Jun 8. pii: S0090-8258(18)30942.
    PubMed     Abstract available


  724. MICHAEL STRAUGHN J JR, Boitano T, Smith HJ, Dilley SE, et al
    Treatment of low-grade endometrial stromal sarcoma in a nulligravid woman.
    Gynecol Oncol. 2018 Jun 7. pii: S0090-8258(18)30923.
    PubMed     Abstract available


  725. BUDA A, Gasparri ML, Puppo A, Mereu L, et al
    Lymph node evaluation in high-risk early stage endometrial cancer: A multi-institutional retrospective analysis comparing the sentinel lymph node (SLN) algorithm and SLN with selective lymphadenectomy.
    Gynecol Oncol. 2018 Jun 7. pii: S0090-8258(18)30945.
    PubMed     Abstract available


  726. WOOLDERINK JM, De Bock GH, de Hullu JA, Hollema H, et al
    Characteristics of Lynch syndrome associated ovarian cancer.
    Gynecol Oncol. 2018 Jun 4. pii: S0090-8258(18)30240.
    PubMed     Abstract available


  727. STOLER MH, Wright TC Jr, Parvu V, Vaughan L, et al
    The Onclarity Human Papillomavirus Trial: Design, methods, and baseline results.
    Gynecol Oncol. 2018;149:498-505.
    PubMed     Abstract available


    May 2018
  728. STOLNICU S, Barsan I, Hoang L, Patel P, et al
    Stromal invasion pattern identifies patients at lowest risk of lymph node metastasis in HPV-associated endocervical adenocarcinomas, but is irrelevant in adenocarcinomas unassociated with HPV.
    Gynecol Oncol. 2018 May 30. pii: S0090-8258(18)30848.
    PubMed     Abstract available


  729. AREND RC, Jones BA, Martinez A, Goodfellow P, et al
    Endometrial cancer: Molecular markers and management of advanced stage disease.
    Gynecol Oncol. 2018 May 27. pii: S0090-8258(18)30902.
    PubMed     Abstract available


  730. LINDEMANN K, Gao B, Mapagu C, Fereday S, et al
    Response rates to second-line platinum-based therapy in ovarian cancer patients challenge the clinical definition of platinum resistance.
    Gynecol Oncol. 2018 May 25. pii: S0090-8258(18)30907.
    PubMed     Abstract available


  731. GIANNOPOULOU L, Mastoraki S, Buderath P, Strati A, et al
    ESR1 methylation in primary tumors and paired circulating tumor DNA of patients with high-grade serous ovarian cancer.
    Gynecol Oncol. 2018 May 25. pii: S0090-8258(18)30922.
    PubMed     Abstract available


  732. YAGUR Y, Weitzner O, Gemer O, Lavie O, et al
    Postoperative radiation rates in stage IIA1 cervical cancer: Is surgical treatment justified? An Israeli Gynecologic Oncology Group Study.
    Gynecol Oncol. 2018 May 25. pii: S0090-8258(18)30903.
    PubMed     Abstract available


  733. AHMED A, Deng W, Tew W, Bender D, et al
    Pre-operative assessment and post-operative outcomes of elderly women with gynecologic cancers, primary analysis of NRG CC-002: An NRG oncology group/gynecologic oncology group study.
    Gynecol Oncol. 2018 May 25. pii: S0090-8258(18)30909.
    PubMed     Abstract available


  734. SALVO G, Frumovitz M, Pareja R, Lee J, et al
    Simple trachelectomy with pelvic lymphadenectomy as a viable treatment option in pregnant patients with stage IB1 (>/=2cm) cervical cancer: Bridging the gap to fetal viability.
    Gynecol Oncol. 2018 May 24. pii: S0090-8258(18)30908.
    PubMed     Abstract available


  735. AGHAJANIAN C, Filiaci V, Dizon DS, Carlson JW, et al
    A phase II study of frontline paclitaxel/carboplatin/bevacizumab, paclitaxel/carboplatin/temsirolimus, or ixabepilone/carboplatin/bevacizumab in advanced/recurrent endometrial cancer.
    Gynecol Oncol. 2018 May 24. pii: S0090-8258(18)30905.
    PubMed     Abstract available


  736. BAIOCCHI G, Mantoan H, Chen MJ, Faloppa CC, et al
    Uterine transposition after radical trachelectomy.
    Gynecol Oncol. 2018 May 23. pii: S0090-8258(18)30896.
    PubMed    


  737. MAYOR P, Starbuck K, Zsiros E
    Adoptive cell transfer using autologous tumor infiltrating lymphocytes in gynecologic malignancies.
    Gynecol Oncol. 2018 May 23. pii: S0090-8258(18)30920.
    PubMed     Abstract available


  738. KALAMPOKAS E, Payne F, Gurumurthy M
    An update on the use of immunohistochemistry and molecular pathology in the diagnosis of pre-invasive and malignant lesions in gynecological oncology.
    Gynecol Oncol. 2018 May 21. pii: S0090-8258(18)30910.
    PubMed     Abstract available


  739. MUELLER JJ, Schlappe BA, Kumar R, Olvera N, et al
    Massively parallel sequencing analysis of mucinous ovarian carcinomas: genomic profiling and differential diagnoses.
    Gynecol Oncol. 2018 May 21. pii: S0090-8258(18)30895.
    PubMed     Abstract available


  740. KOTSOPOULOS J, Gronwald J, Karlan B, Rosen B, et al
    Age-specific ovarian cancer risks among women with a BRCA1 or BRCA2 mutation.
    Gynecol Oncol. 2018 May 21. pii: S0090-8258(18)30898.
    PubMed     Abstract available


  741. VON GRUENIGEN VE, Huang HQ, Cella D, Zevon M, et al
    Quality of life, symptoms and care needs in patients with persistent or recurrent platinum-resistant ovarian cancer: An NRG Oncology/Gynecologic Oncology Group study.
    Gynecol Oncol. 2018 May 17. pii: S0090-8258(18)30904.
    PubMed     Abstract available


  742. ROLSTON A, Spencer RJ, Kevin Reynolds R, Rice LW, et al
    Factors associated with outcomes and inpatient 90-day cost of care in endometrial cancer patients undergoing hysterectomy - implications for bundled care payments.
    Gynecol Oncol. 2018 May 16. pii: S0090-8258(18)30897.
    PubMed     Abstract available


  743. PHILP L, Jembere N, Wang L, Gao J, et al
    Pap tests in the diagnosis of cervical cancer: Help or hinder?
    Gynecol Oncol. 2018 May 15. pii: S0090-8258(18)30906.
    PubMed     Abstract available


  744. O'SHEA A, McCool K, Harrison R, Sampene E, et al
    Neoadjuvant chemotherapy is associated with more anemia and perioperative blood transfusions than primary debulking surgery in women with advanced stage ovarian cancer.
    Gynecol Oncol. 2018 May 15. pii: S0090-8258(18)30901.
    PubMed     Abstract available


  745. TSENG JH, Aloisi A, Sonoda Y, Gardner GJ, et al
    Less versus more radical surgery in stage IB1 cervical cancer: A population-based study of long-term survival.
    Gynecol Oncol. 2018 May 15. pii: S0090-8258(18)30849.
    PubMed     Abstract available


  746. FELIX AS, Sinnott JA, Vetter MH, Rhoades J, et al
    Detection of endometrial cancer cells in the fallopian tube lumen is associated with adverse prognostic factors and reduced survival.
    Gynecol Oncol. 2018 May 10. pii: S0090-8258(18)30893.
    PubMed     Abstract available


  747. RUSCITO I, Darb-Esfahani S, Kulbe H, Bellati F, et al
    The prognostic impact of cancer stem-like cell biomarker aldehyde dehydrogenase-1 (ALDH1) in ovarian cancer: A meta-analysis.
    Gynecol Oncol. 2018 May 10. pii: S0090-8258(18)30892.
    PubMed     Abstract available


  748. NASIOUDIS D, Mastroyannis SA, Albright BB, Haggerty AF, et al
    Adjuvant chemotherapy for stage I ovarian clear cell carcinoma: Patterns of use and outcomes.
    Gynecol Oncol. 2018 May 8. pii: S0090-8258(18)30845.
    PubMed     Abstract available


  749. DAVIS M, Strickland K, Easter SR, Worley M Jr, et al
    The impact of health insurance status on the stage of cervical cancer diagnosis at a tertiary care center in Massachusetts.
    Gynecol Oncol. 2018 May 8. pii: S0090-8258(18)30887.
    PubMed     Abstract available


  750. BAERT T, Van Camp J, Vanbrabant L, Busschaert P, et al
    Influence of CA125, platelet count and neutrophil to lymphocyte ratio on the immune system of ovarian cancer patients.
    Gynecol Oncol. 2018 May 8. pii: S0090-8258(18)30891.
    PubMed     Abstract available


  751. YI Y, Bryce CL, Adambekov S, Edwards RP, et al
    Cost-effectiveness analysis of biopsy strategies for endometrial cancer diagnosis in women with postmenopausal bleeding: Pipelle sampling curette versus dilatation & curettage.
    Gynecol Oncol. 2018 May 7. pii: S0090-8258(18)30843.
    PubMed     Abstract available


  752. TEMPFER CB, Giger-Pabst U, Seebacher V, Petersen M, et al
    A phase I, single-arm, open-label, dose escalation study of intraperitoneal cisplatin and doxorubicin in patients with recurrent ovarian cancer and peritoneal carcinomatosis.
    Gynecol Oncol. 2018 May 6. pii: S0090-8258(18)30851.
    PubMed     Abstract available


  753. KONSTANTINOPOULOS PA, Brady WE, Farley J, Armstrong A, et al
    Phase II study of single-agent cabozantinib in patients with recurrent clear cell ovarian, primary peritoneal or fallopian tube cancer (NRG-GY001).
    Gynecol Oncol. 2018 May 5. pii: S0090-8258(18)30850.
    PubMed     Abstract available


  754. NEBGEN DR, Hurteau J, Holman LL, Bradford A, et al
    Bilateral salpingectomy with delayed oophorectomy for ovarian cancer risk reduction: A pilot study in women with BRCA1/2 mutations.
    Gynecol Oncol. 2018 May 4. pii: S0090-8258(18)30842.
    PubMed     Abstract available


  755. RICE LW
    Expanding the pipeline. The 2018 Society of Gynecologic Oncology presidential address. Sunday, March 25, 2018. By Laurel W. Rice, MD. 2017-2018 SGO president.
    Gynecol Oncol. 2018 May 2. pii: S0090-8258(18)30837.
    PubMed    


  756. TRIMBLE CL
    Towards identifying new therapeutic targets in cancers attributable to HPV.
    Gynecol Oncol. 2018;149:225-226.
    PubMed    


  757. HINTEN F, Molijn A, Eckhardt L, Massuger LFAG, et al
    Vulvar cancer: Two pathways with different localization and prognosis.
    Gynecol Oncol. 2018;149:310-317.
    PubMed     Abstract available


    April 2018
  758. NISKAKOSKI A, Pasanen A, Porkka N, Eldfors S, et al
    Converging endometrial and ovarian tumorigenesis in Lynch syndrome: Shared origin of synchronous carcinomas.
    Gynecol Oncol. 2018 Apr 28. pii: S0090-8258(18)30844.
    PubMed     Abstract available


  759. MAYADEV J, Klapheke A, Yashar C, Hsu IC, et al
    Underutilization of brachytherapy and disparities in survival for patients with cervical cancer in California.
    Gynecol Oncol. 2018 Apr 27. pii: S0090-8258(18)30841.
    PubMed     Abstract available


  760. NAGLE CM, Crosbie EJ, Brand A, Obermair A, et al
    The association between diabetes, comorbidities, body mass index and all-cause and cause-specific mortality among women with endometrial cancer.
    Gynecol Oncol. 2018 Apr 26. pii: S0090-8258(18)30283.
    PubMed     Abstract available


  761. BROWN J, Naumann RW, Brady WE, Coleman RL, et al
    Clinical trial methodology in rare gynecologic tumor research: Strategies for success.
    Gynecol Oncol. 2018 Apr 23. pii: S0090-8258(18)30285.
    PubMed     Abstract available


  762. WANG J, Garbutt C, Ma H, Gao P, et al
    Expression and role of autophagy-associated p62 (SQSTM1) in multidrug resistant ovarian cancer.
    Gynecol Oncol. 2018 Apr 23. pii: S0090-8258(18)30835.
    PubMed     Abstract available


  763. ROSSI A, Frechette L, Miller D, Miller E, et al
    Acceptability and feasibility of a Fitbit physical activity monitor for endometrial cancer survivors.
    Gynecol Oncol. 2018 Apr 21. pii: S0090-8258(18)30838.
    PubMed     Abstract available


  764. FERGUSON SE, Panzarella T, Lau S, Gien LT, et al
    Prospective cohort study comparing quality of life and sexual health outcomes between women undergoing robotic, laparoscopic and open surgery for endometrial cancer.
    Gynecol Oncol. 2018 Apr 19. pii: S0090-8258(18)30836.
    PubMed     Abstract available


  765. EL-ZEIN M, Bouten S, Louvanto K, Gilbert L, et al
    Validation of a new HPV self-sampling device for cervical cancer screening: The Cervical and Self-Sample In Screening (CASSIS) study.
    Gynecol Oncol. 2018 Apr 17. pii: S0090-8258(18)30274.
    PubMed     Abstract available


  766. MATODA M, Takeshima N, Michimae H, Iwata T, et al
    Postoperative chemotherapy for node-positive cervical cancer: Results of a multicenter phase II trial (JGOG1067).
    Gynecol Oncol. 2018 Apr 13. pii: S0090-8258(18)30286.
    PubMed     Abstract available


  767. BERGSTROM JE, Scott ME, Alimi Y, Yen TT, et al
    Narcotics reduction, quality and safety in gynecologic oncology surgery in the first year of enhanced recovery after surgery protocol implementation.
    Gynecol Oncol. 2018 Apr 13. pii: S0090-8258(18)30273.
    PubMed     Abstract available


  768. CHAPEL DB, Yamada SD, Cowan M, Lastra RR, et al
    Immunohistochemistry for mismatch repair protein deficiency in endometrioid endometrial carcinoma yields equivalent results when performed on endometrial biopsy/curettage or hysterectomy specimens.
    Gynecol Oncol. 2018 Apr 13. pii: S0090-8258(18)30282.
    PubMed     Abstract available


  769. JIANG F, Wan XR, Xu T, Feng FZ, et al
    Evaluation and suggestions for improving the FIGO 2000 staging criteria for gestational trophoblastic neoplasia: A ten-year review of 1420 patients.
    Gynecol Oncol. 2018 Apr 10. pii: S0090-8258(18)30271.
    PubMed     Abstract available


  770. UYAR D, Neary J, Monroe A, Nugent M, et al
    Implementation of a quality improvement project for universal genetic testing in women with ovarian cancer.
    Gynecol Oncol. 2018 Apr 10. pii: S0090-8258(18)30239.
    PubMed     Abstract available


  771. LIU J, Nicum S, Reichardt P, Croitoru K, et al
    Assessment and management of diarrhea following VEGF receptor TKI treatment in patients with ovarian cancer.
    Gynecol Oncol. 2018 Apr 4. pii: S0090-8258(18)30238.
    PubMed     Abstract available


  772. ARMBRUSTER SD, Sun CC, Westin SN, Bodurka DC, et al
    Prospective assessment of patient-reported outcomes in gynecologic cancer patients before and after pelvic exenteration.
    Gynecol Oncol. 2018 Apr 2. pii: S0090-8258(18)30234.
    PubMed     Abstract available


  773. DOCKERY LE, Motwani A, Ding K, Doescher M, et al
    Improving cancer care for American Indians with cervical cancer in the Indian Health Service (IHS) system - Navigation may not be enough.
    Gynecol Oncol. 2018;149:89-92.
    PubMed     Abstract available


  774. MANRRIQUEZ E, Chapman JS, Mak J, Blanco AM, et al
    Disparities in genetics assessment for women with ovarian cancer: Can we do better?
    Gynecol Oncol. 2018;149:84-88.
    PubMed     Abstract available


  775. DOLL KM
    Investigating Black-White disparities in gynecologic oncology: Theories, conceptual models, and applications.
    Gynecol Oncol. 2018;149:78-83.
    PubMed     Abstract available


  776. TEMKIN SM, Rimel BJ, Bruegl AS, Gunderson CC, et al
    A contemporary framework of health equity applied to gynecologic cancer care: A Society of Gynecologic Oncology evidenced-based review.
    Gynecol Oncol. 2018;149:70-77.
    PubMed     Abstract available


  777. HAGOPIAN GS, Lieber M, Dottino PR, Margaret Kemeny M, et al
    The impact of nativity on cervical cancer survival in the public hospital system of Queens, New York.
    Gynecol Oncol. 2018;149:63-69.
    PubMed     Abstract available


  778. RAMEY SJ, Asher D, Kwon D, Ahmed AA, et al
    Delays in definitive cervical cancer treatment: An analysis of disparities and overall survival impact.
    Gynecol Oncol. 2018;149:53-62.
    PubMed     Abstract available


  779. DILLEY S, Erickson BK, Phillips CE, Kennemer CR, et al
    Do differences in medical comorbidities and treatment impact racial disparities in epithelial ovarian cancer?
    Gynecol Oncol. 2018;149:49-52.
    PubMed     Abstract available


  780. COWAN RA, Tseng J, Ali N, Dearie H, et al
    Exploring the impact of income and race on survival for women with advanced ovarian cancer undergoing primary debulking surgery at a high-volume center.
    Gynecol Oncol. 2018;149:43-48.
    PubMed     Abstract available


  781. RAUH-HAIN JA, Melamed A, Schaps D, Bregar AJ, et al
    Racial and ethnic disparities over time in the treatment and mortality of women with gynecological malignancies.
    Gynecol Oncol. 2018;149:4-11.
    PubMed     Abstract available


  782. LEE J, Gerber D, Aphinyanaphongs Y, Curtin JP, et al
    Laparoscopy decreases the disparity in postoperative complications between black and white women after hysterectomy for endometrial cancer.
    Gynecol Oncol. 2018;149:22-27.
    PubMed     Abstract available


  783. DUBIL EA, Tian C, Wang G, Tarney CM, et al
    Racial disparities in molecular subtypes of endometrial cancer.
    Gynecol Oncol. 2018;149:106-116.
    PubMed     Abstract available


  784. STAPLES JN, Wong MS, Rimel BJ
    An educational intervention to improve human papilloma virus (HPV) and cervical cancer knowledge among African American college students.
    Gynecol Oncol. 2018;149:101-105.
    PubMed     Abstract available


  785. DEL CARMEN MG, Rice LW
    Towards the elimination of health care disparities in gynecologic oncology: Call to action.
    Gynecol Oncol. 2018;149:1-3.
    PubMed    


  786. MAO X, Qin X, Li L, Zhou J, et al
    A 15-long non-coding RNA signature to improve prognosis prediction of cervical squamous cell carcinoma.
    Gynecol Oncol. 2018;149:181-187.
    PubMed     Abstract available


  787. MOORE KN, Mirza MR, Matulonis UA
    The poly (ADP ribose) polymerase inhibitor niraparib: Management of toxicities.
    Gynecol Oncol. 2018;149:214-220.
    PubMed     Abstract available


    March 2018
  788. BONHOF CS, Mols F, Vos MC, Pijnenborg JMA, et al
    Course of chemotherapy-induced peripheral neuropathy and its impact on health-related quality of life among ovarian cancer patients: A longitudinal study.
    Gynecol Oncol. 2018 Mar 28. pii: S0090-8258(18)30232.
    PubMed     Abstract available


  789. WU H, Zhang J
    Decreased expression of TFAP2B in endometrial cancer predicts poor prognosis: A study based on TCGA data.
    Gynecol Oncol. 2018 Mar 28. pii: S0090-8258(18)30237.
    PubMed     Abstract available


  790. CUNNINGHAM-ERVES J, Forbes L, Ivankova N, Mayo-Gamble T, et al
    Black mother's intention to vaccinate daughters against HPV: A mixed methods approach to identify opportunities for targeted communication.
    Gynecol Oncol. 2018 Mar 24. pii: S0090-8258(18)30219.
    PubMed     Abstract available


  791. MATSUOKA A, Tate S, Nishikimi K, Shozu M, et al
    Efficacy of soft coagulation in retroperitoneal lymphadenectomy for ovarian cancer.
    Gynecol Oncol. 2018 Mar 21. pii: S0090-8258(18)30231.
    PubMed    


  792. LONG J, Zhu JY, Liu YB, Fu K, et al
    Helicase POLQ-like (HELQ) as a novel indicator of platinum-based chemoresistance for epithelial ovarian cancer.
    Gynecol Oncol. 2018 Mar 20. pii: S0090-8258(18)30176.
    PubMed     Abstract available


  793. CHEN L, Luan S, Xia B, Liu Y, et al
    Integrated analysis of HPV-mediated immune alterations in cervical cancer.
    Gynecol Oncol. 2018 Mar 20. pii: S0090-8258(18)30070.
    PubMed     Abstract available


  794. KIM J, Kim S, Lee HS, Yang W, et al
    Prognostic implication of programmed cell death 1 protein and its ligand expressions in endometrial cancer.
    Gynecol Oncol. 2018 Mar 20. pii: S0090-8258(18)30132.
    PubMed     Abstract available


  795. MCDONALD JF
    Back to the future - The integration of big data with machine learning is re-establishing the importance of predictive correlations in ovarian cancer diagnostics and therapeutics.
    Gynecol Oncol. 2018 Mar 20. pii: S0090-8258(18)30233.
    PubMed    


  796. HAN C, Bellone S, Siegel ER, Altwerger G, et al
    A novel multiple biomarker panel for the early detection of high-grade serous ovarian carcinoma.
    Gynecol Oncol. 2018 Mar 20. pii: S0090-8258(18)30230.
    PubMed     Abstract available


  797. WILSON AJ, Stubbs M, Liu P, Ruggeri B, et al
    The BET inhibitor INCB054329 reduces homologous recombination efficiency and augments PARP inhibitor activity in ovarian cancer.
    Gynecol Oncol. 2018 Mar 20. pii: S0090-8258(18)30229.
    PubMed     Abstract available


  798. AGRAWAL S, Chen L, Tergas AI, Hou JY, et al
    Identifying modifiable and non-modifiable risk factors associated with prolonged length of stay after hysterectomy for uterine cancer.
    Gynecol Oncol. 2018 Mar 17. pii: S0090-8258(18)30220.
    PubMed     Abstract available


  799. VENIGALLA S, Chowdhry AK, Shalowitz DI
    Survival implications of staging lymphadenectomy for non-endometrioid endometrial cancers.
    Gynecol Oncol. 2018 Mar 17. pii: S0090-8258(18)30218.
    PubMed     Abstract available


  800. IDAHL A, Hermansson A, Lalos A
    Social support and ovarian cancer incidence - A Swedish prospective population-based study.
    Gynecol Oncol. 2018 Mar 17. pii: S0090-8258(18)30214.
    PubMed     Abstract available


  801. CARLTON AL, Illendula A, Gao Y, Llaneza DC, et al
    Small molecule inhibition of the CBFbeta/RUNX interaction decreases ovarian cancer growth and migration through alterations in genes related to epithelial-to-mesenchymal transition.
    Gynecol Oncol. 2018 Mar 15. pii: S0090-8258(18)30174.
    PubMed     Abstract available


  802. ESKANDER RN, Kauderer J, Tewari KS, Mannel RS, et al
    Correlation between Surgeon's assessment and radiographic evaluation of residual disease in women with advanced stage ovarian cancer reported to have undergone optimal surgical cytoreduction: An NRG Oncology/Gynecologic Oncology Group study.
    Gynecol Oncol. 2018 Mar 14. pii: S0090-8258(18)30216.
    PubMed     Abstract available


  803. TORTORELLA L, Langstraat CL, Weaver AL, McGree ME, et al
    Uterine serous carcinoma: Reassessing effectiveness of platinum-based adjuvant therapy.
    Gynecol Oncol. 2018 Mar 14. pii: S0090-8258(18)30141.
    PubMed     Abstract available


  804. UCCELLA S, Mele MC, Quagliozzi L, Rinninella E, et al
    Assessment of preoperative nutritional status using BIA-derived phase angle (PhA) in patients with advanced ovarian cancer: Correlation with the extent of cytoreduction and complications.
    Gynecol Oncol. 2018 Mar 14. pii: S0090-8258(18)30215.
    PubMed     Abstract available


  805. BRUCE SF, Carr DN, Burton ER, Sorosky JI, et al
    Implementation of an abdominal closure bundle to reduce surgical site infection in patients on a gynecologic oncology service undergoing exploratory laparotomy.
    Gynecol Oncol. 2018 Mar 14. pii: S0090-8258(18)30217.
    PubMed     Abstract available


  806. KO EM, Havrilesky LJ, Alvarez RD, Zivanovic O, et al
    Society of Gynecologic Oncology Future of Physician Payment Reform Task Force report: The Endometrial Cancer Alternative Payment Model (ECAP).
    Gynecol Oncol. 2018 Mar 12. pii: S0090-8258(18)30130.
    PubMed     Abstract available


  807. RAMZAN AA, Fischer S, Buss MK, Urban RR, et al
    Opioid use in gynecologic oncology in the age of the opioid epidemic: Part II - Balancing safety & accessibility.
    Gynecol Oncol. 2018 Mar 12. pii: S0090-8258(18)30127.
    PubMed     Abstract available


  808. QU XM, Velker VM, Leung E, Kwon JS, et al
    The role of adjuvant therapy in stage IA serous and clear cell uterine cancer: A multi-institutional pooled analysis.
    Gynecol Oncol. 2018 Mar 12. pii: S0090-8258(18)30172.
    PubMed     Abstract available


  809. PRZYBYL J, Kidzinski L, Hastie T, Debiec-Rychter M, et al
    Gene expression profiling of low-grade endometrial stromal sarcoma indicates fusion protein-mediated activation of the Wnt signaling pathway.
    Gynecol Oncol. 2018 Mar 12. pii: S0090-8258(18)30177.
    PubMed     Abstract available


  810. MATSUO K, Yabuno A, Hom MS, Shida M, et al
    Significance of abnormal peritoneal cytology on survival of women with stage I-II endometrioid endometrial cancer.
    Gynecol Oncol. 2018 Mar 12. pii: S0090-8258(18)30131.
    PubMed     Abstract available


  811. STEWART LE, Beck TL, Giannakopoulos NV, Rendi MH, et al
    Impact of oophorectomy and hormone suppression in low grade endometrial stromal sarcoma: A multicenter review.
    Gynecol Oncol. 2018 Mar 11. pii: S0090-8258(18)30180.
    PubMed     Abstract available


  812. YI L, Zhang H, Zou J, Luo P, et al
    Adjuvant chemoradiotherapy versus radiotherapy alone in high-risk endometrial cancer: A systematic review and meta-analysis.
    Gynecol Oncol. 2018 Mar 9. pii: S0090-8258(18)30175.
    PubMed     Abstract available


  813. GOSTNER JM, Obermayr E, Braicu IE, Concin N, et al
    Immunobiochemical pathways of neopterin formation and tryptophan breakdown via indoleamine 2,3-dioxygenase correlate with circulating tumor cells in ovarian cancer patients- A study of the OVCAD consortium.
    Gynecol Oncol. 2018 Mar 9. pii: S0090-8258(18)30139.
    PubMed     Abstract available


  814. VON GRUENIGEN VE, Karlan BY
    Sexual harassment in the work place: Its impact on gynecologic oncology and women's health.
    Gynecol Oncol. 2018 Mar 8. pii: S0090-8258(18)30137.
    PubMed     Abstract available


  815. SCHORGE JO, Bregar AJ, Durfee J, Berkowitz RS, et al
    Meigs to modern times: The evolution of debulking surgery in advanced ovarian cancer.
    Gynecol Oncol. 2018 Mar 7. pii: S0090-8258(18)30142.
    PubMed     Abstract available


  816. SCHUURMAN MS, Kruitwagen RFPM, Portielje JEA, Roes EM, et al
    Treatment and outcome of elderly patients with advanced stage ovarian cancer: A nationwide analysis.
    Gynecol Oncol. 2018 Mar 4. pii: S0090-8258(18)30136.
    PubMed     Abstract available


  817. LIAO CI, Chow S, Chen LM, Kapp DS, et al
    Trends in the incidence of serous fallopian tube, ovarian, and peritoneal cancer in the US.
    Gynecol Oncol. 2018 Mar 4. pii: S0090-8258(18)30069.
    PubMed     Abstract available


  818. KANAO H, Aoki Y, Hisa T, Takeshima N, et al
    Laparoscopic laterally extended endopelvic resection (LEER) for cervical carcinoma recurring at the pelvic sidewall after concurrent chemoradiotherapy: Our experience in three cases.
    Gynecol Oncol. 2018 Mar 3. pii: S0090-8258(18)30112.
    PubMed     Abstract available


  819. BUSKWOFIE A, Huang Y, Tergas AI, Hou JY, et al
    Impact of hospital volume on racial disparities and outcomes for endometrial cancer.
    Gynecol Oncol. 2018 Mar 2. pii: S0090-8258(18)30138.
    PubMed     Abstract available


  820. HARKENRIDER MM, Altoos B, Small W Jr.
    Prognostic significance of residual lymph node status after definitive chemoradiotherapy in patients with node-positive cervical cancer.
    Gynecol Oncol. 2018;148:437-438.
    PubMed    


  821. MINION LE, Tewari KS
    Cervical cancer - State of the science: From angiogenesis blockade to checkpoint inhibition.
    Gynecol Oncol. 2018;148:609-621.
    PubMed     Abstract available


  822. POWELL CB, Alabaster A, Stoller N, Armstrong MA, et al
    Bone loss in women with BRCA1 and BRCA2 mutations.
    Gynecol Oncol. 2018;148:535-539.
    PubMed     Abstract available


  823. STECKLEIN SR, Frumovitz M, Klopp AH, Gunther JR, et al
    Effectiveness of definitive radiotherapy for squamous cell carcinoma of the vulva with gross inguinal lymphadenopathy.
    Gynecol Oncol. 2018;148:474-479.
    PubMed     Abstract available


  824. FILIPPOV-LEVY N, Cohen-Schussheim H, Trope CG, Hetland Falkenthal TE, et al
    Expression and clinical role of long non-coding RNA in high-grade serous carcinoma.
    Gynecol Oncol. 2018;148:559-566.
    PubMed     Abstract available


  825. TE GROOTENHUIS NC, Pouwer AW, de Bock GH, Hollema H, et al
    Prognostic factors for local recurrence of squamous cell carcinoma of the vulva: A systematic review.
    Gynecol Oncol. 2018;148:622-631.
    PubMed     Abstract available


    February 2018
  826. XIAO X, Dong D, He W, Song L, et al
    Mismatch repair deficiency is associated with MSI phenotype, increased tumor-infiltrating lymphocytes and PD-L1 expression in immune cells in ovarian cancer.
    Gynecol Oncol. 2018 Feb 26. pii: S0090-8258(18)30128.
    PubMed     Abstract available


  827. WRIGHT JD, Havrilesky LJ, Cohn DE, Huang Y, et al
    Estimating potential for savings for low risk endometrial cancer using the Endometrial Cancer Alternative Payment Model (ECAP): A companion paper to the Society of Gynecologic Oncology Report on the Endometrial Cancer Alternative Payment Model.
    Gynecol Oncol. 2018 Feb 26. pii: S0090-8258(18)30129.
    PubMed     Abstract available


  828. WEAVER DT, Raphel TJ, Melamed A, Rauh-Hain JA, et al
    Modeling treatment outcomes for patients with advanced ovarian cancer: Projected benefits of a test to optimize treatment selection.
    Gynecol Oncol. 2018 Feb 24. pii: S0090-8258(18)30126.
    PubMed     Abstract available


  829. HUVILA J, Laajala TD, Edqvist PH, Mardinoglu A, et al
    Combined ASRGL1 and p53 immunohistochemistry as an independent predictor of survival in endometrioid endometrial carcinoma.
    Gynecol Oncol. 2018 Feb 24. pii: S0090-8258(18)30135.
    PubMed     Abstract available


  830. BARRINGTON DA, Champion ML, Boitano TKL, Walters-Haygood CL, et al
    Characteristics of African American women at high-risk for ovarian cancer in the southeast: Results from a Gynecologic Cancer Risk Assessment Clinic.
    Gynecol Oncol. 2018 Feb 24. pii: S0090-8258(18)30133.
    PubMed     Abstract available


  831. JAREID M, Thalabard JC, Aarflot M, Bovelstad HM, et al
    Levonorgestrel-releasing intrauterine system use is associated with a decreased risk of ovarian and endometrial cancer, without increased risk of breast cancer. Results from the NOWAC Study.
    Gynecol Oncol. 2018 Feb 23. pii: S0090-8258(18)30125.
    PubMed     Abstract available


  832. PAREJA R, Echeverri L, Rendon G, Munsell M, et al
    Radical parametrectomy after 'cut-through' hysterectomy in low-risk early-stage cervical cancer: Time to consider this procedure obsolete.
    Gynecol Oncol. 2018 Feb 23. pii: S0090-8258(18)30134.
    PubMed     Abstract available


  833. LHEUREUX S, McCourt C, Rimel BJ, Duska L, et al
    Moving forward with actionable therapeutic targets and opportunities in endometrial cancer: A NCI clinical trials planning meeting report.
    Gynecol Oncol. 2018 Feb 21. pii: S0090-8258(18)30124.
    PubMed     Abstract available


  834. LEFKOWITS C, Buss MK, Ramzan AA, Fischer S, et al
    Opioid use in gynecologic oncology in the age of the opioid epidemic: Part I - Effective opioid use across clinical settings, a society of gynecologic oncology evidence-based review.
    Gynecol Oncol. 2018 Feb 20. pii: S0090-8258(18)30066.
    PubMed     Abstract available


  835. KELLENBERGER LD, Petrik J
    Hyperglycemia promotes insulin-independent ovarian tumor growth.
    Gynecol Oncol. 2018 Feb 17. pii: S0090-8258(18)30122.
    PubMed     Abstract available


  836. OZA A, Kaye S, Van Tornout J, Sessa C, et al
    Phase 2 study evaluating intermittent and continuous linsitinib and weekly paclitaxel in patients with recurrent platinum resistant ovarian epithelial cancer.
    Gynecol Oncol. 2018 Feb 14. pii: S0090-8258(18)30058.
    PubMed     Abstract available


  837. LI Y, Wu T, Wang Y, Yang L, et al
    gamma-Glutamyl cyclotransferase contributes to tumor progression in high grade serous ovarian cancer by regulating epithelial-mesenchymal transition via activating PI3K/AKT/mTOR pathway.
    Gynecol Oncol. 2018 Feb 8. pii: S0090-8258(18)30062.
    PubMed     Abstract available


  838. CRANE EK, Brown J
    Early stage mucinous ovarian cancer: A review.
    Gynecol Oncol. 2018 Feb 8. pii: S0090-8258(18)30074.
    PubMed     Abstract available


  839. DESAI P, Wallace R, Anderson ML, Howard BV, et al
    An analysis of the association between statin use and risk of endometrial and ovarian cancers in the Women's Health Initiative.
    Gynecol Oncol. 2018 Feb 5. pii: S0090-8258(18)30038.
    PubMed     Abstract available


  840. HACKER KE, Reynolds RK, Uppal S
    Ongoing strategies and updates on pain management in gynecologic oncology patients.
    Gynecol Oncol. 2018 Feb 3. pii: S0090-8258(18)30073.
    PubMed     Abstract available


  841. SWANSON CL, Kumar A, Maharaj JM, Kemppainen JL, et al
    Increasing genetic counseling referral rates through bundled interventions after ovarian cancer diagnosis.
    Gynecol Oncol. 2018 Feb 3. pii: S0090-8258(18)30072.
    PubMed     Abstract available


  842. MILLER KR, Patel JN, Zhang Q, Norris EJ, et al
    HOXA4/HOXB3 gene expression signature as a biomarker of recurrence in patients with high-grade serous ovarian cancer following primary cytoreductive surgery and first-line adjuvant chemotherapy.
    Gynecol Oncol. 2018 Feb 2. pii: S0090-8258(18)30061.
    PubMed     Abstract available


  843. THARAVICHITKUL E, Chakrabandhu S, Klunklin P, Onchan W, et al
    Intermediate-term results of trans-abdominal ultrasound (TAUS)-guided brachytherapy in cervical cancer.
    Gynecol Oncol. 2018 Feb 2. pii: S0090-8258(18)30047.
    PubMed     Abstract available


  844. STROHL AE, Lurain JR
    Nonmetastatic Excised Gestational Choriocarcinoma: To Treat or Not to Treat.
    Gynecol Oncol. 2018;148:237-238.
    PubMed    


  845. NAUMANN RW, Brown J
    Ovarian cancer screening with the Risk of Ovarian Cancer Algorithm (ROCA): Good, bad, or just expensive?
    Gynecol Oncol. 2018 Feb 1. pii: S0090-8258(18)30068.
    PubMed     Abstract available


  846. KIM SI, Lee S, Jeong CW, Kim HS, et al
    Robot-assisted anterior pelvic exenteration in vulvovaginal malignant melanoma.
    Gynecol Oncol. 2018;148:430-431.
    PubMed     Abstract available


  847. FU S, Lairson DR, Chan W, Wu CF, et al
    Mean medical costs associated with vaginal and vulvar cancers for commercially insured patients in the United States and Texas.
    Gynecol Oncol. 2018;148:342-348.
    PubMed     Abstract available


  848. KANG WD, Ju UC, Kim SM
    Is human papillomavirus genotype important in predicting disease progression in women with biopsy-proven negative or CIN1 of atypical squamous cell of undetermined significance (ASC-US) cytology?
    Gynecol Oncol. 2018;148:305-310.
    PubMed     Abstract available


    January 2018
  849. ARMBRUSTER SD, Song J, Gatus L, Lu KH, et al
    Endometrial cancer survivors' sleep patterns before and after a physical activity intervention: A retrospective cohort analysis.
    Gynecol Oncol. 2018 Jan 30. pii: S0090-8258(18)30067.
    PubMed     Abstract available


  850. DEWDNEY SB, Dancisak AC, Lachance JA, Grendys EC Jr, et al
    Society of Gynecologic Oncology Clinical Outcomes Registry: From small beginnings come great things.
    Gynecol Oncol. 2018 Jan 30. pii: S0090-8258(18)30060.
    PubMed     Abstract available


  851. GRIMM C, Polterauer S, Helmy-Bader S, Zikan M, et al
    A collagen-fibrin patch for the prevention of symptomatic lymphoceles after pelvic lymphadenectomy in women with gynecologic malignancies: A randomized clinical trial.
    Gynecol Oncol. 2018 Jan 30. pii: S0090-8258(18)30044.
    PubMed     Abstract available


  852. GUNDERSON CC, Matulonis U, Moore KN
    Management of the toxicities of common targeted therapeutics for gynecologic cancers.
    Gynecol Oncol. 2018 Jan 30. pii: S0090-8258(18)30042.
    PubMed     Abstract available


  853. KESSOUS R, Octeau D, Klein K, Tonin PN, et al
    Distinct homologous recombination gene expression profiles after neoadjuvant chemotherapy associated with clinical outcome in patients with ovarian cancer.
    Gynecol Oncol. 2018 Jan 29. pii: S0090-8258(18)30055.
    PubMed     Abstract available


  854. HENRY CE, Llamosas E, Daniels B, Coopes A, et al
    ROR1 and ROR2 play distinct and opposing roles in endometrial cancer.
    Gynecol Oncol. 2018 Jan 29. pii: S0090-8258(18)30064.
    PubMed     Abstract available


  855. NITECKI R, Diver EJ, Kamdar MM, Boruta DM 2nd, et al
    Patterns of palliative care referral in ovarian cancer: A single institution 5year retrospective analysis.
    Gynecol Oncol. 2018 Jan 27. pii: S0090-8258(18)30056.
    PubMed     Abstract available


  856. ZHANG HR, Lai SY, Huang LJ, Zhang ZF, et al
    Myosin 1b promotes cell proliferation, migration, and invasion in cervical cancer.
    Gynecol Oncol. 2018 Jan 27. pii: S0090-8258(18)30065.
    PubMed     Abstract available


  857. PENNINGTON KP, McTiernan A
    The role of physical activity in breast and gynecologic cancer survivorship.
    Gynecol Oncol. 2018 Jan 27. pii: S0090-8258(18)30059.
    PubMed     Abstract available


  858. KATO K, Okamoto S, Ota E, Takeshima N, et al
    Secondary debulking surgery for para-aortic nodal recurrence in endometrial cancer requiring circumferential resection of the inferior vena cava.
    Gynecol Oncol. 2018 Jan 27. pii: S0090-8258(18)30063.
    PubMed    


  859. SAMIMI G, Trabert B, Duggan MA, Robinson JL, et al
    Processing of fallopian tube, ovary, and endometrial surgical pathology specimens: A survey of U.S. laboratory practices.
    Gynecol Oncol. 2018 Jan 25. pii: S0090-8258(18)30048.
    PubMed     Abstract available


  860. KRISHNAN V, Schaar B, Tallapragada S, Dorigo O, et al
    Tumor associated macrophages in gynecologic cancers.
    Gynecol Oncol. 2018 Jan 22. pii: S0090-8258(18)30046.
    PubMed     Abstract available


  861. DOSTALEK L, Zikan M, Fischerova D, Kocian R, et al
    SLN biopsy in cervical cancer patients with tumors larger than 2cm and 4cm.
    Gynecol Oncol. 2018 Jan 21. pii: S0090-8258(18)30001.
    PubMed     Abstract available


  862. BARROILHET L, Matulonis U
    The NCI-MATCH trial and precision medicine in gynecologic cancers.
    Gynecol Oncol. 2018 Jan 20. pii: S0090-8258(18)30040.
    PubMed     Abstract available


  863. GRAY HJ, Bell-McGuinn K, Fleming GF, Cristea M, et al
    Phase I combination study of the PARP inhibitor veliparib plus carboplatin and gemcitabine in patients with advanced ovarian cancer and other solid malignancies.
    Gynecol Oncol. 2018 Jan 15. pii: S0090-8258(17)31620.
    PubMed     Abstract available


  864. BERGSTROM J, Aloisi A, Armbruster S, Yen TT, et al
    Minimally invasive hysterectomy surgery rates for endometrial cancer performed at National Comprehensive Cancer Network (NCCN) Centers.
    Gynecol Oncol. 2018 Jan 12. pii: S0090-8258(18)30002.
    PubMed     Abstract available


  865. SHALOWITZ DI, Cohn DE
    Cancer care delivery research in gynecologic oncology.
    Gynecol Oncol. 2018 Jan 10. pii: S0090-8258(17)31618.
    PubMed    


  866. TRABERT B, Aarestrup J, Ulrich LG, Wentzensen N, et al
    Birth weight and the risk of histological subtypes of ovarian and endometrial cancers: Results from the Copenhagen School Health Records Register.
    Gynecol Oncol. 2018 Jan 10. pii: S0090-8258(17)31622.
    PubMed     Abstract available


  867. PARK SH, Cheon H, Chong GO, Jeong SY, et al
    Prognostic significance of residual lymph node status after definitive chemoradiotherapy in patients with node-positive cervical cancer.
    Gynecol Oncol. 2018 Jan 9. pii: S0090-8258(18)30037.
    PubMed     Abstract available


  868. HAGEMANN AR, McCourt CK, Varaday SS, Moore KN, et al
    Defining and mitigating the challenges of an older and obese population in minimally invasive gynecologic cancer surgery.
    Gynecol Oncol. 2018 Jan 9. pii: S0090-8258(17)31608.
    PubMed     Abstract available


  869. SAED GM, Fletcher NM, Diamond MP, Morris RT, et al
    Novel expression of CD11b in epithelial ovarian cancer: Potential therapeutic target.
    Gynecol Oncol. 2018 Jan 9. pii: S0090-8258(17)31606.
    PubMed     Abstract available


  870. BACORRO W, Dumas I, Escande A, Gouy S, et al
    Dose-volume effects in pathologic lymph nodes in locally advanced cervical cancer.
    Gynecol Oncol. 2018 Jan 8. pii: S0090-8258(17)31621.
    PubMed     Abstract available


  871. MATSUOKA A, Tate S, Nishikimi K, Shozu M, et al
    Retroperitoneal lymphadenectomy for ovarian cancer with double inferior vena cava.
    Gynecol Oncol. 2018 Jan 5. pii: S0090-8258(17)31619.
    PubMed    


  872. MUKERJI B, Baptiste C, Chen L, Tergas AI, et al
    Racial disparities in young women with endometrial cancer.
    Gynecol Oncol. 2018 Jan 4. pii: S0090-8258(17)31623.
    PubMed     Abstract available


  873. DONG L, Wang MZ, Zhao XL, Feng RM, et al
    Human papillomavirus viral load as a useful triage tool for non-16/18 high-risk human papillomavirus positive women: A prospective screening cohort study.
    Gynecol Oncol. 2018;148:103-110.
    PubMed     Abstract available


  874. GOROSTIDI M, Villalain C, Ruiz R, Jaunarena I, et al
    Technique for precaval and laterocaval nodes excision at extraperitoneal paraaortic lymphadenectomy.
    Gynecol Oncol. 2018;148:233-234.
    PubMed     Abstract available


  875. SATMARY W, Holschneider CH, Brunette LL, Natarajan S, et al
    Vulvar intraepithelial neoplasia: Risk factors for recurrence.
    Gynecol Oncol. 2018;148:126-131.
    PubMed     Abstract available


    December 2017
  876. TOUHAMI O, Gregoire J, Renaud MC, Sebastianelli A, et al
    The utility of sentinel lymph node mapping in the management of endometrial atypical hyperplasia.
    Gynecol Oncol. 2017 Dec 28. pii: S0090-8258(17)31617.
    PubMed     Abstract available


  877. SOISSON S, Ganz PA, Gaffney D, Rowe K, et al
    Long-term, adverse genitourinary outcomes among endometrial cancer survivors in a large, population-based cohort study.
    Gynecol Oncol. 2017 Dec 27. pii: S0090-8258(17)31616.
    PubMed     Abstract available


  878. XIANG L, Jiang W, Ye S, He T, et al
    ERBB2 mutation: A promising target in non-squamous cervical cancer.
    Gynecol Oncol. 2017 Dec 23. pii: S0090-8258(17)31614.
    PubMed     Abstract available


  879. SUD S, Holmes J, Eblan M, Chen R, et al
    Clinical characteristics associated with racial disparities in endometrial cancer outcomes: A surveillance, epidemiology and end results analysis.
    Gynecol Oncol. 2017 Dec 21. pii: S0090-8258(17)31607.
    PubMed     Abstract available


  880. MONTEALEGRE JR, Peckham-Gregory EC, Marquez-Do D, Dillon L, et al
    Racial/ethnic differences in HPV 16/18 genotypes and integration status among women with a history of cytological abnormalities.
    Gynecol Oncol. 2017 Dec 21. pii: S0090-8258(17)31597.
    PubMed     Abstract available


  881. GEPPERT B, Lonnerfors C, Bollino M, Persson J, et al
    Sentinel lymph node biopsy in endometrial cancer-Feasibility, safety and lymphatic complications.
    Gynecol Oncol. 2017 Dec 20. pii: S0090-8258(17)31602.
    PubMed     Abstract available


  882. TRAN AQ, Erim DO, Sullivan SA, Cole AL, et al
    Cost effectiveness of neoadjuvant chemotherapy followed by interval cytoreductive surgery versus primary cytoreductive surgery for patients with advanced stage ovarian cancer during the initial treatment phase.
    Gynecol Oncol. 2017 Dec 19. pii: S0090-8258(17)31598.
    PubMed     Abstract available


  883. FORNALIK H, Fornalik N
    Robotic hysterectomy and pelvic lymphadenectomy without Trendelenburg position (BMI 36).
    Gynecol Oncol. 2017 Dec 19. pii: S0090-8258(17)31549.
    PubMed    


  884. LEE J, Lin JB, Chang CL, Sun FJ, et al
    Impact of para-aortic recurrence risk-guided intensity-modulated radiotherapy in locally advanced cervical cancer with positive pelvic lymph nodes.
    Gynecol Oncol. 2017 Dec 18. pii: S0090-8258(17)31550.
    PubMed     Abstract available


  885. MIAO M, Deng G, Luo S, Zhou J, et al
    A phase II study of apatinib in patients with recurrent epithelial ovarian cancer.
    Gynecol Oncol. 2017 Dec 13. pii: S0090-8258(17)31596.
    PubMed     Abstract available


  886. MATSUO K, Ross MS, Im DD, Klobocista MM, et al
    Significance of venous thromboembolism in women with uterine carcinosarcoma.
    Gynecol Oncol. 2017 Dec 13. pii: S0090-8258(17)31546.
    PubMed     Abstract available


  887. BRAGA A, Campos V, Filho JR, Lin LH, et al
    Is chemotherapy always necessary for patients with nonmetastatic gestational trophoblastic neoplasia with histopathological diagnosis of choriocarcinoma?
    Gynecol Oncol. 2017 Dec 13. pii: S0090-8258(17)31554.
    PubMed     Abstract available


  888. CASTLE PE, Pierz A, Stoler MH
    A systematic review and meta-analysis on the attribution of human papillomavirus (HPV) in neuroendocrine cancers of the cervix.
    Gynecol Oncol. 2017 Dec 13. pii: S0090-8258(17)31548.
    PubMed     Abstract available


  889. DILLEY S, Miller K, Huh W
    HPV vaccination.
    Gynecol Oncol. 2017 Dec 12. pii: S0090-8258(17)31547.
    PubMed    


  890. BERNARDS SS, Pennington KP, Harrell MI, Agnew KJ, et al
    Clinical characteristics and outcomes of patients with BRCA1 or RAD51C methylated versus mutated ovarian carcinoma.
    Gynecol Oncol. 2017 Dec 9. pii: S0090-8258(17)31551.
    PubMed     Abstract available


  891. KIM SI, Lee JW, Lee M, Kim HS, et al
    Genomic landscape of ovarian clear cell carcinoma via whole exome sequencing.
    Gynecol Oncol. 2017 Dec 9. pii: S0090-8258(17)31552.
    PubMed     Abstract available


  892. COYLE C, Short D, Jackson L, Sebire NJ, et al
    What is the optimal duration of human chorionic gonadotrophin surveillance following evacuation of a molar pregnancy? A retrospective analysis on over 20,000 consecutive patients.
    Gynecol Oncol. 2017 Dec 9. pii: S0090-8258(17)31555.
    PubMed     Abstract available


  893. BIZZARRI N, Ghirardi V, Kucukmetin A
    Indocyanine green-assisted parametrial dissection during type C1 radical hysterectomy after sentinel lymph node biopsy in early stage cervical cancer.
    Gynecol Oncol. 2017 Dec 6. pii: S0090-8258(17)31496.
    PubMed     Abstract available


  894. WALLACE S, Hanson KT, Dowdy SC, Habermann EB, et al
    Impact of surgical approach and patient factors on Hospital Consumer Assessment of Healthcare Providers and Systems (HCAHPS) survey scoring in gynecologic surgery.
    Gynecol Oncol. 2017 Dec 5. pii: S0090-8258(17)31525.
    PubMed     Abstract available


  895. SMITH D, Stewart CJR, Clarke EM, Lose F, et al
    ER and PR expression and survival after endometrial cancer.
    Gynecol Oncol. 2017 Dec 4. pii: S0090-8258(17)31537.
    PubMed     Abstract available


  896. WORLEY MJ JR, Elias KM, Horowitz NS, Quade BJ, et al
    Durable remission for a woman with refractory choriocarcinoma treated with anti-endoglin monoclonal antibody and bevacizumab: A case from the New England Trophoblastic Disease Center, Brigham and Women's Hospital and Dana-Farber Cancer Institute.
    Gynecol Oncol. 2017 Dec 4. pii: S0090-8258(17)31539.
    PubMed     Abstract available


  897. ANNUNZIATA CM, Kohn EC
    Clinical trials in gynecologic oncology: Past, present, and future.
    Gynecol Oncol. 2017 Dec 3. pii: S0090-8258(17)31536.
    PubMed     Abstract available


  898. URBAN RR, He H, Alfonso R, Hardesty MM, et al
    The end of life costs for Medicare patients with advanced ovarian cancer.
    Gynecol Oncol. 2017 Dec 3. pii: S0090-8258(17)31533.
    PubMed     Abstract available


  899. WEN KC, Sung PL, Chou YT, Pan CM, et al
    The role of EpCAM in tumor progression and the clinical prognosis of endometrial carcinoma.
    Gynecol Oncol. 2017 Dec 2. pii: S0090-8258(17)31543.
    PubMed     Abstract available


  900. AVIKI EM, Abu-Rustum NR
    A call to standardize our approach to fertility-sparing surgery in patients with gynecologic cancers.
    Gynecol Oncol. 2017;147:491-492.
    PubMed    


  901. BITLER BG, Watson ZL, Wheeler LJ, Behbakht K, et al
    PARP inhibitors: Clinical utility and possibilities of overcoming resistance.
    Gynecol Oncol. 2017;147:695-704.
    PubMed     Abstract available


  902. NOMURA H, Nagashima M, Aoki Y, Takeshima N, et al
    Resection of the inferior pubic ramus to completely remove locally advance adenoid cystic carcinoma of Bartholin's gland.
    Gynecol Oncol. 2017;147:723-724.
    PubMed     Abstract available


  903. PEI X, Xiang L, Ye S, He T, et al
    Cycles of cisplatin and etoposide affect treatment outcomes in patients with FIGO stage I-II small cell neuroendocrine carcinoma of the cervix.
    Gynecol Oncol. 2017;147:589-596.
    PubMed     Abstract available


  904. KUMAR A, Hurtt CC, Cliby WA, Martin JR, et al
    Concomitant venous thromboembolism at the time of primary EOC diagnosis: Perioperative outcomes and survival analyses.
    Gynecol Oncol. 2017;147:514-520.
    PubMed     Abstract available


  905. REISER E, Aust S, Seebacher V, Reinthaller A, et al
    Preoperative C-reactive protein serum levels as a predictive diagnostic marker in patients with adnexal masses.
    Gynecol Oncol. 2017;147:690-694.
    PubMed     Abstract available


  906. CYBULSKA P, Goss C, Tew WP, Parameswaran R, et al
    Corrigendum to "Indications for and complications of transfusion and the management of gynecologic malignancies" [Gynecol. Oncol. 146 (2017) 416-426].
    Gynecol Oncol. 2017 Dec 1. pii: S0090-8258(17)31540.
    PubMed    


  907. MAHANTSHETTY U, Teni T, Naga P, Hotwani C, et al
    Impact of HPV 16/18 infection on clinical outcomes in locally advanced cervical cancers treated with radical radio (chemo) therapy - A prospective observational study.
    Gynecol Oncol. 2017 Dec 1. pii: S0090-8258(17)31544.
    PubMed     Abstract available


  908. LI J, Li S, Yu H, Wang J, et al
    The efficacy and safety of first-line single-agent chemotherapy regimens in low-risk gestational trophoblastic neoplasia: A network meta-analysis.
    Gynecol Oncol. 2017 Dec 1. pii: S0090-8258(17)31541.
    PubMed     Abstract available


    November 2017
  909. HAMILTON CA, Miller A, Casablanca Y, Horowitz NS, et al
    Clinicopathologic characteristics associated with long-term survival in advanced epithelial ovarian cancer: an NRG Oncology/Gynecologic Oncology Group ancillary data study.
    Gynecol Oncol. 2017 Nov 28. pii: S0090-8258(17)31528.
    PubMed     Abstract available


  910. ZHU J, Chen Z, Yong L
    Systematic profiling of alternative splicing signature reveals prognostic predictor for ovarian cancer.
    Gynecol Oncol. 2017 Nov 27. pii: S0090-8258(17)31538.
    PubMed     Abstract available


  911. KITSON SJ, Lindsay J, Sivalingam VN, Lunt M, et al
    The unrecognized burden of cardiovascular risk factors in women newly diagnosed with endometrial cancer: A prospective case control study.
    Gynecol Oncol. 2017 Nov 24. pii: S0090-8258(17)31529.
    PubMed     Abstract available


  912. MURALI R, Grisham RN, Soslow RA
    The roles of pathology in targeted therapy of women with gynecologic cancers.
    Gynecol Oncol. 2017 Nov 23. pii: S0090-8258(17)31530.
    PubMed     Abstract available


  913. MOSS HA, Havrilesky LJ
    The use of patient-reported outcome tools in Gynecologic Oncology research, clinical practice, and value-based care.
    Gynecol Oncol. 2017 Nov 23. pii: S0090-8258(17)31507.
    PubMed     Abstract available


  914. GULERIA S, Jensen A, Kjaer SK
    Risk of borderline ovarian tumors among women with benign ovarian tumors: A cohort study.
    Gynecol Oncol. 2017 Nov 23. pii: S0090-8258(17)31534.
    PubMed     Abstract available


  915. HOROWITZ NS, Larry Maxwell G, Miller A, Hamilton CA, et al
    Predictive modeling for determination of microscopic residual disease at primary cytoreduction: An NRG Oncology/Gynecologic Oncology Group 182 Study.
    Gynecol Oncol. 2017 Nov 22. pii: S0090-8258(17)31371.
    PubMed     Abstract available


  916. LEE YJ, Chung YS, Lee JY, Nam EJ, et al
    Impact of the time interval from completion of neoadjuvant chemotherapy to initiation of postoperative adjuvant chemotherapy on the survival of patients with advanced ovarian cancer.
    Gynecol Oncol. 2017 Nov 21. pii: S0090-8258(17)31532.
    PubMed     Abstract available


  917. TOZZI R, Casarin J, Garruto-Campanile R, Majd HS, et al
    Morbidity and reversal rate of ileostomy after bowel resection during Visceral-Peritoneal Debulking (VPD) in patients with stage IIIC-IV ovarian cancer.
    Gynecol Oncol. 2017 Nov 20. pii: S0090-8258(17)31527.
    PubMed     Abstract available


  918. HEINZELMANN-SCHWARZ V, Knipprath Meszaros A, Stadlmann S, Jacob F, et al
    Letrozole may be a valuable maintenance treatment in high-grade serous ovarian cancer patients.
    Gynecol Oncol. 2017 Nov 17. pii: S0090-8258(17)31458.
    PubMed     Abstract available


  919. CHAMPER M, Huang Y, Hou JY, Tergas AI, et al
    Adherence to treatment recommendations and outcomes for women with ovarian cancer at first recurrence.
    Gynecol Oncol. 2017 Nov 15. pii: S0090-8258(17)31504.
    PubMed     Abstract available


  920. CHOLLI P, Bradford L, Manga S, Nulah K, et al
    Screening for cervical cancer among HIV-positive and HIV-negative women in Cameroon using simultaneous co-testing with careHPV DNA testing and visual inspection enhanced by digital cervicography: Findings of initial screening and one-year follow-up.
    Gynecol Oncol. 2017 Nov 15. pii: S0090-8258(17)31497.
    PubMed     Abstract available


  921. CHONG GO, Lee YH, Han HS, Lee HJ, et al
    Prognostic value of pre-treatment human papilloma virus DNA status in cervical cancer.
    Gynecol Oncol. 2017 Nov 15. pii: S0090-8258(17)31498.
    PubMed     Abstract available


  922. SHISLER R, Sinnott JA, Wang V, Hebert C, et al
    Life after endometrial cancer: A systematic review of patient-reported outcomes.
    Gynecol Oncol. 2017 Nov 14. pii: S0090-8258(17)31503.
    PubMed     Abstract available


  923. LIE AK, Trope A, Skare GB, Bjorge T, et al
    HPV genotype profile in a Norwegian cohort with ASC-US and LSIL cytology with three year cumulative risk of high grade cervical neoplasia.
    Gynecol Oncol. 2017 Nov 11. pii: S0090-8258(17)31453.
    PubMed     Abstract available


  924. TAKIUCHI T, Blake EA, Matsuo K, Sood AK, et al
    Aspirin use and endometrial cancer risk and survival.
    Gynecol Oncol. 2017 Nov 10. pii: S0090-8258(17)31448.
    PubMed     Abstract available


  925. SHAH JS, Gard GB, Yang J, Maidens J, et al
    Combining serum microRNA and CA-125 as prognostic indicators of preoperative surgical outcome in women with high-grade serous ovarian cancer.
    Gynecol Oncol. 2017 Nov 10. pii: S0090-8258(17)31500.
    PubMed     Abstract available


  926. COSGROVE CM, Tritchler DL, Cohn DE, Mutch DG, et al
    An NRG Oncology/GOG study of molecular classification for risk prediction in endometrioid endometrial cancer.
    Gynecol Oncol. 2017 Nov 10. pii: S0090-8258(17)31459.
    PubMed     Abstract available


  927. TIMMERMANS M, Schuurman MS, Ho VKY, Massuger LF, et al
    Centralization of ovarian cancer in the Netherlands: Hospital of diagnosis no longer determines patients' probability of undergoing surgery.
    Gynecol Oncol. 2017 Nov 9. pii: S0090-8258(17)31505.
    PubMed     Abstract available


  928. MERT I, Kumar A, Sheedy SP, Weaver AL, et al
    Clinical significance of enlarged cardiophrenic lymph nodes in advanced ovarian cancer: Implications for survival.
    Gynecol Oncol. 2017 Nov 9. pii: S0090-8258(17)31446.
    PubMed     Abstract available


  929. NIETO K, Adams W, Pham N, Block AM, et al
    Adjuvant therapy in patients with clear cell endometrial carcinoma: An analysis of the National Cancer Database.
    Gynecol Oncol. 2017 Nov 9. pii: S0090-8258(17)31506.
    PubMed     Abstract available


  930. HOPPENOT C, Eckert MA, Tienda SM, Lengyel E, et al
    Who are the long-term survivors of high grade serous ovarian cancer?
    Gynecol Oncol. 2017 Nov 8. pii: S0090-8258(17)31454.
    PubMed     Abstract available


  931. HINCHCLIFF E, Melamed A, Bregar A, Diver E, et al
    Factors associated with delivery of neoadjuvant chemotherapy in women with advanced stage ovarian cancer.
    Gynecol Oncol. 2017 Nov 8. pii: S0090-8258(17)31460.
    PubMed     Abstract available


  932. SPAANS VM, Nyoman Bayu Mahendra I, Purwoto G, Trietsch MD, et al
    The landscape of somatic mutations in Indonesian cervical cancer is predominated by the PI3K pathway.
    Gynecol Oncol. 2017 Nov 4. pii: S0090-8258(17)31369.
    PubMed     Abstract available


  933. ISHIKAWA M, Kasamatsu T, Tsuda H, Fukunaga M, et al
    Prognostic factors and optimal therapy for stages I-II neuroendocrine carcinomas of the uterine cervix: A multi-center retrospective study.
    Gynecol Oncol. 2017 Nov 4. pii: S0090-8258(17)31449.
    PubMed     Abstract available


  934. CHAN JK, Kapp DS
    Clear Cell Ovarian Cancer: Optimum Management and Prognosis Remain Hazy.
    Gynecol Oncol. 2017;147:237-239.
    PubMed    


  935. ALTMAN AD, McGee J, May T, Lane K, et al
    Neoadjuvant chemotherapy and chemotherapy cycle number: A national multicentre study.
    Gynecol Oncol. 2017;147:257-261.
    PubMed     Abstract available


    October 2017
  936. FONNES T, Berg HF, Bredholt T, Edqvist PD, et al
    Asparaginase-like protein 1 is an independent prognostic marker in primary endometrial cancer, and is frequently lost in metastatic lesions.
    Gynecol Oncol. 2017 Oct 30. pii: S0090-8258(17)31447.
    PubMed     Abstract available


  937. MAESTA I, Nitecki R, Horowitz NS, Goldstein DP, et al
    Effectiveness and toxicity of first-line methotrexate chemotherapy in low-risk postmolar gestational trophoblastic neoplasia: The New England Trophoblastic Disease Center experience.
    Gynecol Oncol. 2017 Oct 29. pii: S0090-8258(17)31450.
    PubMed     Abstract available


  938. NING MS, Ahobila V, Jhingran A, Stecklein SR, et al
    Outcomes and patterns of relapse after definitive radiation therapy for oligometastatic cervical cancer.
    Gynecol Oncol. 2017 Oct 28. pii: S0090-8258(17)31420.
    PubMed     Abstract available


  939. LEE JH, Lee SW, Kim JR, Kim YS, et al
    Tumour size, volume, and marker expression during radiation therapy can predict survival of cervical cancer patients: a multi-institutional retrospective analysis of KROG 16-01.
    Gynecol Oncol. 2017 Oct 27. pii: S0090-8258(17)31360.
    PubMed     Abstract available


  940. CHENG H, Peng J, Yang Z, Zhang G, et al
    Prognostic significance of lymphadenectomyin malignant ovarian sex cord stromal tumor: A retrospective cohort study and meta-analysis.
    Gynecol Oncol. 2017 Oct 26. pii: S0090-8258(17)31444.
    PubMed     Abstract available


  941. RONCOLATO FT, Berton-Rigaud D, O'Connell R, Lanceley A, et al
    Validation of the modified Glasgow Prognostic Score (mGPS) in recurrent ovarian cancer (ROC) - Analysis of patients enrolled in the GCIG Symptom Benefit Study (SBS).
    Gynecol Oncol. 2017 Oct 26. pii: S0090-8258(17)31422.
    PubMed     Abstract available


  942. LIN DI, Chudnovsky Y, Duggan B, Zajchowski D, et al
    Comprehensive genomic profiling reveals inactivating SMARCA4 mutations and low tumor mutational burden in small cell carcinoma of the ovary, hypercalcemic-type.
    Gynecol Oncol. 2017 Oct 25. pii: S0090-8258(17)31355.
    PubMed     Abstract available


  943. SHALOWITZ DI, Nivasch E, Burger RA, Schapira MM, et al
    Are patients willing to travel for better ovarian cancer care?
    Gynecol Oncol. 2017 Oct 24. pii: S0090-8258(17)31421.
    PubMed     Abstract available


  944. YI Y, Tsai SH, Cheng JC, Wang EY, et al
    APELA promotes tumour growth and cell migration in ovarian cancer in a p53-dependent manner.
    Gynecol Oncol. 2017 Oct 24. pii: S0090-8258(17)31419.
    PubMed     Abstract available


  945. LAAN JJ, van Lonkhuijzen LRCW, van Os RM, Tytgat KM, et al
    Socioeconomic status as an independent risk factor for severe late bowel toxicity after primary radiotherapy for cervical cancer.
    Gynecol Oncol. 2017 Oct 23. pii: S0090-8258(17)31416.
    PubMed     Abstract available


  946. MATSUO K, Ross MS, Yunokawa M, Johnson MS, et al
    Salvage chemotherapy with taxane and platinum for women with recurrent uterine carcinosarcoma.
    Gynecol Oncol. 2017 Oct 19. pii: S0090-8258(17)31368.
    PubMed     Abstract available


  947. TANNER E, Puechl A, Levinson K, Havrilesky LJ, et al
    Use of a novel sentinel lymph node mapping algorithm reduces the need for pelvic lymphadenectomy in low-grade endometrial cancer.
    Gynecol Oncol. 2017 Oct 19. pii: S0090-8258(17)31423.
    PubMed     Abstract available


  948. YAMAMOTO K, Nagao S, Suzuki K, Kogiku A, et al
    Pelvic fractures after definitive and postoperative radiotherapy for cervical cancer: A retrospective analysis of risk factors.
    Gynecol Oncol. 2017 Oct 18. pii: S0090-8258(17)31359.
    PubMed     Abstract available


  949. ARIMA R, Hautakoski A, Marttila M, Arffman M, et al
    Cause-specific mortality in endometrioid endometrial cancer patients with type 2 diabetes using metformin or other types of antidiabetic medication.
    Gynecol Oncol. 2017 Oct 17. pii: S0090-8258(17)31417.
    PubMed     Abstract available


  950. JONES MR, Kamara D, Karlan BY, Pharoah PDP, et al
    Genetic epidemiology of ovarian cancer and prospects for polygenic risk prediction.
    Gynecol Oncol. 2017 Oct 17. pii: S0090-8258(17)31361.
    PubMed     Abstract available


  951. CHEN BJ, Byrne FL, Takenaka K, Modesitt SC, et al
    Transcriptome landscape of long intergenic non-coding RNAs in endometrial cancer.
    Gynecol Oncol. 2017 Oct 16. pii: S0090-8258(17)31367.
    PubMed     Abstract available


  952. SCHULTZ KAP, Harris AK, Finch M, Dehner LP, et al
    DICER1-related Sertoli-Leydig cell tumor and gynandroblastoma: Clinical and genetic findings from the International Ovarian and Testicular Stromal Tumor Registry.
    Gynecol Oncol. 2017 Oct 13. pii: S0090-8258(17)31358.
    PubMed     Abstract available


  953. DOCKERY LE, Tew WP, Ding K, Moore KN, et al
    Tolerance and toxicity of the PARP inhibitor olaparib in older women with epithelial ovarian cancer.
    Gynecol Oncol. 2017 Oct 13. pii: S0090-8258(17)31364.
    PubMed     Abstract available


  954. POZZAR RA, Berry DL
    Patient-centered research priorities in ovarian cancer: A systematic review of potential determinants of guideline care.
    Gynecol Oncol. 2017 Oct 10. pii: S0090-8258(17)31365.
    PubMed     Abstract available


  955. DE LIMA MAP, Neto PJN, Lima LPM, Goncalves Junior J, et al
    Association between Epstein-Barr virus (EBV) and cervical carcinoma: A meta-analysis.
    Gynecol Oncol. 2017 Oct 9. pii: S0090-8258(17)31366.
    PubMed     Abstract available


  956. NASIOUDIS D, Frey MK, Chapman-Davis E, Caputo TA, et al
    Fertility-preserving surgery for advanced stage ovarian germ cell tumors.
    Gynecol Oncol. 2017 Oct 9. pii: S0090-8258(17)31370.
    PubMed     Abstract available


  957. XIA Z, Cochrane DR, Anglesio MS, Wang YK, et al
    LINE-1 retrotransposon-mediated DNA transductions in endometriosis associated ovarian cancers.
    Gynecol Oncol. 2017 Oct 9. pii: S0090-8258(17)31356.
    PubMed     Abstract available


  958. BUDA A, Di Martino G, Restaino S, De Ponti E, et al
    The impact on survival of two different staging strategies in apparent early stage endometrial cancer comparing sentinel lymph nodes mapping algorithm and selective lymphadenectomy: An Italian retrospective analysis of two reference centers.
    Gynecol Oncol. 2017 Oct 9. pii: S0090-8258(17)31357.
    PubMed     Abstract available


  959. PEPIN K, Bregar A, Davis M, Melamed A, et al
    Intensive care admissions among ovarian cancer patients treated with primary debulking surgery and neoadjuvant chemotherapy-interval debulking surgery.
    Gynecol Oncol. 2017 Oct 4. pii: S0090-8258(17)31352.
    PubMed     Abstract available


  960. MATSUO K, Machida H, Frimer M, Marcus JZ, et al
    Prognosis of women with stage I endometrioid endometrial cancer and synchronous stage I endometrioid ovarian cancer.
    Gynecol Oncol. 2017 Oct 3. pii: S0090-8258(17)31351.
    PubMed     Abstract available


  961. SINGH S, Swarer K, Resnick K
    Longer operative time is associated with increased post-operative complications in patients undergoing minimally-invasive surgery for endometrial cancer.
    Gynecol Oncol. 2017 Oct 2. pii: S0090-8258(17)31348.
    PubMed     Abstract available


  962. HENSLEY ML
    Difficult Choices in Stage I Uterine Leiomyosarcoma- it's okay to "stand there".
    Gynecol Oncol. 2017;147:1-2.
    PubMed    


  963. POLTERAUER S, Schwameis R, Grimm C, Macuks R, et al
    Prognostic value of lymph node ratio and number of positive inguinal nodes in patients with vulvar cancer.
    Gynecol Oncol. 2017;147:92-97.
    PubMed     Abstract available


    September 2017
  964. DEVOR EJ, Miecznikowski J, Schickling BM, Gonzalez-Bosquet J, et al
    Dysregulation of miR-181c expression influences recurrence of endometrial endometrioid adenocarcinoma by modulating NOTCH2 expression: An NRG Oncology/Gynecologic Oncology Group study.
    Gynecol Oncol. 2017 Sep 29. pii: S0090-8258(17)31349.
    PubMed     Abstract available


  965. DUCIE JA, Eriksson AGZ, Ali N, McGree ME, et al
    Comparison of a sentinel lymph node mapping algorithm and comprehensive lymphadenectomy in the detection of stage IIIC endometrial carcinoma at higher risk for nodal disease.
    Gynecol Oncol. 2017 Sep 28. pii: S0090-8258(17)31354.
    PubMed     Abstract available


  966. PHILP L, Covens A, Vicus D, Kupets R, et al
    Feasibility and safety of same-day discharge after laparoscopic radical hysterectomy for cervix cancer.
    Gynecol Oncol. 2017 Sep 28. pii: S0090-8258(17)31350.
    PubMed     Abstract available


  967. QIU C, Lu N, Wang X, Zhang Q, et al
    Gene expression profiles of ovarian low-grade serous carcinoma resemble those of fallopian tube epithelium.
    Gynecol Oncol. 2017 Sep 28. pii: S0090-8258(17)31353.
    PubMed     Abstract available


  968. TORRES D, Kumar A, Wallace SK, Bakkum-Gamez JN, et al
    Intraperitoneal disease dissemination patterns are associated with residual disease, extent of surgery, and molecular subtypes in advanced ovarian cancer.
    Gynecol Oncol. 2017 Sep 27. pii: S0090-8258(17)31345.
    PubMed     Abstract available


  969. COSGROVE CM, Cohn DE, Goodfellow PJ
    Primum non nocere: Are we ready for POLE testing in endometrial cancer?
    Gynecol Oncol. 2017 Sep 22. pii: S0090-8258(17)31339.
    PubMed    


  970. CYBULSKA P, Schiavone MB, Sawyer B, Gardner GJ, et al
    Trocar site hernia development in patients undergoing robotically assisted or standard laparoscopic staging surgery for endometrial cancer.
    Gynecol Oncol. 2017 Sep 22. pii: S0090-8258(17)31302.
    PubMed     Abstract available


  971. NELSON G, Dowdy SC, Lasala J, Mena G, et al
    Enhanced recovery after surgery (ERAS(R)) in gynecologic oncology - Practical considerations for program development.
    Gynecol Oncol. 2017 Sep 22. pii: S0090-8258(17)31347.
    PubMed    


  972. MAKKONEN P, Heinavaara S, Sarkeala T, Anttila A, et al
    Impact of organized and opportunistic Pap testing on the risk of cervical cancer in young women - A case-control study from Finland.
    Gynecol Oncol. 2017 Sep 21. pii: S0090-8258(17)31335.
    PubMed     Abstract available


  973. TOUHAMI O, Gregoire J, Renaud MC, Sebastianelli A, et al
    Performance of sentinel lymph node (SLN) mapping in high-risk endometrial cancer.
    Gynecol Oncol. 2017 Sep 21. pii: S0090-8258(17)31338.
    PubMed     Abstract available


  974. SHAH JS, Guerra R, Bodurka DC, Sun CC, et al
    Factors influencing fertility-sparing treatment for gynecologic malignancies: A survey of Society of Gynecologic Oncology members.
    Gynecol Oncol. 2017 Sep 21. pii: S0090-8258(17)31343.
    PubMed     Abstract available


  975. BARBER EL, Rossi EC, Gehrig PA
    Surgical readmission and survival in women with ovarian cancer: Are short-term quality metrics incentivizing decreased long-term survival?
    Gynecol Oncol. 2017 Sep 20. pii: S0090-8258(17)31340.
    PubMed     Abstract available


  976. DO JH, Choi KH, Ahn JS, Jeon JY, et al
    Effects of a complex rehabilitation program on edema status, physical function, and quality of life in lower-limb lymphedema after gynecological cancer surgery.
    Gynecol Oncol. 2017 Sep 20. pii: S0090-8258(17)31272.
    PubMed     Abstract available


  977. RUSTIN G, Vergote I, Micha JP, Duska LR, et al
    A multicenter, open-label, expanded phase 2 study to evaluate the safety and efficacy of etirinotecan pegol, a polymer conjugate of irinotecan, in women with recurrent platinum-resistant or refractory ovarian cancer.
    Gynecol Oncol. 2017 Sep 18. pii: S0090-8258(17)31264.
    PubMed     Abstract available


  978. MOORE KN, Tritchler D, Kaufman KM, Lankes H, et al
    Genome-wide association study evaluating single-nucleotide polymorphisms and outcomes in patients with advanced stage serous ovarian or primary peritoneal cancer: An NRG Oncology/Gynecologic Oncology Group study.
    Gynecol Oncol. 2017 Sep 18. pii: S0090-8258(17)31261.
    PubMed     Abstract available


  979. LEE SW, Lee SH, Kim J, Kim YS, et al
    Magnetic resonance imaging during definitive chemoradiotherapy can predict tumor recurrence and patient survival in locally advanced cervical cancer: A multi-institutional retrospective analysis of KROG 16-01.
    Gynecol Oncol. 2017 Sep 18. pii: S0090-8258(17)31265.
    PubMed     Abstract available


  980. TANGEN IL, Veneris JT, Halle MK, Werner HM, et al
    Expression of glucocorticoid receptor is associated with aggressive primary endometrial cancer and increases from primary to metastatic lesions.
    Gynecol Oncol. 2017 Sep 16. pii: S0090-8258(17)31337.
    PubMed     Abstract available


  981. DANTAS PRS, Maesta I, Filho JR, Junior JA, et al
    Does hormonal contraception during molar pregnancy follow-up influence the risk and clinical aggressiveness of gestational trophoblastic neoplasia after controlling for risk factors?
    Gynecol Oncol. 2017 Sep 16. pii: S0090-8258(17)31310.
    PubMed     Abstract available


  982. RAUH LA, Pannone AF, Cantrell LA
    Hormone replacement therapy after treatment for cervical cancer: Are we adhering to standard of care?
    Gynecol Oncol. 2017 Sep 16. pii: S0090-8258(17)31333.
    PubMed     Abstract available


  983. GEBHARDT B, Gill B, Glaser S, Kim H, et al
    Image-guided tandem and cylinder brachytherapy as monotherapy for definitive treatment of inoperable endometrial carcinoma.
    Gynecol Oncol. 2017 Sep 15. pii: S0090-8258(17)31309.
    PubMed     Abstract available


  984. AZAIS H, Ghesquiere L, Petitnicolas C, Borghesi Y, et al
    Pretherapeutic staging of locally advanced cervical cancer: Inframesenteric paraaortic lymphadenectomy accuracy to detect paraaortic metastases in comparison with infrarenal paraaortic lymphadenectomy.
    Gynecol Oncol. 2017 Sep 14. pii: S0090-8258(17)31334.
    PubMed     Abstract available


  985. BINDER PS, Kuroki LM, Zhao P, Cusworth S, et al
    Benefit of combination chemotherapy and radiation stratified by grade of stage IIIC endometrial cancer.
    Gynecol Oncol. 2017 Sep 12. pii: S0090-8258(17)31269.
    PubMed     Abstract available


  986. LILYQUIST J, LaDuca H, Polley E, Davis BT, et al
    Frequency of mutations in a large series of clinically ascertained ovarian cancer cases tested on multi-gene panels compared to reference controls.
    Gynecol Oncol. 2017 Sep 7. pii: S0090-8258(17)31268.
    PubMed     Abstract available


  987. PISU M, Kenzik KM, Rim SH, Funkhouser EM, et al
    Values and worries of ovarian cancer patients.
    Gynecol Oncol. 2017 Sep 6. pii: S0090-8258(17)31267.
    PubMed     Abstract available


  988. COWAN RA, Tseng J, Murthy V, Srivastava R, et al
    Feasibility, safety and clinical outcomes of cardiophrenic lymph node resection in advanced ovarian cancer.
    Gynecol Oncol. 2017 Sep 6. pii: S0090-8258(17)31270.
    PubMed     Abstract available


  989. SCHLUMBRECHT M, Baeker Bispo JA, Balise RR, Huang M, et al
    Variation in type II endometrial cancer risk by Hispanic subpopulation: An exploratory analysis.
    Gynecol Oncol. 2017 Sep 6. pii: S0090-8258(17)31271.
    PubMed     Abstract available


  990. HUO D, Anderson D, Palmer JR, Herbst AL, et al
    Incidence rates and risks of diethylstilbestrol-related clear-cell adenocarcinoma of the vagina and cervix: Update after 40-year follow-up.
    Gynecol Oncol. 2017;146:566-571.
    PubMed     Abstract available


  991. POUWER AW, Hinten F, van der Velden J, Smolders RGV, et al
    Volume-controlled versus short drainage after inguinofemoral lymphadenectomy in vulvar cancer patients: A Dutch nationwide prospective study.
    Gynecol Oncol. 2017;146:580-587.
    PubMed     Abstract available


  992. RAO YJ, Chin RI, Hui C, Mutch DG, et al
    Improved survival with definitive chemoradiation compared to definitive radiation alone in squamous cell carcinoma of the vulva: A review of the National Cancer Database.
    Gynecol Oncol. 2017;146:572-579.
    PubMed     Abstract available


  993. LOPEZ LABROUSSE MI, Frumovitz M, Guadalupe Patrono M, Ramirez PT, et al
    Sentinel lymph node mapping in minimally invasive surgery: Role of imaging with color-segmented fluorescence (CSF).
    Gynecol Oncol. 2017;146:676-677.
    PubMed     Abstract available


    May 2017
  994. ARGENTA PA
    Attacking obesity-related diseases at the source - Is bariatric surgery the next wave in cancer prevention?
    Gynecol Oncol. 2017;145:219-220.
    PubMed    


    April 2017
  995. BOULAY E, Galczynski K, Canis M, Bourdel N, et al
    Laparoscopic pelvic lymphadenectomy in 10 steps - let's make it easier!
    Gynecol Oncol. 2017;145:217-218.
    PubMed    


  996. HERZOG TJ, Cohn DE
    Dose Dense Chemotherapy for Front-line Ovarian Cancer Treatment: The Price is Right?
    Gynecol Oncol. 2017;145:1-2.
    PubMed    


    February 2017
  997. WESTIN SN, Coleman RL
    Individualized Medicine in Ovarian Cancer: Are We There Yet?
    Gynecol Oncol. 2017;144:229-231.
    PubMed    


    January 2017
  998. KIM HS, Lee M
    Video endoscopic inguinal lymphadenectomy (VEIL) for vulvar cancer.
    Gynecol Oncol. 2017;144:225-226.
    PubMed    


  999. FRUMOVITZ M
    Sentinel Lymph Node Biopsy for Cervical Cancer Patients - What's It Gonna Take?
    Gynecol Oncol. 2017;144:3-4.
    PubMed    


    December 2016
  1000. NAROD S, Sopik V
    Neoadjuvant chemotherapy for advanced-stage ovarian cancer: Are the ASCO and SGO recommendations warranted?
    Gynecol Oncol. 2016 Dec 22. pii: S0090-8258(16)31615.
    PubMed    


    April 2016
  1001. NAROD SA
    Talc and ovarian cancer.
    Gynecol Oncol. 2016 Apr 16. pii: S0090-8258(16)30139.
    PubMed    


  1002. ALVAREZ RD, Matulonis UA, Herzog TJ, Coleman RL, et al
    Moving beyond the platinum sensitive/resistant paradigm for patients with recurrent ovarian cancer.
    Gynecol Oncol. 2016 Apr 3. pii: S0090-8258(16)30063.
    PubMed    


    February 2016
  1003. NAROD SA, Sopik V, Giannakeas V
    Should we screen for ovarian cancer? A commentary on the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS) randomized trial.
    Gynecol Oncol. 2016 Feb 25. pii: S0090-8258(16)30044.
    PubMed    


Thank you for your interest in scientific medicine.


AMEDEO Gynecology is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: